

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
GERHARD HOEFLE, ET AL.	)	Examiner: Taofiq A. Solola
	)	
Application No.: 09/313,524	)	Group Art Unit: 1625
	)	
Filed: May 17, 1999	)	Confirmation No.: 4030
	)	
For: EPOTHILONES C, D, E, AND F,	)	
PREPARATION AND	)	
COMPOSITIONS	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

DECLARATION UNDER 37 C.F.R. §1.131

Sir:

Pursuant to the provisions of MPEP 715, Applicants hereby aver as follows

1. I, Gerhard Hoefle, am a named inventor of the above-identified application.
2. I actually reduced to practice various species within the scope of the claims, or supervised the actual reduction to practice various species within the scope of the claims, before September 26, 1996. Copies of various laboratory notebook pages confirming this are attached. Dates on the attached photocopies are redacted, but as to paragraphs 1- 59, they are all prior to September 26, 1996, with the balance at least occurring prior to filing, as developed in the course of Interference No. 105,298. For the Examiner's convenience, an initial table is provided as a summary sheet (labeled

“Evidence for the discovery of epothilones C and D from...” as well. Note too that the laboratory notebook pages have been labeled “Exhibit 3-1, 3-2, etc.” by me simply for easy reference herein.

3. Dr. Klaus Gerth, a microbiologist at Gesellschaft für Biotechnologische Forschung mbH (“GBF”), instructed Carmen Fischer, a laboratory technician in the Chemistry Group at GBF, to commence cultivation and screening using a culture sample of *Sorangium cellulosum*, Soce1198 45/30.

4. Accordingly, Ms. Fischer took a sample of this Soce1198 45/30 strain, and inoculated it in heso; she recorded her work on a Sample Table, Exhibit 3-1, and in particular, she recorded the growth of this strain to be “good.” Id.

5. Likewise, Ms. Fischer took a second sample of this Soce1198 45/30 strain, inoculated it in Probian (this is a protein supplied by, at that time, Hoechst AG as nutrient component), and took the resultant product and used it to inoculate a 250 ml shaking flask with medium S (S is the lab term for a culture medium used for the screening of *Sorangium* strains). Id.

6. Ms. Fischer used that material in turn to inoculate three 250 ml flasks with medium S, which she recorded was harvested. Exhibits 3-1 and 3-2.

7. Ms. Fischer recorded that two (“second” is a misinterpretation of “2 K.” in the English translation) of the three 250 ml flasks were “good.” Exhibit 3-1.

8. The product harvested by Ms. Fischer was then given to Dr. Gerth, who proceeded to conduct an HPLC-UV absorbance analysis on the product – this analysis

was a “production check”; i.e., to check whether the strain was producing the desired materials.

9. In particular, Dr. Gerth injected the product onto an HPLC column and ran a UV absorbance analysis on the eluent, and the resultant spectrum is found in Exhibit 3-3.

10. On the spectrum found in Exhibit 3-3, Dr. Gerth wrote “Epo A” above the UV absorbance peak for the material eluted at 13.282 minutes, and wrote “Epo B” above the absorbance peak for the material eluted at the 14.584 minutes. Id. at page 1.

11. Dr. Gerth was able to identify these materials as epothilone A and epothilone B based upon his previous work with these materials.

12. His identification was also confirmed by the two UV peaks observed at the 13.282 and 14.584 time slices, characteristic of the presence of the thiazole side-chain (only thiazoles with the adjacent double bond show this peak pattern) found in epothilones A and B. See id. at page 4.

13. Additionally, Dr. Gerth noted at the same day the presence of an additional material or materials, which he recorded as “epo unbekannt” (meaning “unknown epothilones”) on the spectrum. Id. at page 1.

14. Dr. Gerth identified this material in this manner because it also exhibited the characteristic UV bands of epothilone A and epothilone B, but plainly was not those materials, since it eluted at a different time. [See id. at page 6.]

15. C. Fischer summarized these results on the Sample Table (Exhibit 3-1), where she recorded the names “epothilon A,” “epothilon B,” and “epo. Unbekannt” adjacent their respective peaks.

16. Ms. Fischer provided Mr. Steinmetz with a 20 microliter (erroneously “ml” in the english translation) into sample of So cel 198 45/30 in a high pressure liquid chromatography (“HPLC”) tube for analysis. Exhibit 3-4.

17. Mr. Steinmetz in turn gave the sample to Ms. Antje Ritter, a laboratory technician who also worked in the Chemistry group, and asked her to analyze the sample of So cel 198 using HPLC/UV and on-line mass spectrometry (“MS”).

18. Ms. Ritter conducted the requested HPLC-UV analysis. Exhibit 3-5. In the same HPLC run she also conducted the MS analysis on the sample. Id.

19. The same day that the HPLC/UV/MS analysis was conducted, Ms. Pohlan reviewed the print-outs from the HPLC/UV/MS analysis and wrote down “Epo A” and “Epo B” next to the peaks in the chromatogram (page 1) and next to their corresponding UV spectra (pages 2 and 3); she additionally wrote down “Epo neu” (“new epothilones”) next to the two peaks in the chromatogram as well as UV spectra corresponding to the newly identified, but as yet unisolated and uncharacterized, materials. Id.

20. Mr. Steinmetz reviewed the results of the ESI-MS analysis, and found that the two new materials showed protonated molecular ion ( $M+H^+$ ) of 478.2 and



492.5 respectively, as compared to those of epothilone A, 494.4, and epothilone B, 508.6. Exhibit 3-5.

21. Mr. Steinmetz therefore realized that the new materials each differed from epothilones A and B by the atomic mass 16, which is the mass of an oxygen atom.

22. In addition, Mr. Steinmetz reviewed with Ms. Pohlen the HPLC/UV/MS results, and noted that the new materials, which exhibited the characteristic UV bands of epothilones, each had an atomic mass 16 less than epothilones A and B; accordingly, Ms. Pohlen then recorded "Epo neu" (meaning "new epothilone") adjacent the UV absorbance curves taken for the 29.25 and 30.57 time slices. Exhibit 3-5.

23. Mr. Steinmetz discussed with Ms. Pohlen the 16 amu mass difference, and she recorded below the "Epo new" entries the equation " $mz = -16$ ," meaning that these new materials differed in mass from epothilones A and B by 16, respectively. Exhibit 3-5, at page 3.

24. Upon analyzing the data, Dr. Hoefle and Mr. Steinmetz concluded that the new materials had the same structures as epothilones A and B, except that they were missing an oxygen atom, presumably the epoxide group (one oxygen atom, atomic mass 16).

25. A departmental meeting was attended by Drs. Hoefle, Gerth, Reichenbach, Mr. Steinmetz and others, and was recorded in Meeting Minutes prepared by Dr. Reichenbach. Exhibit 3-6.

26. At the departmental meeting, Dr. Gerth reported his finding that the *Sorangium cellulosum* Soce 1198 strain produced epothilones A and B, and additionally produced small quantities of two unknown compounds exhibiting the characteristic ultraviolet (UV) spectrum of epothilone A and B, and that the new compounds were more lipophilic than epothilones A and B.

27. The “two peaks” referred to by Dr. Gerth at the departmental meeting were the thiazole double peaks exhibited by the UV absorbance spectrum.

28. In the Minutes of the meeting Dr. Höfle wrote:

According to HPLC/MS studies carried out by Herr Steinmetz, the substance is composed of homologues ( $\Delta 14$ ) possessing one oxygen atom less than epothilone A and B. There were ca. 1-2 mg of the new epothilones present in the shaken culture.

Exhibit 3-6 (English translation).

29. Dr. Höfle’s reference to “homologues” was intended to indicate that the new compounds had a similar structure to the known compounds epothilone A and epothilone B, except for the absence of an oxygen atom. Id.

30. Dr Höfle recorded that the next step was to isolate the new compounds individually, or as a mixture. Id.

31. Ms. Pohlen received from Dr. Gerth a methanol extract of adsorber resin collected by Dr. Gerth from the shaking flasks in the screening, which was labeled “So ce1198-45/30, Screening.” Exhibit 3-7.

32. Ms. Pohlen evaporated the MeOH off, and recorded that she had obtained 198 mg ( “g”, gram is an error in the English translation) of material. On the same day she run an analytical tlc (on the left hand side of Exhibit 3-7) comparing the extract with authentic epothilone A. Exhibit 3-7.

33. Ms. Pohlen fractionated the material using a Sephadex LH-20 column 1.5 cm in diameter and 70 cm long, and obtained six fractions, which she recorded as “LH-1” through “LH-6,” respectively. Exhibit 3-7.

34. Ms. Pohlen spotted these fractions onto different positions of a thin layer plate, and she recorded that the developed chromatogram showed spots in fraction “LH-2,” which indicated that the epothilones A and B as well as the new compounds would be present in that fraction. Exhibit 3-7.

35. Ms. Pohlen conducted an analytical check on fraction LH-2 by subjecting a small sample to reverse phase HPLC separation and UV detection. Exhibit 3-9.

36. The UV absorption trace of the analytical check on fraction LH-2 displayed in the 2.43 time slice the characteristic UV spectrum of epothilones which confirmed the presence of epothilone A and epothilone B. Exhibit 3-9.

37. The UV absorption trace of the analytical check on fraction LH-2 further displayed in the 4.26 and 5.04 time slices the characteristic UV spectrum of epothilones, thus confirming that this sample also contained the new compounds. Exhibit 3-9.

38. Ms. Pohlen recorded in her notebook that she had conducted a reverse phase ("RP") chromatographic fractionation on sample LH-2, using a Nucleosil 100 column (20 x 250 mm) and a solvent consisting of 73 parts methanol and 27 parts water. Exhibit 3-10.

39. Ms. Pohlen also obtained a UV absorbance trace of the eluent, and on that trace she noted that fractions 35 to 37 exhibited the peaks corresponding to epothilone A and epothilone B, which she labeled "epo A" and "epo B" respectively on the trace. Exhibit 3-11.

40. However, Ms. Pohlen also noted a UV absorption peak spanning fractions [46 and 47], which she labeled "RP-1" on the trace, and another UV absorption peak spanning fractions 50 and 51, which she labeled "RP-2" on the trace.

41. These UV absorbance peaks were believed to have been produced by the new compounds, and thus eluted fractions 46 and 47 were believed to contain one of the new compounds, and eluted fractions 50 and 51 were believed to contain the other of the new compounds.

42. Ms. Pohlen used a thin layer chromatograph technique to analyze a small amount of each of the eluents corresponding to peaks RP-1 and RP-2, and she recorded that the resultant spots had a violet color, which is the color that epothilones A and B were known to develop after spraying with vanillin/sulfuric acid. Exhibit 3-10.

43. Dr. Hoefle instructed Ms. Pohlen to submit the fraction corresponding to peak RP-2 for NMR analysis. Id.

44. Ms. Pohlen submitted the sample with an NMR Request Form, requesting a proton analysis (standard spectrum and COSY, 1D and 2D, respectively); the NMR analyses were conducted on the same day, and the resultant standard spectrum was given Spectrum no. 2550. Exhibit 3-12.

45. Spectrum no. 2550 for sample RP-2 was given to Dr. Hoefle; he reviewed it and found it to have characteristics of epothilone B, such as the five methyl singlets in the range of 1 to 2.7 ppm, and an olefinic singlet around 6.6 ppm. Exhibit 3-12.

46. However, Dr. Hoefle noted the presence in the NMR spectrum for sample RP-2 of a singlet at about 1.7 ppm; if the substance were epothilone B, this singlet would have been present at about the 1.2 ppm position.

47. Thus the singlet location was shifted, relative to epothilone B.

48. Given the previously recognized mass difference of 16, which is the weight of an atom of oxygen, Dr. Hoefle attributed the singlet shift in the RP-2 sample, relative to epothilone B, to the presence of a double bond, which had replaced the epoxide group.

49. After reviewing the NMR print-out, Dr. Hoefle sketched on it the  $\text{CH}_3$  structure that he attributed to the singlet on the NMR print-out. See Exhibit 3-12.

50. Dr. Hoefle also drew a more complete picture of the molecular structure of the RP-2 material on the COSY NMR spectrum, which shows in addition to the structure of the  $-\text{CH}=\text{CHCH}_3-$  group that replaced the epoxide group, the surrounding partial structures of epothilone. Exhibit 3-12.

51. The RP-2 eluent material, which Dr. Hoefle structurally characterized in the manner explained above, is the material that Dr. Hoefle and Mr. Steinmetz named “epothilone D.”

52. As to the eluent material identified as RP-1, Dr. Hoefle noticed from the chromatograph (Exhibit 3-11) that it sat on a broader peak, which would suggest that it was mixed with other material.

53. Accordingly, Dr. Hoefle directed that the material RP-1 be further purified, and Ms. Pohlan subjected sample RP-1 to separation on silica gel plate. Exhibit 3-13.

54. Ms. Pohlan then used a thin layer chromatographic technique to analyze the resultant RP-1/DC, (DC means purified by thin-layer chromatography), and recorded that it exhibited a single band only, indicating a purified product. Id.

55. The next day, Ms. Pohlan submitted the purified sample of RP-1 for NMR proton analysis, and the resultant NMR was given Spectrum no. 2630. Exhibit 3-15.

56. Ms. Pohlan showed the NMR print-out for sample RP-1 to Dr. Hoefle, and he was immediately able to characterize the structure of the material, which he drew on the right-hand side of the NMR print-out. Exhibit 3-15.

57. The RP-1 eluent material, which Dr. Hoefle structurally characterized in the manner explained above, is the material that Dr. Hoefle and Mr. Steinmetz named “epothilone C.”

58. A departmental meeting was held which was attended by a number of people, including Drs. Hoefle, Reichenbach, Sasse and Mr. Steinmetz and was recorded in Meeting Minutes prepared by Dr. Reichenbach. Exhibit 3-16.

59. At the meeting, Dr. Gerth, Mr. Steinmetz and Dr. Sasse reported to the attendees the following:

The strains So cel198, So cel275 and So cel294 form two new epothilones as well as epthilone, but with the epoxide missing (Gerth, Steinmetz). They had considerably reduced action, but were not abolished: the IC50 for L929 cells was 150 ng/ml for RP1 (from So cel198), and 100 ng/ml for RP2. Noticeable effect on Tubulin could be detected in cell cultures. (Sasse)  
Perhaps patenting is possible?

Exhibit 3-16 (English translation).

60. Notably, the above, initial work was completed using strains So cel198, 1275 and 1294. Further isolation work of epothilone C and D was then conducted using a variant or mutant strain of *Sorangium cellulosum*, So ce90. The wild version of So ce90 had previously been deposited with the German Collection for Microorganisms ("Deutsche Sammlung von Mikroorganismen") as DSM 6773.

61. A number of cultures were prepared from DSM 6773. These cultures, which were called "clones" generally do not have the same population mixture or production profile as DSM 6773.

62. In particular, So ce90 A3, which based on earlier work was known to be a good producer of epothilone A and epothilone B, was used for this further isolation work since its production profile was similar to that of So cel198. Ms. Fischer recorded

the preparation of cultures medium for 15 L and 150 L fermentors (having working volumes of 10 L and 100 L respectively). Exhibits 4-10 to 4-12. The details and monitoring of these fermentations were also recorded, including a description of the fermentation medium used. Exhibits 4-13 to 4-26.

63. The product of these fermentations was then used to charge a 750 L fermenter. The details and monitoring of this fermentation was also recorded, including a description of the fermentation medium used. Exhibit 4-27 to 4-34.

64. The harvest of this fermentation was then undertaken by recovering the XAD absorber resin from the 750 L fermenter, filtering the absorber resin, (Exhibit 4-35 to 4-36); eluting the absorber resin with methanol, (Exhibit 4-37 to 4-38); concentrating the eluent by evaporation to a 20 L concentrate, (Exhibit 4-39 to 4-40); performing an ethyl acetate extraction, (Exhibit 4-41 to 4-42); and then subjecting the extract to rotary evaporation to yield crude extract, (Exhibit 4-43 to 4-44).

65. The crude extract was next tested for the presence of epothilone A, B, C and D. See Exhibits 4-45 to 4-49, particularly the mass spectrometer results shown in Exhibit 4-49, which depict the peaks indicative of the presence of these species.

66. The crude extract was then dried, distributed between methanol and heptane (the heptane was discarded), (Exhibit 4-50 to 4-51); and passed through a Sephadex LH20 chromatographic column, (Exhibit 4-52). Fractions were collected and utilized for further analysis. Exhibits 4-53 to 4-57. Again, the mass spectrometer results shown in Exhibit 4-57 exhibited peaks indicating epothilone A, B, C and D were present.



67. A reverse phase chromatography was next performed using fractions 6-12. Exhibits 4-58 to 4-60. A UV absorbance analysis indicated that fractions 8-12 contained epothilone A and B. Exhibits 4-61 to 4-63. Fraction 24, on the other hand, was subject to HPLC MS analysis, and was found to exhibit a peak indicating the presence of epothilone C. Exhibit 4-64. Similarly, fraction 28 was found to exhibit a peak indicating the presence of epothilone D. Exhibit 4-66. Mass spectrometer analyses confirmed these results. Exhibits 4-65, 4-67.

68. The epothilone C and D in the fractions referenced above were next purified using reverse phase RP-18 chromatography, and then analyzed. Exhibits 4-68 to 4-75. In particular, fraction RP-1 was subjected to UV absorbance analysis and exhibited a clean peak, indicating that it contained pure epothilone D. Exhibit 4-74. Fraction RP-2, which was epothilone C, was subject to TLC analysis. That analysis showed it to be free of trace contaminants. Exhibit 4-71.

69. There followed an NMR analysis of fraction RP-2, which confirmed the peaks as those of epothilone C. Exhibit 4-78 to 4-91. An NMR analysis was also conducted of fraction RP-1, which confirmed the peaks as those of epothilone D. Exhibit 4-92 to 4-105.

70. The data from the tests run with the So ce90 A3 clone were then used to prepare Example 1 in the subject application. Thus, the data reported in Example 1 were not generated with DSM 6773, and DSM 6773 was erroneously listed in the application as the starting material.

71. To demonstrate that wild strain DSM 6773 produces epothilones C and D, the strain DSM 6773 was ordered in 2005 and the production process as reported in the subject application was followed to generate and isolate epothilones C and D. These experiments are described at page 5 of the accompanying document, titled "Reply to the Opposition Statement against EP-B-1186606." (For completeness of the record, "epothilones A and B" at page 6, line 6 therein should read --epothilones C and D--.) The experiment produced 1.4 mg epothilone C and 0.5 mg epothilone D as reported in the attached Reply.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

  
\_\_\_\_\_  
Gerhard Hoefle

Date: June 10, 2008

Evidence for the discovery of epothilones C and D from *Sorangium cellulosum* at the GBF in early [REDACTED]

No.	Date of document	Type of document	Operation, Results
1.	[REDACTED]	Screening record	<i>Sorangium cellulosum</i> , strain So cell198 produces two new epothilones
2.	[REDACTED]	Screening record	HPLC sample preparation
3.	[REDACTED]	HPLC/DAD chromatogram	Two minor components identified as new lipophilic epothilones
4.	[REDACTED]	Sampling record	Sample given to H. Steinmetz for HPLC/MS analysis
5.	[REDACTED]	HPLC/MS chromatogram	The new epothilones contain one oxygen less than epothilones A and B
6.	[REDACTED]	Record of project meeting No. 230	Two new epothilone homologues with one oxygen less than epothilones A and B
7.	[REDACTED]	Isolation record	TLC and Sephadex LH 20 chromatography, enriched fraction
8.	[REDACTED]	LH 20 chromatogram	Separation of crude extract
9.	[REDACTED]	Analytical HPLC	The two new epothilones localised (X)
10.	[REDACTED]	Separation record	Fractions RP1 (0.7 mg) and RP2 (1.0 mg) isolated
11.	[REDACTED]	RP18 chromatogram	Separate peaks for RP1 and RP2
12.	[REDACTED]	NMR Spectra	<sup>1</sup> H and COSY spectra prove that RP2 is an epothilone with a methyl substituted 12,13 double bond later named epothilone D
13.	[REDACTED]	TLC	Purification of fraction RP1 to give RP1/DC
14.	[REDACTED]	Flow diagram	Origin of the two new epothilones (C and D)
15.	[REDACTED]	NMR spectra	<sup>1</sup> H spectrum proves that RP1/DC is an epothilone with a 12,13 double bond later named epothilone C
16.	[REDACTED]	Record of project meeting No. 231	The two new epothilones show reduced cytotoxicity and tubulin activity

# Exhibit 3-1

1

EXHIBIT A

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

  
\_\_\_\_\_

Date: 5. August 2003

Table 1

Strain: 1198 - 45/30	Aim: Screening	Growth	Liquid culture	Growth
Received on: [REDACTED]	Inoculated on heso: [REDACTED]	good	Inoculated in 50 ml heso: [REDACTED]	good
Preserved:	Inoculated on propion: [REDACTED]		Inoculated in 50 ml propion (German assumed to be misspelled): Inoculated in 250 ml S : [REDACTED]	moderate
			Inoculated in 3 x 250 ml am (formate?): [REDACTED]	
			Medium 360: 1st flask very dark, Medium propion (German assumed to be misspelled): Medium heso:	Harvest: 30.4 2nd flask good
Screening on:				
	Inhibition dil. step:			
E.coli			HPLC	Substances
Micrococcus			Method screen 1	
Staph				
Nocardia				
Mucor			Method screen 2	
Hansenula				
Candida				
Schizo				
Rhodotorula				
			Special comments:	

No b. ser.  
sample was  
prepared by  
Herr  
Steinmetz!

13.282 HP  
14.584 NP  
20.204 + 21.458 NP

Epothione A  
Epothione B  
Unknown epo



# Exhibit 3-2



2

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

RRichards

Date: 5. August 2003

Monda

- Sample from F100 fetched, microscope inspection → OK  
Can be inoculated
- Protocol for fermentation comp. 55 taken to Herr Schüller,  
Flask order to Frau Heiber.
- Medium + XAD from Ratjadon – fermentation taken to Herr Ebert
- Strain cultures inoculated + for fermentation
- Antifoam flask + alkali flask autoclaved, antifoam sterilised in drying cupboard →  
transferred/decanted (sterile)
- Sample from F900 checked → OK
- 1 litre P medium boiled; E medium → thorax treatment → autoclaved.

2

100% gluc - 0% H<sub>2</sub>O  
    \        /  
      35% gluc  
      /        \  
35 ml gluc    65 ml H<sub>2</sub>O = 100 ml  
3 times amount added    —    300 µl / 50 ml P medium

Tue

- Screening - strains : Harvest!  
1198 – 45/30, 1230, 1233, 1235 :
- 7.30 - sample removed, preparation as for HPLC →  
take methanol flask to Herr Steinmetz →  
carries out analysis
- check other fermentation protocols
- HPLC of Soce90 clone (medium with skimmed milk from KS)
- 2 new screening - strains prepared in 10 ml H medium : Soce1266 + 1257
- For fermentor : Soce360A1 further inoculated / 6 flasks available  
                              : Soce 1149    "        "        / 3 flasks available

Thu

- Fermentor sample : HPLC – preparation (Herr Steinmetz)
- Screening – strains -- analysis (1198 – 45/30; 1227; 1230; 1233; 1235; 1251)
- Protocol 44 – first evaluation
- Fermentor protocols : sterility check, further inoculation
- Mon, Soce 1149 3 flasks, further inoculation → 6 flasks
- Fri, Soce 360A1 1,5 litres in inoculation flask → inoculation deadline 10.15



# Exhibit 3-3

Epo unknown  
Epo unbekannt


Injection Date : 01/13/88 13:38:30  
Sample Name : 1198-45/30  
Acq. Operator : Gerth

Seq. Line : 1  
Vial : 0  
Inj : 1  
Inj Volume : 10 µl

Sequence File : C:\HPCHEM\1\SEQUENCE\DEF.LC.S  
Method : C:\HPCHEM\1\METHODS\SCREEN1.M  
Last changed : 01/12/88 12:36:13 by Gerth  
Screening 1 Methode

Instrument Conditions: At Start At Stop  
Temperature: 39.8 39.8 °C  
Pressure: 190.0 213.0 bar  
Flow: 0.500 0.500 ml/min

Solvent Description :  
LC, Solvent A : Wasser  
LC, Solvent B : Methanol



## Area Percent Report

Sorted by Signal

Multiplier : 1.000000  
Dilution : 1.000000


Signal 1: DAD1 A, Sig=300,200 Ref=598,4

Peak #	RT [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.544	BB	0.208	580.48407	37.79762	2.0091
2	3.447	BB	0.380	6948.34668	277.56702	24.0491
3	4.922	BB	0.443	3222.51660	111.79380	11.1535

RT [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
8.715	BB	0.689	1983.70227	39.05926	6.8658
10.388	BB	0.513	3327.00781	91.31287	11.5152
11.921	BB	0.400	344.29031	11.95683	1.1916
13.282	BB	0.466	6934.54688	215.95573	24.0013
14.584	BB	0.355	3090.42578	125.53922	10.6963
17.392	BB	0.289	759.20789	37.43296	2.6277
18.577	BB	0.231	320.88089	20.30108	1.1106
20.207	BB	0.265	701.43530	37.26771	2.4278
21.458	BB	0.228	453.19839	28.68863	1.5686
42.724	BB	0.213	226.30806	17.73971	0.7833

Totals : 28892.35156 1052.41248


Peak :1 at 2.544 min Name : ?



-> The purity factor exceeds the thres

Purity factor : 796.557 (100%  
of spectra)  
Threshold : 990 (Set by user)  
Reference : Peak Apex  
(integrated) (2.545167)  
Spectra : 2 (Selection  
automatic, 3)


Peak :2 at 3.447 min Name : ?



-> The purity factor exceeds the thres

Purity factor : 842.491 (100%  
of spectra)  
Threshold : 990 (Set by user)  
Reference : Peak Apex  
(integrated) (3.444667)  
Spectra : 2 (Selection  
automatic, 3)


Peak :3 at 4.922 min Name : ?



-> Not enough data for purity calculat

Purity factor : Not available  
Threshold :  
Reference : Peak Apex  
(integrated) (4.925)  
Spectra : 1 (Selection  
automatic, 3)


Peak :4 at 8.715 min Name : ?



-> Not enough data for purity calculat

Purity factor : Not available  
Threshold :  
Reference : Peak Apex  
(integrated) (8.719333)  
Spectra : 1 (Selection  
automatic, 3)

Peak :5 at 10.388 min Name : ?




-> Not enough data for purity calculat

Purity factor : Not available  
Threshold :  
Reference : Peak Apex  
(integrated) (10.38833)  
Spectra : 1 (Selection  
automatic, 3)




Peak :6 at 11.921 min Name : ?



-> Not enough data for purity calculation

Purity factor : Not available  
 Threshold :  
 Reference : Peak Apex  
 (integrated) (11.91916)  
 Spectra : 1 (Selection  
 automatic, 3)


Peak :7 at 13.282 min Name : ?



-> The purity factor is within the threshold

Purity factor : 999.671 (100%  
 of spectra)  
 Threshold : 990 (Set by user)  
 Reference : Peak Apex  
 (integrated) (13.28033)  
 Spectra : 2 (Selection  
 automatic, 3)  
 Warning : Spectral  
 absorbances > 1000 mAU


Peak :8 at 14.584 min Name : ?



-> The purity factor is within the threshold

Purity factor : 999.896 (100%  
 of spectra)  
 Threshold : 990 (Set by user)  
 Reference : Peak Apex  
 (integrated) (14.5725)  
 Spectra : 2 (Selection  
 automatic, 3)


Peak :9 at 17.392 min Name : ?



-> The purity factor is within the threshold

Purity factor : 997.584 (100%  
 of spectra)  
 Threshold : 990 (Set by user)  
 Reference : Peak Apex  
 (integrated) (17.38966)  
 Spectra : 2 (Selection  
 automatic, 3)


Peak :10 at 18.577 min Name : ?



-> The purity factor exceeds the threshold

Purity factor : 922.261 (100%  
 of spectra)  
 Threshold : 990 (Set by user)  
 Reference : Peak Apex  
 (integrated) (18.57533)  
 Spectra : 2 (Selection  
 automatic, 3)


Peak :11 at 20.207 min Name : ?



-&gt; The purity factor is within the thr

Purity factor : 994.925 (100%  
of spectra)  
Threshold : 990 (Set by user)  
Reference : Peak Apex  
(integrated) (20.2055)  
Spectra : 2 (Selection  
automatic, 3)


Peak :12 at 21.458 min Name : ?



-&gt; Not enough data for purity calculat

Purity factor : Not available  
Threshold :  
Reference : Peak Apex  
(integrated) (21.45866)  
Spectra : 1 (Selection  
automatic, 3)

Peak :13 at 42.724 min Name : ?



-&gt; Not enough data for purity calculat

Purity factor : Not available  
Threshold :  
Reference : Peak Apex  
(integrated) (42.72333)  
Spectra : 1 (Selection  
automatic, 3)

\*\*\* End of Report \*\*\*

# Exhibit 3-4

4

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

  
\_\_\_\_\_

Date: \_\_\_\_\_

S. Hughes 2003

[page of handwritten notes]

4

- Soce 660 Epo

H (only survivors inoculated) very good

(illegible comment in margin) H very good

H very good

HPLC, Tues. 21.5

Tues. [REDACTED]

- HPLC of different samples or cultures
- New : prepare in liquid culture + plate :  
Soce 1241 sci.  
1198 - 45/30 several plates  
1199  
471 Epo  
523 Epo  
613 Epo

- Check Soce's on plate - mould?
- Plates from protocol 44 cleared away into cool room
- 20 ml Soce 1198 - 45/30 given to Herr Steinmetz in HPLC tube for analysis

PROTOCOL 45 STILL HAS TO BE CARRIED OUT USING SOCE 1198 - 45/30 !

ALSO PROTOCOL 37 ! ALSO PROTOCOL 44 !

- Protocol 37 :

Boil 1.5 litres E medium

E medium for 1500 ml :

0.4%	skimmed milk KS	6g
0.2%	yeast extract	3g
1%	starch	15g
0.1%	CaCl <sub>2</sub>	1.5g
0.1%	MgSO <sub>4</sub>	1.5g
50mM	hepes	17.85g
8 mg/l	Fe EDTA	12mg

PH 7.4

After autoclaving in the thorax the runny skimmed milk homogenises.

Divide up into 30 x 50 ml portions in 250ml flasks + 1 ml XAD per flask each time.

Inoculate Soce 90 clone , Soce 950 Epo + Soce 660 Epo  
25 ml of each culture are required !

Addition of malonic acid diamide (malonamide) + succinate

- Soce 660 Epo  
H (nur überstand: überimpft) sehr gut  
H sehr gut  
H sehr gut

4

HPLC, Di 21.8.

- HPLC von verschiedenen Proben bzw. Kulturen

- Geü. ansetzen in Flüssigkultur + Platte:

Soce 1241 Scr.  
1198-45/30 mehrere Platten  
1199  
471 Epo  
523 Epo  
613 Epo

- Kontrolle der Soce's auf Platte — Pilze?

- Platten vom Protokoll 44 in den Kühlraum geräumt

• 20ml in HPLC-Röhrchen gegeben von Soce 1198-45/30 für H.-Stemmreihe zur Analyse

PROTOKOLL 45 MUSS NOCH MIT SOCE 1198-45/30 DURCHGEFÜHRT WERDEN.  
PROTOKOLL 37 AUCH! PROTOKOLL 44 AUCH!

- Protokoll 37

1.5 l E-Med. Kulturen

E-Medium für 1500 ml

0,4 l. Nagermilch ES	6 g	} PH 7,4
0,2 l. Yeast extract	3 g	
1 l. Stärke	15 g	
0,1 l. CaCl <sub>2</sub>	1,5 g	
0,1 l. MgSO <sub>4</sub>	1,5 g	
SDMH Hepes	17,85 g	
8mg/ml Tris-EDTA	12mg	

nach dem Autoklavieren im Thermo die gesamte Nagermilch hinzugeben  
auf 30 250 ml Kolben  
250 ml aufkochen + je 15 ml XAD/Kolbe

Soce 90klon, Soce 950 Epo + Soce 660 Epo animpfen.  
Von jeder Kultur werden 25 ml benötigt.

(Malonat)  
Zugabe von Malonsäurediamid + Succinat (Brenztraubensäure)

# Exhibit 3-5

Epo new.  
Epo neu  
Epo new  
Epo neu







Data File name: C:\HPCHEM\1\DATA\M11W004\AS000000~

Method name: C:\HPCHEM\1\METHODS\ISO1.M


16.18 19416.5




17.11 2073.1




18.24 3374.3




18.59 3811.6




18.93 7105.5




19.24 10912.9



21.38 7113.0



23.48 47866.2




Epo A

Data file name: C:\HPCHEM\1\DATA\MITTWOCH\HS00000->


Method name: C:\HPCHEM\1\METHODS\ISO1.M

24.29 21613.5




E<sub>10</sub>B

25.37 2684.5




29.25 4218.0




E<sub>10</sub> uen  
(M<sub>2</sub> = -16)

30.57 2971.2




E<sub>10</sub> uen  
(M<sub>2</sub> = -16)


33.39 2040.5




36.36 10485.2




39.41 5935.8




Plot of TIC from So 1198/2. pos




Plot of "Device A" from So 1198/2. pos




Plot of Spectrum from 23:38 min (8 scans) from So 1198/2. pos,




Plot of Spectrum from 24:18 min (6 scans) from So 1198/2. pos,




Plot of Spectrum from 29:15 min (9 scans) from So 1198/2. pos,



Plot of Spectrum from 30:49 min (9 scans) from So 1198/2. pos,



Plot of Spectrum from 36:19 min (12 scans) from So 1198/2. pos, subtracted



# Exhibit 3-6

6

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

  
\_\_\_\_\_

Date: \_\_\_\_\_

S. Hugen Se 2003

Minutes no. 230 of meeting held at 09.00 on [REDACTED]

Present: Frau Kunze, Herr Augustiniak, Forche, Gerth, Höfle, Irschik, Jansen (not full time due to EDP Committee), Reichenbach, Sasse, Steinmetz, Washausen.

**Epothilone** (Reichenbach): During a visit to **Asta Medica**, first test results were presented. They showed that epothilone A and B had similar or better action than Taxol on four selected tumor cell lines. Epothilone B was up to ten times more potent. The LD<sub>50</sub> in mice was determined to be ca. 100 mg/kg. In the case of a rapidly growing leukemia, a therapeutic dose of 20 - 30 mg/kg was able to achieve approximately 40% prolongation of life, a value similar to that of the standard cyclophosphamide. There is great interest in testing epothilone further and developing it as a cytostatic agent. Preclinical trials would require 10 - 20 grams of substance, and ca. 100 g - 1 kg would be required up to clinical phase II. Authorisation could be applied for in three years in most favourable circumstances.

Testing of epothilones at **Boehringer Mannheim** has been delayed due to their tumor research being transferred to Italy. Nonetheless 100 mg of Epo A has been supplied, with which an in-vivo study in Mannheim will be run in parallel. **Bayer AG** has also expressed interest in epothilone and received 10 mg Epo A for initial trials. They are not primarily interested in using the natural product, but in derivatives for drug targeting. **Behringwerke** became aware of epothilone from a newspaper article and will be getting in touch with us shortly. Following a suggestion from Prof. Flohé, the US company **Sugen** has requested and already received 2 mg epothilone. **Bristol-Meyers-Squibb** has made an order for 100 mg epothilone. The state of testing at **Upjohn-Pharmacia** is not known. According to information from various sources, **Merck**, **Sharp** and **Dohme** stopped work on epothilone some time ago. **Ciba-Geigy** continues to express interest but has not yet made any definite orders.

**Ciba test results** (Reichenbach): Testing of Condramid is complete, the results do not require further work and the substance will shortly be released. The second attempt to carry out testing of Thuggacine against *Mykobakterium tuberculosis* in England again went wrong. Ciba will provide further material from its own supplies.

**Epothilone** (Steinmetz): Stocks of A/B mixture have decreased to 0.4 g after 100 mg were again used for derivatisation. The mixture needs further cleaning before using for test purposes. About 1-2 g epothilone mixture are available as raw extract.

**Epothilone** (Gerth): A 700 litre F-24 fermentor was run with So ce90 under sterile conditions but hardly produced anything. It was channelled using 0.5 mg/l epothilone and 6 - 7 mg Spirangien. The preculture for this fermentor had produced ca. 20 mg/l epothilone according to expectations, however. Another fermentor for producing epothilone using strain So ce660 is planned to run next week. This strain only produces Epo A and Spirangiens. We have now been successful in plating strain So ce90. As already discovered for other strains, 10% of an old autoclaved culture has to be added to the strain. The usual procedures for optimising the strain can now be implemented.

It is very important that we should try to incorporate butyrate instead of acetate and propionate in the epoxide area, following the concept of mutasynthesis. The resulting ethyl analogue of epothilone could be more biologically active and would be patentable (ask Herr Boeters).

The following strains have been identified as new epothilone producers: So ce611, So ce498, So ce931, So ce618, So ce414, So ce320 and So ce1087. All these strains are less effective producers and also form Spirangins or Icumazole. An exception is strain So ce1198, which in addition to epothilones A and B also produces a small quantity of an unknown substance with two peaks in the uV spectrum that are more lipophilic than the epothilones. According to HPLC/MS studies carried out by Herr Steinmetz, the substance is composed of homologues ( $\Delta M 14^*$ ) possessing one oxygen less than epothilone A and B. There were ca. 1-2 mg of the new epothilones present in the shaken culture. They should be isolated individually or as a mixture. According to the NMR measurement, a biological test should be carried out. While optimising the media, the strains So ce90, So ce660 and So ce950 were cultivated in 10 different media. There were significant variations in growth and production between different strains.

\* (handwritten note)  $\Delta M 14$  is typing mistake, should be  $\Delta M 16$



6

Vertraulich

## Protokoll Nr. 230 der Besprechung vom [REDACTED], 9.00 Uhr

Teilnehmer: Frau Kunze, die Herren Augustiniak, Forche, Gerth, Höfle, Irschik, Jansen (zeitweise wegen EDV-Kommission), Reichenbach, Sasse, Steinmetz, Washausen.

**Epothilon (Reichenbach):** Bei einem Besuch bei der Asta Medica wurden erste Versuchsergebnisse vorgestellt. Danach wirken Epothilon A und B bei vier ausgewählten Tumorzelllinien ähnlich oder besser als Taxol. Epothilon B erwies sich dabei bis zu 10x aktiver. Die LD<sub>50</sub> in der Maus wurde zu ca. 100 mg/kg bestimmt. Im Fall einer schnell wachsenden Leukämie konnte mit einer therapeutischen Dosis von 20 - 30 mg/kg eine ca. 40%ige Lebensverlängerung erzielt werden, ein Wert, der dem Standard Cyclophosphamid entspricht. Es besteht großes Interesse, Epothilon exklusiv weiter zu testen und als Cytostatikum zu entwickeln. Für Vorklinische-Versuche würden 10 - 20 Gramm Substanz, bis zur klinischen Phase II, ca. 100 g - 1 kg benötigt. Eine Zulassung könnte im günstigsten Fall in drei Jahren beantragt werden.

Bei Boehringer Mannheim hat sich die Testung der Epothilone verzögert, da die Tumorforschung nach Italien verlegt worden ist. Es wurden jedoch 100 mg Nachsubstanz Epo A geliefert, mit denen parallel eine in-vivo Studie in Mannheim durchgeführt wird. Die Bayer AG hat ebenfalls Interesse an Epothilon bekundet und für erste Versuche 10 mg Epo A erhalten. Dort ist man nicht an der Anwendung des Naturstoffs primär interessiert, sondern an Derivaten im Sinne von Drug-Targeting. Die Behringwerke sind durch einen Zeitungsartikel auf Epothilon aufmerksam geworden und werden demnächst mit uns Kontakt aufnehmen. Auf einen Hinweis von Prof. Flohé hat die Firma Sugan (USA) um 2 mg Epothilon A gebeten und es bereits bekommen. Von Bristol-Meyers-Squibb liegt eine Bestellung für 100 mg Epothilon vor. Der Stand der Testung bei Upjohn-Pharmacia ist nicht bekannt. Nach Informationen aus verschiedenen Quellen hat Merck, Sharp and Dohme die Bearbeitung von Epothilon bereits seit längerer Zeit aufgegeben. Ciba-Geigy ist weiterhin interessiert, allerdings ist bis jetzt keine konkrete Substanzbestellung eingegangen.

**Testergebnisse Ciba (Reichenbach):** Die Testung von Condramid ist abgeschlossen, die Ergebnisse rechtfertigen keine weitere Bearbeitung, und die Substanz wird demnächst frei-

gegeben. Auch beim zweiten Anlauf ist die Testung des Thuggacins gegen *Mycobacterium tuberculosis* in England schiefgegangen. Die Ciba wird Nachsubstanz aus dem eigenen Vorrat bereitstellen.

**Epothilon** (Steinmetz): Der Vorrat an einem A/B-Gemisch ist auf 0,4 g geschrumpft nachdem für die Derivatisierung wieder 100 mg verbraucht worden sind. Für eine Abgabe zu Testzwecken muß das Gemisch noch weiter gereinigt werden. Als Rohextrakt liegen ca. 1-2 g Epothilongemisch vor.

**Epothilon** (Gerth): Ein 700 l Fermenter F-24 mit Soce 90 ist steril gelaufen, hat jedoch kaum produziert. Er wurde bei 0,5 mg/l Epothilon und 6 - 7 mg Spirangien kanalisiert. Die Vorkultur für diesen Fermenter hatte allerdings mit ca. 20 mg/l Epothilon erwartungsgemäß produziert. Nächste Woche soll ein weiterer Fermenter zur Herstellung von Epothilon mit Stamm Soce 660 laufen. Dieser Stamm produziert nur Epo A und Spirangle.

Es ist jetzt gelungen den Stamm Soce 90 zu plattieren. Dazu muß, wie bereits früher bei anderen Stämmen gefunden, 10% einer alten, autoklavierten Kultur des Stammes zugegeben werden. Damit können nun die üblichen Verfahren zur Stammoptimierung eingesetzt werden.

Sehr wichtig ist es, u.a. zu versuchen, im Sinne einer Mutasyntese statt Acetat und Propionat im Bereich des Epoxids Butyrat einzubauen. Das resultierende Ethylanaloge Epothilon könnte biologisch aktiver sein und wäre patentierbar (bei Herrn Boeters nachfragen).

Als neue Epothilonproduzenten wurden identifiziert: Soce 611, Soce 498, Soce 931, Soce 618, Soce 414, Soce 320 und Soce 1087. Alle diese Stämme sind schlechtere Produzenten und bilden daneben Spriangiene oder Icumazole. Eine Ausnahme bildet der Stamm Soce 1198 der neben Epothilon A und B eine unbekannte Substanz und in geringer Menge zwei lipophilere Peaks mit dem UV-Spektrum der Epothilone. Nach HPLC/MS -Untersuchungen von Herrn Steinmetz handelt es sich dabei um Homologe ( $\Delta M 14$ ) die einen Sauerstoff weniger als Epothilon A und B besitzen. In der vorliegenden Schüttelkultur liegen ca. 1-2 mg der neuen Epothilone vor. Sie sollen einzeln oder als Gemisch isoliert werden. Nach der NMR-Messung soll ein biologischer Test versucht werden.

Bei einer Medienoptimierung wurden die Stämme Soce 90, Soce 660 und Soce 950 in 10 verschiedenen Medien kultiviert. Die Variation von Wachstum und Produktion waren groß und bei den einzelnen Stämmen unterschiedlich.

*AM14 ist  
schreibfehler  
muß  $\Delta M 16$   
sein*

# Exhibit 3-7

7

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

  
\_\_\_\_\_

Date: S. August 2003

Soce 1198 - 45/30 / Screening / [REDACTED]

MeOH - extract : Weight: 198g *mg*

7

(Illegible)

(Illegible)

(HPLC Test Result)

(HPLC Test Result)

95 CH<sub>2</sub>Cl<sub>2</sub> / 5 MeOH

95 CH<sub>2</sub>Cl<sub>2</sub> / 5 MeOH

→ LH-20 - Separation

Column = LH-20,  $\approx 70$  cm long, diam. 1.5 cm

Solvent = MeOH,  $\lambda = 227$  nm

Flow = 1.4 ml / min, Range = 0.1 -

Paper = 2mm / min, Fractionation time = 3 min

Fractionation

LH-1 = gl. 1-9 =

HPLC

LH-2 = gl. 10-17 = Weight 82mg

HPLC

LH-3 = gl. 18-23 =

HPLC

LH-4 = gl. 24-30 =

HPLC

LH-5 = gl. 31-41 =

HPLC

LH-6 = gl. 42-51 =

HPLC

---

→ RP separation [REDACTED]

---

---

discarded

---

---


Soce M98-45130 / Screening

*Sorangium cellulosum*

Soce M98-45130  
Screening: 02.05.96  
K. Riedl

MeOH-Extrakt: Gewicht: 198 mg

7



→ LH-20-Trennung

Säule = LH-20, ≈ 70 cm lang, Ø 1,5 cm

LM = MeOH,  $\lambda = 227 \text{ nm}$

Fluss = 1,4 ml/min, Range = 0.1-

Papier = 2 mm/min, Fraktionszeit = 3 min

Fraktionierung

LH-① = 6.1-9 =  
HPLC

LH-② = 6.10-17 = Gewicht 82 mg → RP-Trennung

LH-③ = 6.18-23 =  
HPLC


LH-④ = 6.24-30 =  
HPLC

LH-⑤ = 6.31-41 =  
HPLC

LH-⑥ = 6.42-51 =  
HPLC

unverfärbt

# Exhibit 3-8





# Exhibit 3-9

Sample: Sol198 LH 2

Report Method: Spectrum\_Index\_Plot


Printed: 3/1/98

Page: 1 of 1

Project Name: Silke 1  
 Sample Name: Sol198 LH 2  
 Date Acquired: 12.06.96 10:57:38  
 Date Processed: 12.06.96 11:59:31  
 SampleWeight: 1.00000  
 Dilution: 1.00000  
 Channel: 996 PDA 210.0 nm  
 Acq Meth Set: Sora\_MS\_210nm  
 Processing Method: Epothilon\_210\_PM

Sample Type: Unknown  
 Vial: 3 Inj. 1  
 Volume: 3.00  
 Run Time: 20.0 min  
 Laufmittel: 76MeOH/24H2O, NH4Ac

9



# Exhibit 3-10

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

  
\_\_\_\_\_

Date: 5. August 2003

RP separation of So1198 – LH-2

So1198 LH-2 Weight: 82mg separated in 2 runs

Column = Nucleosil 100 C18, 7 $\mu$ m , 20 x 250 mm

Solvent = 73 MeOH / 27 H<sub>2</sub>O +0.05M NH<sub>4</sub>Ac

$\lambda$  = 210 nm , Range = 016 - 128

Pump = 200 , Paper = 5 mm/ min

Fractions concentrated up to H<sub>2</sub>O phase, extracted 2 x with EE, EE phase washed with H<sub>2</sub>O and dried with Na<sub>2</sub>SO<sub>4</sub>.

(Test Result)

95 CH<sub>2</sub>Cl<sub>2</sub> / 5 MeOH

Sprayed with vanillin – H<sub>2</sub>SO<sub>4</sub>

Epo A/B = 2mg/ml

Fractionation

So1198 – RP –1 = Weight 0.7 mg , NMR 002549 , .. 660 ..

→ 0.1 mg 2nd test 150 ng/ ml

→ prep. DC 19.6.96

So 1198 – RP –2 = Weight: 1.0 mg, NMR 002550, .. 661 ..

COSY

→ 0.1mg 2nd test 100 ng/ml

## RP-Trennung von So.1198-LH-(2)

10

So.1198-LH-(2) = Gewicht: 82mg in 2 Säufen getrennt  
Säule = Whelcoil 100 C18, 7µm, 120x250mm  
LM = 73 MeOH 127 H<sub>2</sub>O J+0,05M NH<sub>4</sub>Ac  
λ = 210nm, Range = 016 - 128  
Pump = 200, Papi = Sumulin

Fractionen bis zu H<sub>2</sub>O-Phase injiziert, 2x mit  
EE extrahiert, EE-Phase mit 60 gewaschen und mit  
Na<sub>2</sub>SO<sub>4</sub> getrocknet.



angespült mit Vanillin-H<sub>2</sub>SO<sub>4</sub>

Epo AIB = 2mg/ml

### Fractionierung:


~~So.1198-RP-(1)~~ = Gewicht: 0,7mg, NMR 002549, Ubr. 660gr  
→ 0,1mg 2. Test 150mg/ml  
→ inj. DC (13.6.96)

So.1198-RP-(2) = : 1,0mg, NMR 002550, Ubr. 660gr  
→ 0,1mg 2. Test 100mg/ml

# Exhibit 3-1 1

26271

73/1001  
27 (170) J-1000M UH4AC





# Exhibit 3-12

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

  
\_\_\_\_\_

Date: S. August 2003

11

NMR REQUEST  
GBF -- Dept. of Molecular structure research

Date received: [REDACTED]

Spectrum no. 002550

Substance name: So 1198 -- RP-2

Substance producer: Pohlaus

Dept.: NC (1.1-2) tel. 343

Nuclear species:  $^1\text{H}_1$

Amount of substance : 1.0 mg

Suitable solvent:  $\text{CD}_3\text{OD}$

Return substance? Yes

**General Information**

Store sample in fridge Y

Signal expected between

$\delta = 0$  and 9

Requested: only spectra Y  
plus integral Y

**Type of experiment**

$^1\text{H}_1$  Standard spectrum Y

**Plot and Data manipulation**

$\delta = 8.9$  to  $-0.1$  (0.15 ppm/cm) Y

Special requests: COSY Y

Measured on AM-300 Y

Filed under no. SIPZ 2550110/ + COSY

Einlieferungsdatum:                     

Spektr.-Nr.:

002550

## NMR-ANTRAG

GBF — Abt. Molekulare Strukturforschung

Substanz-Bez.: 51198-27-0Summenformel:                     Substanzersteller: PoliansAbteilung: NC (1.1-7)Tel.: 343Kernart (<sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P, andere?)                     Substanz-Menge: 1.0 mg, Molmasse:                     

geeignetes

Lösungsmittel: CD<sub>3</sub>OD weitere Messung  
nach Zugabe von                     Substanz zurück: ja ☒nein ☐Strukturvorschlag:                     Radioaktiv ☐Toxisch ☐

## Allgemeine Angaben

Probe lagern im Kühlschrank ☒im Tiefkühlfach ☐im Dunkeln ☐Probe auf Abruf beim Hersteller ☐

Signale erwartet zwischen

 $\delta$  = 0 und 9Gewünscht: nur Spektrum ☒plus Integral ☒Interpretation ☐Zahl der Akkumulationen (falls > 104):                     

## Art des Experiments

☒ <sup>1</sup>H Standardspektrum ☒Entkopplung ☐Differenz-NOE ☐Differenz-Entkopplung ☐Entkoppler-Frequenz(en):                     ☒ <sup>13</sup>C <sup>1</sup>H-Entkopplung:Breitband ☐selektiv ☐DEPT ☐ohne ☐

## Plot und Datenmanipulation

Gauss-Multiplikation ☐Linienausdruck ☐☒ <sup>1</sup>H $\delta$  = 8.9 bis — 0.1 (0.15 ppm/cm) ☒11.9 bis — 0.1 (0.2 ppm/cm) ☐

Drehungen:

10 Hz/cm ☐ von  $\delta$  =                      bis                     ☒ <sup>13</sup>Cnormal ( $\delta$  = 220 bis 0) ☐anderes Format:                     Sonderwünsche: COSY ☒<sup>13</sup>C — <sup>1</sup>H Korrel.Direkt ☐Long-range ☐gemessen auf ☒

AM-300

☐ ARX-400☐ DMX-600Bitte um Rücksprache ☐Kommentar:                     


(Nicht vom Antragsteller auszufüllen)

gespeichert unter Nr. 51225010in copy

(Unterschrift)



SIPZ2550 10 1 Pohlman












STPZ550 10 i Rohlan





# Exhibit 3-13

13

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.



---

Date:

S. August 2003

Preparative DC of Sol198 / RP-1

13

Sol198/ RP-1 = Weight = 0.6 mg put in  $\text{CH}_2\text{Cl}_2$

KG<sub>60</sub> F<sub>254nm</sub>, diam. 0.2 mm, Al foil, 7 x 7 cm

DC solvent = 95  $\text{CH}_2\text{Cl}_2$  / 5 MeOH

front

Bands cut out, extracted 3 x with MeOH in centrifuge tube, oil pump, absorbed in  $\text{CH}_2\text{Cl}_2$ , filtered through cotton wool, concentrated, oil pump

(Test result)

(254nm)

Sol198-RP-1 / DC Weight 0.4 mg, NMR 002630  
→ 0.1 mg 2nd test

(Test result)

Sprayed with  
vanillin -  $\text{H}_2\text{SO}_4$

Präparatives DC von 501198 RP-①


13

501198 RP-① = Gewicht: 0,6 mg in  $\text{CH}_2\text{Cl}_2$  aufgetragen  
KG 60 F25mm, Ø 0,2mm, Alufolie, 7x7cm  
DC-LM = 95  $\text{CH}_2\text{Cl}_2$  5  $\text{MeOH}$



Bande herausgeschnitten, mit  $\text{MeOH}$  in Fein-  
brüfugungsglas  $\text{I}_2$  erhalten,  $\text{MeOH}$ -Extrakt an-  
gedunstet, Ölumpump, in  $\text{CH}_2\text{Cl}_2$  aufgenommen,  
über Watte filtriert, eingedunstet, Ölumpump.

501198-RP-①/DC = Gewicht: 0,4 mg, NMR 200 2630  
→ 0,1 mg 2. Teil



angereichert mit  
Vanillin 6650g

# Exhibit 3-14



16

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

  
\_\_\_\_\_

Date: S. Heuger 8/2003

Soce 1198 - 45/30 / screening / [redacted]

from 5-10 subcultures [14]

Soce 1198 - 45/30 / screening / [redacted]

MeOH extract  
198 mg

from microalgae

LH-20 separation

LH-1  
discarded

LH-2  
82 mg  
Epo A,B + Epo un

LH-3, LH-4, LH-5, LH-6  
discarded

RP separation

See #9

See #10

RP-1  
0.7 mg  
NMR 002549  
Epo un

RP-2  
1.0 mg  
NMR 002550, COSY  
Epo un

Prep DC

not pure  
so further  
separation

#13

Rp-1 / DC  
0.4 mg  
NMR 002630  
Epo un

selects RP-2  
EPO D

→ EPOC

50a 1198-45130 Kernening

MeOH-Extrakt  
198 mg

CH-20-Trennung

CH-① Kernen  
CH-② 82 mg Epoxid, Epone  
CH-③ - CH-④ Kernen

RP-Trennung

RP-① 0,7 mg  
NMR 00 2549  
Epone  
RP-② 10 mg  
NMR 00 2550, 604  
Epone

purif. DC

RP-② DC  
0,4 mg  
NMR 00 2630  
Epone

# Exhibit 3-15

EXHIBITDECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and German languages and am a competent translator of German into English. I declare further that to the best of my knowledge and belief the following is a true and correct translation prepared and reviewed by me of the document in the German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of U.S. Patent Application Serial No. 09/313,524 or any patent issued thereon.



---

Date: 5. August 2003

**NMR REQUEST**  
GBF - Dept. of Molecular structure research

Date received: [REDACTED]

Spectrum no. 002630

Substance name: So 1198 - RP-1 / DC

Substance producer: Pohlaus

Dept.: NC (1.1-2) tel. 343

Nuclear species:  $^1\text{H}_1$

Amount of substance : 0.4 mg

Suitable solvent:  $\text{CD}_3\text{OD}$

Return substance? Yes

**General Information**

Store sample in fridge Y

Signal expected between

$\delta = 0$  and 9

Requested: only spectra Y

plus integral Y

**Type of experiment**

$^1\text{H}_1$  Standard spectrum Y

**Plot and Data manipulation**

$\delta = 8.9$  to  $-0.1$  (0.15 ppm/cm) Y

Filed under no. SIPR 2640\ ??

Einlieferungsdatum:                     Spektren-Nr.:                     

002630

## NMR-ANTRAG

GBF — Abt. Molekulare Strukturforchung

Substanz-Bez.: Se 1198 (RP-01DC)Summenformel:                     Substanzersteller: PoldansAbteilung: ML (A.A.2) Tel.: 343Kernart: (<sup>1</sup>H, <sup>13</sup>C, <sup>31</sup>P, andere?)                     Substanz-Menge: 0.4 mg, Molmasse:                     geeignetes Lösungsmittel: CD<sub>3</sub>OD weitere Messung nach Zugabe von                     Substanz zurück: ja ☒ nein ☐Strukturvorschlag:                     Radioaktiv ☐ Toxisch ☐

## Allgemeine Angaben

Probe lagern im Kühlschrank ☒im Tiefkühlfach ☐im Dunkeln ☐Probe auf Abruf beim Hersteller ☐Signale erwartet zwischen  $\delta =$  0 und 9Gewünscht: nur Spektrum ☒  
plus Integral ☒  
Interpretation ☐Zahl der Akkumulationen (falls > 104):                     

## Art des Experiments

☒ Standardspektrum ☒Entkopplung ☐ Differenz-NOE ☐Differenz-Entkopplung ☐Entkoppler-Frequenz(en):                     ☒ <sup>13</sup>C <sup>1</sup>H-Entkopplung:Breitband ☐ selektiv ☐DEPT ☐ ohne ☐

## Plot und Datenmanipulation

Gauss-Multiplikation ☐Linienausdruck ☐☒ $\delta =$  8.9 bis — 0.1 (0.15 ppm/cm) ☒11.9 bis — 0.1 (0.2 ppm/cm) ☐

Drehungen:

10 Hz/cm ☐ von  $\delta =$                       bis                     ☒ <sup>13</sup>C normal ( $\delta = 220$  bis 0) ☐anderes Format:                     Sonderwünsche: COSY ☐<sup>13</sup>C — <sup>1</sup>H Korrel. Direkt ☐ Long-range ☐

(Nicht vom Antragsteller auszufüllen)

gemessen auf ☐ AM-300gespeichert unter Nr. 5188800000☐ ARX-400☐ DMX-600Bitte um Rücksprache ☐Kommentar:                     

(Unterschrift)

50 1198.1  
RP-① DC

0.4mg

15

SIPR2630 10 1

Current Data Parameters  
NAME SIPR2630  
EXPNO 10  
PROCNO 1

F2 - Acquisition Parameters


Date\_ 11.39  
Time\_ 07:40  
INSTRUM 5 an QNP 1H  
PROBHD 5 an QNP 1H  
PULPROG zgpg30  
TD 32768  
SOLVENT MDSH  
NS 280  
DS 2  
SWH 8337.374 Hz  
FIDRES 0.254913 Hz  
AQ 1.8661300 sec  
RG 6496  
AQRES 60.000 usec  
DE 60.000 usec  
TE 300.2 K  
D1 1.00000000 sec  
D2 1.00000000 sec  
DE 60.000 usec  
D3 1.00000000 sec  
DE 60.000 usec  
SFO1 400.1324710 MHz  
NUC1 1H

F2 - Processing parameters

SI 12984  
SF 400.1298912 MHz  
WDW no  
SSB no  
GB 0.00 Hz  
PC 1.40

1D 1H NMR parameters

CH 4.00 usec  
FID 4.00 usec  
F1 1760.57 Hz  
F2 -0.100 ppm  
F3 0.000 ppm  
PPHCH 0.15000 ppm/c  
NUCH 60.01800 Hz/c






EP3C  
NMR Puzant -  
Amjinder

20.6.96

SIPR2630 10 1




Current Data Parameters  
NAME SIPR2630  
EXPNO 10  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 11.39  
Time 11.39  
INSTRUM spect  
PROBHD 5 mm QNP 1H  
PULPROG zgpg30  
TD 32768  
SOLVENT MeOH  
DS 2  
SS 8311.333 Hz  
FIDRES 0.254113 Hz  
AQ 1.9688351 sec  
RG 480  
DZ 62.000 usec  
DE 85.71 usec  
TE 300.2 K  
D1 1.6000000 sec  
P1 14.00 usec  
DE 85.71 usec  
TE 300.2 K  
SOLIDS 400.1324710 MHz  
IN


F3 - Processing parameters  
SI 32768  
SF 400.1324710 MHz  
WDW 64396  
SSB 2  
LB 0.09 Hz  
GB 0  
PC 1.40

1D data plot parameters  
SI 32768  
SF 400.1324710 MHz  
WDW 64396  
SSB 2  
LB 0.09 Hz  
GB 0  
PC 1.40

SIPR2630 10 1



SIFR2630 10 1



# Exhibit 3-16

16

EXHIBIT

DECLARATION OF TRANSLATOR

I, Ronald Richards, of the Technical Translation Agency, 2136  
Laa/Thaya, Austria,

do hereby avow and declare that I am conversant with the English and  
German languages and am a competent translator of German into English. I  
declare further that to the best of my knowledge and belief the following is a true  
and correct translation prepared and reviewed by me of the document in the  
German language attached hereto.

I hereby declare that all statements made herein of my own knowledge are  
true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful  
false statements may jeopardize the validity of U.S. Patent Application Serial No.  
09/313,524 or any patent issued thereon.

  
\_\_\_\_\_

Date: S. Heger 2003

Confidential

16

Minutes no. 231 of meeting held at 09.00 on [REDACTED]

Present: Frau Herrmann, Herr Augustiniak, Forche, Gerth, Höfle, Irschik, Jansen, Reichenbach, Sasse, Steinmetz, Washausen

Information:

- Two written offers of contract for epothilone have now been received, three more are expected in the near future.
- ASTRA has expressed an interest in testing etnangien in its polymerase tests. A test sample should be sent after concluding a confidentiality agreement.
- The NBI department plans to make TA culture extracts from myxobacteria available on payment to each of several firms for them to screen. GBF retains the rights to the strains and will have an appropriate share in any success.
- Rhone-Poulenc has applied for two patents covering a substance from actinomycete A 9738 (CBS 162.94), which is identical to Citterlin from Mx x48. The compound is described as a neurotensin antagonist. GBF's patent law firm is being asked to check whether these patents can't be challenged on the basis of our two publications and if necessary overturned.
- Ciba-Geigy Pharma in a letter dated [REDACTED] has released the following substances: eliamid, etnangien, argyria A and B. A verbal indication suggested that chondramid might be released, since the substance has no in vivo effect.
- Myxothiazol must be given further medium-term fermentation (Kunze).

**Epothilone** (Gerth, Sasse, Steinmetz): In addition to the 15 known producers we already have, 9 were recently added from Herr Irschik's screening; eight of them formed Spirangien at the same time, one formed icumazol, one only formed epothilone A; productivity was not significantly high in any of the cases. A suitable production strain has to be selected from these known 24 producers. The strains So ce90 (the original producer), So ce660 (only forms

epothilone A), So ce950 (only forms icumazol), So ce1198 (free of extra substances) as well as So ce1275 and 1294 (both originate from the same sample, grow better, form no known extra substances) are at present being investigated in more detail (adaptation to homogenous growth, plating, clone selection). Tests on medium optimisation indicated that the different strains react in different ways. The addition of propionate with So ce90 caused increased formation of epothilone B; for the other strains this did not occur, synthesis in part even being totally blocked despite good growth (So ce1198, So ce1275). The addition of formate to So ce90 caused increased formation of epothilone B and a reduction in epothilone A as well as increased synthesis overall; succinate on the other hand had no effect. So ce1198 and So ce1275 formed no epothilone at all with formate. The type of starch added also has dramatic effect on epothilone synthesis: for So ce90 the best results are achieved with Cerestar (100 %); the results with wheatmeal or ryemeal were considerably worse; using Ciba starch 37 % of the Cerestar yield was achieved, soluble starch achieved 74 %; with soluble starch the ratio of A to B shifted from 1.26 (Cerestar) to 0.83. For skimmed milk and yeast extract a quality comparison still needs to be carried out. Using complex substrates such as banana, plum, or mushroom flour resulted in good growth, but epothilone production was poor or even completely suppressed. So ce477 grew well in full-fat soya flour, So ce90 only grew in low-fat soya flour. While So ce90 did not produce anything on agar plates, So ce1198 still appeared to form epothilone on certain types of agar, which would make strain selection much easier. None of the strains have grown homogeneously so far. Plating is possible with So ce1148: 50 clones have recently been isolated, of which 10 produce epothilone and 40 do not. The formation of Spirangien can easily be detected during cloning, so Spirangien producers can quickly be eliminated.

**Fermentations of 9.8.-18.8.:** F25 (10 l), starter culture: good growth, clean; transferred to F26 (100 l): good growth, clean; F27 (1000 l) had meanwhile been prepared: it frothed over and lost 450 l medium; the reactor was filled again and autoclaved, but again lost another 80 l; it nonetheless remained sterile and was then inoculated from F27. An aliquot of 10 l was at the same time taken from F26 and inoculated into F28 (830 l): F27 and F28 were both infected with a bacillus after 1 day; it was discovered that the inoculation tube used for both inoculations had a hole. F29 (3000 l) was still planned however: after autoclaving the skimmed milk medium the reactor was unsterile after 1 day; it was then autoclaved again and was then still sterile after 4 days; the rest of the medium was then added: 2 days later the reactor was again unsterile and was autoclaved again, it was again unsterile shortly afterwards and was discarded. Since the Biotechnikum is totally closed from Week 37 to 40 due to the ITP, the next series of fermentations will only be possible from 20.9 to 10.10; it might be possible to

add a second cascade afterwards; it is planned to run with a total of 6340 l and 5400 l production volume. From Week 43 to 46 the brine plant is being repaired but this should not affect epothilone production. Due to frothing over of reactors and infections at early stages, 50 l of expensive XAD were lost.

At present there is about 600 mg epothilone A and 400 mg epothilone B available in very impure extracts and the material is being purified at great expense. The substance is urgently needed for test samples.

100 mg epothilone A and 100 mg epothilone B have recently been sold to Bristol-Myers, 150 mg A and 150 mg B to Boehringer.

A batch of about 1.5 g epothilone got lost during recovery. Following preparative HPLC the substance was still all right, it was rotated and left overnight; It was then chlorinated by adding HCl and was inactive.

The strains So cel198, So cel275 and So cel294 form two new epothilones as well as epothilone, but with the epoxide missing. They had considerably reduced action, but were not inactive: The  $IC_{50}$  for L929 cells was 150 ng/ml for RP1 (from So cel198), and 100 ng/ml for RP2. Noticeable effect on Tubulin could be detected in cell cultures. Perhaps patenting could be possible?

Epothilone had lost all activity in mouse serum after 4 h at 37°, and showed a similar result in rat serum; however, the substance was not inactivated in serum of humans, cattle, rabbits, goat or sheep (only serums that were not heat inactivated were used). In human serum the substance was completely stable for 2 days at 37° (HPLC analysis). Lyophilized mouse serums were inactive and hamster serum slightly active. Pig liver esterase opens the lactone ring.

**Ambruticin** (Gerth): Following feeding of  $^{14}C$  Ambruticin A, only VS3 and S could subsequently be detected; radioactivity could not be found anywhere else.

From 2.9 Herr Dipl. Biol. Knauth will be working on the mechanism of action of ambruticin and jerangolid (NBI Dept.).



Vertraulich

Protokoll Nr. 231 der Besprechung am [REDACTED] 9.00 Uhr

Teilnehmer: Frau Herrmann, die Herren Augustiniak, Forche, Gerth, Höfle, Irschik, Jansen, Reichenbach, Sasse, Steinmetz, Washausen

Zur Information:

- Für Epothilon liegen inzwischen zwei schriftliche Vertragsangebote vor, drei weitere sind in naher Zukunft zu erwarten.
- Die Firma ASTRA hat Interesse angemeldet, Etnangien in ihren Polymerase-Tests zu prüfen. Nach Abschluß eines Vertraulichkeitsabkommens soll ein Prüfmuster versandt werden.
- Die Abteilung NBI plant, an mehrere Firmen gegen Bezahlung von je einer TA Kulturextrakte von Myxobakterien für deren Screening zur Verfügung zu stellen. Die GBF behält die Rechte auf die Stämme und wird am Erfolg angemessen beteiligt.
- Rhône-Poulenc hat zwei Patente für eine Substanz aus Actinomycet A 9738 (CBS 162.94) angemeldet, die mit Clitilin aus Mx x48 identisch ist. Die Verbindung ist als Neurotensin-Antagonist beschrieben. Das Patentbüro der GBF wird gebeten zu prüfen, ob diese Patente nicht auf Basis unserer zwei Veröffentlichungen angegriffen werden können und diese dann ggf. auch zu kippen.
- Ciba-Geigy Pharma hat mit Schreiben vom [REDACTED] folgende Substanzen freigegeben: Eliamid, Etnangien, Argyrin A und B. Mündlich wurde eine Freigabe von Chondramid in Aussicht gestellt, da die Substanz in vivo nicht wirkt.
- Myxothiazol muß mittelfristig nachfermentiert werden (Kunze).

Epothilon (Gerth, Sasse, Steinmetz): Zu den 15 schon bekannten eigenen Produzenten kamen neuerdings 9 aus dem Screening von Herrn Irschik hinzu; von diesen bildeten 8 gleichzeitig Spirangien, einer Icomazol, einer nur Epothilon A; die Produktivität war in keinem Fall ungewöhnlich hoch. Aus den somit bekannten 24 Produzenten muß ein geeigneter

Produktionsstamm ausgewählt werden. Zur Zeit werden So ce90 (der ursprüngliche Produzent), So ce660 (bildet nur Epothilon A), So ce950 (bildet nur Icumazol), So ce1198 (frei von Begleitsubstanzen) sowie So ce1275 und 1294 (stammen beide aus derselben Bodenprobe, wachsen besser, bilden keine bekannten Begleitsubstanzen) näher charakterisiert (Adaption zu homogenem Wachstum, Plattierung, Klonselektion). Versuche zur Mediumsoptimierung zeigten, daß die einzelnen Stämme unterschiedlich reagieren. Zusatz von Propionat führt bei So ce90 zu einer verstärkten Bildung von Epothilon B; für die anderen Stämme gilt dies nicht, zum Teil wird die Synthese sogar trotz guten Wachstums total blockiert (So ce1198, So ce1275). Zusatz von Formiat zu So ce90 führt zur verstärkten Bildung von Epothilon B und einer Reduzierung von Epothilon A sowie insgesamt zu einer verstärkten Synthese; Succinat hat dagegen keinen Effekt. So ce1198 und So ce1275 bilden mit Formiat überhaupt kein Epothilon. Auch die Art der zugesetzten Stärke beeinflusst die Epothilonsynthese dramatisch: Bei So ce90 werden die besten Ergebnisse mit Cerestar erhalten (100 %); mit Weizen- oder Roggenmehl Ergebnisse erheblich schlechter; mit Ciba-Stärke werden 37 %, mit löslicher Stärke 74 % der Ausbeute mit Cerestar erreicht; mit löslicher Stärke verschiebt sich dabei das Verhältnis von A zu B von 1.26 (Cerestar) zu 0.83. Für Magermilch und Hefeextrakt muß erst noch ein Qualitätsvergleich durchgeführt werden. Komplexe Substrate wie Bananen-, Pflaumen- oder Pilzmehl erhält man gutes Wachstum, aber die Epothilon-Produktion ist schlecht oder ganz unterdrückt. So ce477 wächst gut in Sojamehl vollfett, So ce90 dagegen nur in entfettetem Sojamehl. Während So ce90 auf Agarplatten nichts produziert, scheint So ce1198 auf bestimmten Agarsorten noch Epothilon zu bilden, was die Stammselektion sehr erleichtern würde. Keiner der Stämme wächst bisher homogen. So ce1148 kann plattiert werden: Inzwischen sind 50 Klone isoliert, von denen 10 Epothilon produzieren, 40 dagegen nicht. Die Bildung von Spirangien läßt sich beim Klonieren leicht erkennen, so daß Spirangien-Produzenten schnell ausgeschieden werden können.

Fermentationen vom 9.8.-18.8.: F25 (10 l), Starterkultur: gut gewachsen, sauber; überführt in F26 (100 l): gutes Wachstum, sauber; inzwischen war F27 (1000 l) vorbereitet worden: dieser schäumte aber über und verlor 450 l Medium; der Reaktor wurde wieder aufgefüllt und autoklaviert, verlor aber anschließend nochmals 80 l; trotzdem blieb er steril und wurde dann aus F27 angeimpft. Ein Aliquot von 10 l wurde aus F26 parallel in F28 (830 l) überimpft: F27 sowie F28 waren beide nach 1 d mit einem Bacillus infiziert; wie sich herausstellte, hatte der für beide Impfvorgänge verwendete Impfschlauch ein Loch. Außerdem war noch F29 (3000 l) geplant: Nach Autoklavieren des Magermilch-Mediums war der Reaktor nach 1 d unsteril; er wurde danach nochmals autoklaviert und war anschließend für 4 d steril; danach wurde der Rest des Mediums zugesetzt: 2 d später war der Reaktor wieder unsteril und wurde erneut autoklaviert, kurz danach war er wieder unsteril und wurde verworfen. Da das Biotechnikum in

der 37. - 40. Woche durch den ITP total blockiert ist, ist die nächste Fermentationsserie erst vom 20.9.-10.10. möglich; vielleicht läßt sich danach eine zweite Kaskade anschließen; vorgesehen ist insgesamt 6340 l Arbeitsvolumen mit 5400 l Produktionsvolumen. Von der 43.-46. Woche wird die Soleanlage repariert, was aber keine Auswirkungen für die Epothilon-Produktion haben sollte. Durch das Übersäumen der Reaktoren und die Infektionen auf frühem Stadium gingen 50 l teures XAD verloren.

Derzeit liegen in +/- stark verunreinigten Extrakten rund 600 mg Epothilon A und 400 mg Epothilon B vor und werden unter großem Aufwand gereinigt. Die Substanz wird dringend für Prüfmuster benötigt.

Vor kurzem wurden an Bristol-Myers 100 mg Epothilon A und 100 mg Epothilon B verkauft, an Boehringer 150 mg A und 150 mg B.

Eine Charge von rund 1.5 g Epothilon gingen bei der Aufarbeitung verloren. Nach präparativer HPLC war die Substanz noch in Ordnung, sie wurde einrotiert und stand über Nacht: Danach war sie durch HCl Addition chloriert und unwirksam.

Die Stämme So ce1198, So ce1275 und So ce1294 bilden neben Epothilon auch zwei neue Epothilone, denen das Epoxid fehlt. Deren Wirksamkeit war stark reduziert, jedoch nicht aufgehoben: Die  $IC_{50}$  für L929-Zellen betrug für RP1 (aus So ce1198) 150 ng/ml, für RP2 100 ng/ml. In Zellkulturen war auch eine deutliche Wirkung auf Tubulin zu erkennen. Vielleicht wäre eine Patentierung möglich?

Epothilon in Serum der Maus hatte nach 4 h bei 37° alle Aktivität verloren, ebenso in Serum der Ratte; in Serum von Mensch, Rind, Kaninchen, Ziege und Schaf wurde die Substanz dagegen nicht inaktiviert (verwendet wurden ausschließlich Seren, die nicht hitzeinaktiviert waren). In Humanserum war die Substanz über 2 d bei 37° völlig stabil (HPLC-Analytik). Lyophilisierte Seren der Maus waren unwirksam, des Hamsters etwas wirksam. Schweineleberesterase öffnet den Lactonring.

Ambruticin (Gerth): Nach Verfütterung von  $^{14}C$ -Ambruticin A waren anschließend nur VS3 und S nachweisbar; nirgendwo sonst war Radioaktivität zu entdecken.

Ab 2.9. wird sich Herr Dipl.Biol. Knauth mit dem Wirkmechanismus von Ambruticin und Jerangolid beschäftigen (Abt. NBI).

- Soce M98 A5 (A37) in Flüssigkultur + auf Platte angeimpft 4-10  
(kouservieren 10.5 + als Stammkultur weiter laufen lassen)  
M98 A2 verlaufen (5x kouservieren)

## Laborbuch Fischer

- F-Medium für 1,2  
Grundmedium

1.5g MgSO<sub>4</sub>  
1.5g Pepsin (Mallinor)  
1.5g H<sub>2</sub>O<sub>2</sub> } pH 7.2

- Stammlog herstellen

- Flaschen !!!

- Medium Fermenter !!! T 15/

- Screening - Stämme weiterimpfen (3x 250 ml) B32, B35, B38, B39

- E-Medium für 1,2 (Protokoll 89 + 90)

4.8g ✓ Magermehl  
2.4g ✓ Yeast extrakt  
12g ✓ Stärke  
12g ✓ CaCl<sub>2</sub>  
1.2g ✓ MgSO<sub>4</sub>  
14.3g ✓ H<sub>2</sub>O<sub>2</sub>  
1.2g ✓ Fe-EDTA  
4.8g ✓ Sojamehl  
6g ✓ Glycerin } pH 7.4 + 2ml KNO<sub>3</sub>/Tollen

- Protokoll 88 + Vorbereitung P 89 + P 90 auch

- Protokoll 88, 89 + 90 animpfen

- Soce 90 A3 weitergeimpft für Fermentation (4x 250 ml)

- Erste von Protokoll 77 + DSLI-Stamm

- Stammlsg herstellen

Protokoll 88 : • 10%ige Propionatlsg = 10g Propionat + 90 ml H<sub>2</sub>O

Protokoll 90 : • 10%ige Torvalatlsg = 10g Torvalat + 90 ml H<sub>2</sub>O

Med. T : • Stammlsg 1 : 20% KNO<sub>3</sub> = 20g KNO<sub>3</sub> + 100 ml H<sub>2</sub>O  
1.25% K<sub>2</sub>HPO<sub>4</sub> = 1.25g K<sub>2</sub>HPO<sub>4</sub> + 100 ml H<sub>2</sub>O

• Stammlsg - 2 : 10% CaCl<sub>2</sub> = 10g CaCl<sub>2</sub> + 90 ml H<sub>2</sub>O

80mg/l Fe-EDTA = 80mg Fe-EDTA + 99.2 ml H<sub>2</sub>O

• Stammlsg - 3 : 25% Glukose = 25g Glukose + 75 ml H<sub>2</sub>O

• 35%ige Glukose : 70g Glukose + 130 ml H<sub>2</sub>O

Ca<sub>2</sub>-Agar : • Stammlsg 1 : 15.0g KNO<sub>3</sub> + 180 ml H<sub>2</sub>O

• Stammlsg 2 : 30g MgSO<sub>4</sub> + 170 ml H<sub>2</sub>O

• Stammlsg 3 : 0.4g CaCl<sub>2</sub> + 0.3g FeCl<sub>3</sub> + 199.30 ml H<sub>2</sub>O

→ PROPIONAT? ←

- 10 Kolben M9P A2 erufen: XAD zu Hr. Steinmetz
- Glucose 25 l + 35 l ~~...~~ Skl. f. Mineral
- E-Medium für 52

4-11

- 20g Magermilch
- 20g Sojamehl
- 10g Yeast extrakt
- 50g Stärke
- 5g Cellulose
- 5g MgSO<sub>4</sub>
- 5g H<sub>2</sub>O<sub>2</sub>
- 5ml Fe-EDTA

pH 7.4

20 Kolben à 250 ml + 10 ml XAD

- F-Medium für 2 L Grundmedium

- 5g MgSO<sub>4</sub>
- 2g N<sub>2</sub>O<sub>4</sub> (Mannit)
- 23g H<sub>2</sub>O<sub>2</sub>

pH 7.2

20 Kolben à 200 ml + 2 ml XAD

→ wenn das Medium erkaltet ist, die Stammlog. + Glukose hinzugeben

- Stammkulturen überimpfen
- 12 x 250 ml Sose 90 A3 → Fermenter
- Versuch 10 x 250 ml mit 1198 A2 angereicht
- Analyse von Pro.punkt + Fermenter bei den Protokollen 89 + 90
- Ende von Protokoll 86

Fr

- Stammkulturen überimpfen
- 12 x 100 ml Sose 90 A3 weiterimpfen
- Screening Stammkulturen (1 x 250 ml) Sose 1271 + 1270
- Stamme Sose 1305 Verwerfen → wächst nicht!
- Ende der Screening Stammkulturen Sose 1325 + 1328
- Protokoll 77 + 86 ansetzen + HPLC
- 12 Lager Medium abgeben (F 150 x 2) (1198 A2)
- Floue von Sose 90 punkte (148 Skl.) Dr. Gith selbst
- 7 Medium mit Sose 90 A3, 1275 + 1198 A5 → Fr. 27.9
- nach 1 Woche HPLC Überprüfung ansetzen
- Konservierung -71°C Sose 90 A3 10x, Sose 1198 A2 10x
- 20 Kolben à 20 ml E-Medium kochen (1°C)

Mo

- 50 Kolben (100 ml) à 20 ml E-Medium + XAD (0.5 ml) (1°C Medium)
- restliche Medien für Fermentation abgeben + ins Fermenter bringen (Flasche + XAD ebenfalls)
- 18 (2x) ansetzen → parallel (10.15 Uhr)
- Ende: Screening Stammkulturen Sose 1333

Di

→ Biologisches Screening! ←

# E-Medium für 1L

- 4g Magermilch
- 4g Sojamehl, entfettet
- 2g Yeast extrakt
- 10g Stärke
- 1g  $CaCl_2$
- 1g  $MgSO_4$
- 11,8g H<sub>2</sub>O<sub>2</sub>
- 1ml K-EDTA

SD Kolben à 20ml  
+ 0,5 ml XAD

pH 7,4 ✓

## Ernte von Protokoll 88, 89, 90

- ✓ E-Medium animpfen mit 90A3, 1198 A5 + 1275 & Skolben

## Soc 1198 A5 10 x 2ml bei -71°C konservieren

- ✓ E-Medium animpfen mit Soc 90A3, 1275 + 1198 A5  
in Skolben (Zusätze nicht vergessen beim Mischen) →
- ✓ nach 1 Woche HPLC-Überprüfung ✓ ok dr. g.M.
- ✓ Biologisches Screening (22 Stämme) ✓

krank → Strohhöhlenverfäuerung

- ✓ Soc 1198 A5 + 1300 10 x 2ml kons. -71°C
- ✓ Ernte von Screening-Stämmen Soc 1334, 1336, 1332, 1335, 1338 + 1339
- ✓ Soc 1328 schon in SD ml
- ✓ Screening-Stämme Soc 1247 + 1270 weiterimpfen in 3x250 ml
- ✓ Versuch mit 1198 A2 ein Kolben ernten + Analytik vorstellen
- ✓ Screening-Stämme von animpfen Soc 1308, 1342, 1349, 1332, 1364
- ✓ MLC-Bestimmung für Oliver Gronwald 6 Stck.
- ✓ 600ml E-Medium fischen für Protokoll 91 (Soc 90A3 aussetzen)

## Konzentrationsbestimmung von Eptonilou

$$\text{Fläche} \times 4 \times 0,0007072 \text{ µg}$$

$$= \frac{\text{Fläche} \times 0,0028288}{(\text{Area Lmalu} \times S)}$$

FERMENTER: Blatt 1

Kostenstelle: 10330

Vers.Nr.: 96/145/02/02

Betreiber:

K. Gule

Betreuer:

M. Haeber

Organismus:

Soc 90

Kulturführung: Aerob: o

Anaerob: o Phototroph: o

Prozessführung: Batch: o

Feed-Batch: o Konti: o

Fermenteraufbau:

Fermenter Nr. 15 L 150 L	Verwendung: Fermentation <input checked="" type="checkbox"/> Vorlage <input type="checkbox"/>	Sterilttest <input type="checkbox"/> für Protokoll-Nr. 1
Sicherheitsmaßnahmen	Abluftfilter: Nein <input checked="" type="checkbox"/> Ja <input type="checkbox"/> Handschuhe tragen: Nein <input type="checkbox"/> Ja <input checked="" type="checkbox"/>	
Betrieb-Beginn	Datum: [redacted] Uhrzeit: 8 <sup>00</sup>	
Rührerart	3 x Schwimmer	
Sondergeräte		
Pumpe für <input checked="" type="checkbox"/>	Typ: <input checked="" type="checkbox"/> Pumprate: <input checked="" type="checkbox"/> Durchmischbauch: <input checked="" type="checkbox"/>	
Pumpe für <input checked="" type="checkbox"/>	Typ: <input checked="" type="checkbox"/> Pumprate: <input checked="" type="checkbox"/> Durchmischbauch: <input checked="" type="checkbox"/>	
	Medien und Kultursubstrat	

Elektroden:

pH-Elektrode	Nr.: 8	Puffer 1: H <sub>2</sub> O Poti/ mV: <input checked="" type="checkbox"/>	Puffer 2: Li <sub>2</sub> O Poti/ mV: <input checked="" type="checkbox"/>
pH-Elektrode	Nr.:	Puffer 1: Poti/ mV:	Puffer 2: Poti/ mV:
pO <sub>2</sub> -Elektrode	Nr.: 02013	Nr.:	

Reaktorgewicht:

Gesamtgewicht

Sollgewicht	32	[KG]
leer	—	[KG]
Wassermenge	14.52	[l] [KG]
Medium-Zugabe	Name: Soc-90	Herk.: Nutzer SE: 1 [KG]
	XAD Zugabe: <input checked="" type="checkbox"/> Ja <input type="checkbox"/> Nein	
Antischaum	Art: Desimp	Volumen: 30 [ml]
pH vor Sterilisation	Ist: 6,25	Soll: 7,0
pH eingestellt mit	Name: 1404	Konz.: 5,6 Menge: 134 ml

Sterilisation:

Steril. Gleitringdichtung	Datum:	Uhrzeit:	Dauer: min
1. Sterilisation Fermenter	Datum: [redacted]	Uhrzeit: 8 <sup>00</sup>	Dauer: 60 min
2. Sterilisation Fermenter	Datum:	Uhrzeit:	Dauer: min
pH nach Sterilisation	14,0	Reaktorgewicht nach St.	32 kg

4-14

Fermenter: Blatt 3

Kostenstelle: 103310

Vers.Nr.: 96/145702/02

Inokulation:

Inokulum 1	Herk.: Nutzer <del>3</del> Protokoll-Nr.: 1 Flasche Nr. 6510	Volumen: 1 [l]
Fermentation Beginn	Datum: [redacted] Uhrzeit: 10:00	
Inokulum 2	Herk.: Nutzer 0 Protokoll-Nr.: 1 Flasche Nr. [redacted]	Volumen: [ ] [l]
Inokulum 2 Zeitpunkt	Datum: [redacted] Uhrzeit: [redacted]	
Fermentergewicht nach	Inokulierung 1: 10 [kg]	Inokulierung 2: [ ] [kg]

Fermentation-Ende:

Fermentation-Ende	Datum: [redacted] Uhrzeit: 14:25	
Fermenter-Gewicht	82	
Korrekturmittel: Volumen nach der Fermentation	Säure 1: [redacted] Säure 2: [redacted] Säure 3: [redacted] Lauge 1: [redacted] Lauge 2: [redacted] Lauge 3: [redacted] Antischaum 1: [redacted] Antischaum 2: [redacted]	
Volumen nach Ferm. von	Zufütterung 1: [redacted] Zufütterung 2: [redacted]	
wie geplant	<input checked="" type="checkbox"/>	
Kontamination	<input type="checkbox"/> Zeitpunkt: Vor den Animpfen <input type="checkbox"/> Vorkultur <input type="checkbox"/> Nach dem Animpfen <input type="checkbox"/>	
Defekt	<input type="checkbox"/> Art: [redacted]	
überschäumt	<input type="checkbox"/> Zeitpunkt: Sterilisation: <input type="checkbox"/> Kultivierung: <input type="checkbox"/> Aufheizphase <input type="checkbox"/> Vor den Animpfen <input type="checkbox"/> Haltephase <input type="checkbox"/> während der Kultivierung <input type="checkbox"/> Abkühlphase <input type="checkbox"/> am Ende der Kultivierung <input type="checkbox"/>	
sonstiges		

Weiterverarbeitung:

Transferleitung Sterilisat	Datum: [redacted] Uhrzeit: [redacted] Dauer: [redacted]	
Ablasseleitung Sterilisat	Datum: [redacted] Uhrzeit: 11:00 Dauer: 120	
Nächster Schritt der Weiterverarbeitung:	Aufarbeitung <input type="checkbox"/> Übergeimpft auf einen Fermenter <input checked="" type="checkbox"/> An Nutzer übergeben <input type="checkbox"/> Übergeimpft auf mehrere Fermenter <input type="checkbox"/>	
Volumen [l]	82	
Protokoll-Nr. der nächsten Schritte	22153 1 1 1 1 1 1 1 1	

Entsorgung:

Sterilisation Abluftfilter	Datum: [redacted] Zeit: [redacted] Dauer: [redacted]	
Inaktivierung Fermenter	gesamter Inhalt <input type="checkbox"/> restl. Inhalt <input type="checkbox"/> Vol: [ ] [l] Überstand <input type="checkbox"/> Datum: 30.08.86 Uhrzeit: 15:00 Dauer: 5 Temp: 20°C	
Besonderheiten	Wt + A 20% H <sub>2</sub> O <sub>2</sub> + 20% NaOH	
Betriebs-Ende	Datum: 30.08.86 Uhrzeit: 11:20	



Anmerkungen/Besonderheiten zur Fermentation: Medizin mit Ultramax Suspendier

30 ml Tegospo

**Aufarbeitung**

Zieleinstellung:.....

Feststoffabtrennung: ☐ Zentrifugation ☐ Mikrofiltration ☐ Dead-end-Filtration  
☐ Adsorberharzabtrennung

benötigt werden ==> ☐ Filtrat/Überstand ☐ Feststoff

☐ Lyophilisation ☐ Ultrafiltration

n Verdampfung gewünschtes Endvolumen ..... (L/ml)  
max. Temp. ..... (°C)

Extraktion: ☐ Kulturbrühe ☐ Überstand ☐ Feststoff

Verteilungskoeffizient:.....

Lösungsmittel/Zusätze:.....

Phasenverhältnis:..... Stufenzahl:.....

Zusatzprotokolle:.....

Produktspezifische Besonderheiten/weitergehende Aufarbeitungsschritte/Analytik:

.....  
.....  
.....  
.....  
.....

Toxische Eigenschaften/Sicherheitsmaßnahmen:.....  
.....  
.....

Besonderheiten der Entsorgung/Dekontamination von Mikroorganismen bzw. toxischen Produkten:  
.....  
.....

**ACHTUNG!!!** Lagerzeiten von EZHgut max.3 Arbeitstagen, von Gefriergut max.3 Monate! Nach Terminüberschreitung erfolgt Entsorgung!!

Datum/Unterschrift:  C. F. 588

Wägeprotokoll

2012/02/02

06 0000

5 - Modificarea

1	
2	
3	
4	

156

254.)

das Protokoll kann für mehrere Behälter benutzt werden, die Nr. in der ersten Spalte ist die Behälternummer (siehe Behälterbeschriftung) / bei Lösungen unter Substanz z.B. Wasser aufführen und Menge in ml oder l angeben / werden Stammlösungen verwendet, ist deren Zusammensetzung beizufügen

[illegible]

4-16



# Fermentations- und Anlageneigungsprotokoll

Technikumsleitung : Dr. A. Roß Tel. 130 priv. (0 53 1) 34 35 49  
 Formulation : H. Schüler Tel. 131 priv. (0 53 71) 79 48  
 Aufarbeitung : R. Krüger Tel. 137 priv. (0 53 07) 45 62  
 Technik : 103310 Tel. priv. 0

Antragnummer: 0043-0000 Reaktor-Nr.: 0045.2 Anmeldedatum: 00.00.00

Name: Fischer... Bericht/Nr.: NBI

Dienststelle: 465 Privatschule

Stamm/Medium: Sacc 40 o Stammangabe liegt vor / X liegt bei

Ziel: Vorfermenter

Prozessbeginn am: 10.10. um 10<sup>00</sup> Uhr Prozessende am: 10.10. um 10<sup>00</sup> Uhr

Startvolumen: 10 L Volumen der Vor- u. Zusatzstoffe: 1 L

Vorkultur: Schüttkultur X Anforderer o Biotechnikum o Reaktor Exp.Nr.

Medium: Nr. E X trocken o gelöst ca. kg/l X AS

o wird vom Biotechnikum angestellt o wird geliefert von am

Vorlage Art Inhalt / Konz. / Menge (oder kg) Pumpentyp / Rate (max.)

- 1
- 2
- 3
- 4
- 5

Waagen o 1 o 2 o 3 o 4 o 5 Timer o 1 o 2 o 3 o 4 o 5  
 o pH-Einstellung vor Sterilisation auf 7.0 mit ca. ml KOH

Sterilisation bei 121°C für min / fraktioniert h / Sterilität h

Startwerte für die Kultivierung

Temperatur: 30 °C Belüftung: 0.1 vvm No<sup>3</sup>/h

Drehzahl: 150 rpm pH-Wert: > 7.0 <

Druck: mbar

pO<sub>2</sub>-Messung o nein X ja

Abgasmessung o nein o ja Kaal

pO<sub>2</sub>-Regelung o nein o ja Sollwert % Sättigung

Druckregelung o nein o ja Sollwert mbar

Rechneraufzeichnung o nein o ja, Exp.Nr.

Parameter ändern

- nach h →
- nach h →
- nach h →
- nach h →

weitere Angaben siehe umseitig →

GVO o ja

Das Fermentationsprotokoll sollte in der Fermentation vorangehenden Kalenderwoche fertig vorliegen, spätestens jedoch zwei Tage vor Beginn der Fermentation. Mündliche Fermentationsvereinbarungen werden nur bis zu diesem Zeitpunkt berücksichtigt. Der Nutzer verpflichtet sich, nicht abgesprochene Manipulationen an Geräten zu unterlassen und im Technikum die Sicherheitsvorschriften (z.B. UVV 102) einzuhalten.

## Substrat und Hilfsmittel Zugabe: (nach Sterilisation)

Art	Herkunft	Vol. (ml)	Datum	Zeit	Gew. (KG)
<del>Flasche Nr. _____</del>					
<del>Flasche Nr. _____</del>					
<del>Flasche Nr. _____</del>					
<del>Flasche Nr. _____</del>					
<del>Flasche Nr. _____</del>					
<del>Flasche Nr. _____</del>					
<del>Flasche Nr. _____</del>					

## Vorlagen und Korrekturmittel:

<del>Lauge 1:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Lauge 2:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Lauge 3:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Säure 1:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Säure 2:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Säure 3:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Antischaum 1:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Antischaum 2:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Zufütterung 1 Art:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>
<del>Zufütterung 2 Art:</del>	<del>Vol. <sub>Anfang</sub> :</del>	<del>Dat./Zeit:</del>	<del>Herk.: Flasche Nr.</del>

## Regelung und Fermentationsstrategie, Startwerte:

pH-Sollwert: <u>8.0</u>	eingestellt mit: _____		pH-Regelung von _____ bis _____	
pO <sub>2</sub>	Messung	nein o	ja <input checked="" type="checkbox"/>	Regelung
			nein <input checked="" type="checkbox"/>	ja o
pO <sub>2</sub> Sollwert:	Strategie: Drehzahl o Zuluft o sonstige o _____			
Temperatur <u>30</u> (°C)	Druck	(mbar)	Drehzahl <u>150</u>	(rpm)
Parameter:	Sollwert:	[.....]	Strategie:	
Parameter:	Sollwert:	[.....]	Strategie:	
Parameter:	Sollwert:	[.....]	Strategie:	
Begasung: Luft	_____	/min	<u>0.25</u>	vvm
andere: <u>Quellwasser</u>	_____	/min	_____	vvm
	_____	/min	_____	vvm
	_____	/min	_____	vvm
Überlagerung GLRD	Luft o	Dampf o		
Abgasmessung	nein <input checked="" type="checkbox"/>	ja o	Kanal:	<u>K1/K2</u>
Rechnererfassung nein o	Exp.: <u>201452</u>	Start-Datum: _____	Zeit:	_____

# Fermentations- und Aufarbeitungsprotokoll

4-20

Technikumstörung : De A. Rob. Tel. 130 price (0.53 1) 34 35 49  
Fermentation : H. Schöler Tel. 131 price (0.53 71) 79 48  
Aufarbeitung : R. Krüfddt Tel. 137 price (0.53 02) 45 62  
Technik : 103, 3, 40 Tel. price 0

Anfrage nummer: 0003-0000 Reaktor Nr.: 0003-02 Anschlussstrom: 00.00.00

Name: Gerth / Fischer Bericht/Form: NBI

Kontaktdaten: 433 / 465 Privatkdoz:

Stamm/Medium: Soce 90 o Stammzusammeng. liegt vor 1 X liegt bei

Ziel: Vorfermenter o Produktion von Epithilon (wenn anderer Stiel)

Prozessbeginn am: 10.11.11 Prozessende am: 10.11.11

Startvolumen: 100 L Volumen der Vorkultur + sonst. Zugabe: 10 L

Vorkultur: Schüttkultur o Anforderer o Biochemikum o Reaktor Exp.Nr.

Medium: Nr. E X trocken o gelöst ca. kg/l X 15  
o wird vom Biochemikum angeliefert o wird geliefert von am

Vorgabe: Art Anzahl / Konz. / Menge (oder kg) Pumpentyp / Rate (max)

1. Lauge, Koff, 10 l

2. A.S., 1 Tag, 5, 100

3.

4.

5.

Wagen: 01 02 03 04 05 Timer: 01 02 03 04 05

o pH-Einstellung vor Sterilisation auf 7.6 mit ca. ml Koff

Sterilisation bei 121°C für min / Inaktiviert h / Sterilisiert h

Startwerte für die Kultivierung:

Temperatur: 30 °C Belüftung: 0.1 von No<sup>3</sup>/h

Drehzahl: 200 rpm pH-Wert: 7.0 konstant

Druck: mbar

pO<sub>2</sub>-Messung o nein X ja

Abgasmessung o nein o ja Kanal

pO<sub>2</sub>-Regelung o nein o ja Sollwert % Sättigung

Druckregelung o nein o ja Sollwert mbar

Rechnerfassung o nein o ja, Exp.Nr.

Parameter ändern

nach h -> nach h ->

nach h -> nach h ->

nach h -> nach h ->

weitere Angaben siehe unten

GVO o ja

Das Fermentationsprotokoll sollte in der der Fermentation vorangehenden Kalenderwoche freigelegt werden, spätestens jedoch zwei Tage vor Beginn der Fermentation. Mündliche Fermentationsvereinbarungen werden nur bis zu diesem Zeitpunkt berücksichtigt. Der Nutzer verpflichtet sich, nicht abgesprochene Manipulationen an Geräten zu unterlassen und im Technikum die Sicherheitsvorschriften (z.B. UVV 102) einzuhalten.

Anmerkungen/Besonderheiten zur Fermentation: Medium mit Ultramax ergänzen

70 ml. Immunoprecipitation; KAD-Zugabe

# Aufarbeitung

Zielsetzung: evk

Feststoffabtrennung: ☐ Zentrifugation ☐ Mikrofiltration ☐ Dead-end-Filtration  
☐ Adsorbentabtrennung

Benötigt werden ----> ☐ Filtrat/Überstand ☐ Feststoff

☐ Lyophilisation ☐ Ultrafiltration

Verdampfung gewünschtes Endvolumen : ..... (L/ml)  
 max. Temp. : ..... (°C)

Extraktion: ☐ Kulturbrühe ☐ Überstand ☐ Feststoff

Verteilungskoeffizient: .....

Lösungsmittel/Zusätze: .....

Phasenverhältnis: ..... Stufenzahl: .....

Zusatzprotokolle: .....

Produktspezifische Besonderheiten/weltengende Aufarbeitungsschritte/Analytik:

.....  
 .....  
 .....  
 .....  
 .....

Toxische Eigenschaften/Sicherheitsmaßnahmen: .....

Besonderheiten der Entsorgung/Dekontamination von Mikroorganismen bzw. toxischen Produkten: .....

ACHTUNG!! Lagerzeiten von Kühlgut max. 3 Arbeitstagen, von Gefriergut max. 3 Monate! Nach Terminüberschreitung erfolgt Entsorgung!!

Datum/Unterschrift: C. Fischer





FERMENTER: Blatt 1

Kostenstelle: 103310

Vers.Nr.: 96/14570203

Betreiber: H. Gunk

Betreuer: S. Link

Organismus: *S. cerevisiae*

Kulturführung: Aerob: o

Anaerob: o

Phototroph: o

Prozessführung: Batch: o

Feed-Batch: o

Kontin.: o

Fermenteraufbau:

Fermenter Nr. 100.2	Verwendung: Fermentation <input checked="" type="checkbox"/> Vorlage <input type="checkbox"/>	Steriltest <input type="checkbox"/> für Protokoll-Nr. 1
Sicherheitsmaßnahmen	Abluftfilter: Nein <input type="checkbox"/> Ja <input type="checkbox"/> Handschuhe tragen: Nein <input type="checkbox"/> Ja <input checked="" type="checkbox"/>	
Betrieb-Beginn	Datum: <del>20.08.00</del>	Uhrzeit: 15:00
Rührerart	3x Schwebel	
Sondergeräte		
Pumpe für <i>Lauge</i>	Typ: <i>Flacon 500</i>	Pumprate: Durchmischungs:
Pumpe für	Typ:	Pumprate: Durchmischungs:
	<i>Medien und Luftversorgung</i>	

Elektroden:

pH-Elektrode	Nr.: 200.7	Puffer 1: <i>2</i> Poti/ mV: <i>5.16</i>	Puffer 2: <i>4</i> Poti/ mV: <i>2.80</i>
pH-Elektrode	Nr.:	Puffer 1: Poti/ mV:	Puffer 2: Poti/ mV:
pO <sub>2</sub> -Elektrode	Nr.: 500.7	Nr.: 520.9	

Reaktorgewicht:

Gesamtgewicht

Sollgewicht	<i>92.2</i>			[KG]
leer				-5 [KG]
Wassermenge	<i>0.8</i> l			<i>63</i> [KG]
Medium-Zugabe	Name:	Herk.: Nutzer 0 SE: 03102	<i>84</i> [KG]	
	XAD Zugabe:	<i>Ja</i> <input checked="" type="checkbox"/> <i>Nein</i> <input type="checkbox"/>	<i>82</i>	
Antischaum	Art: <i>Greiner</i>	Volumen: <i>20</i>	[ml]	
pH vor Sterilisation	Ist: <i>6.82</i>	Soll: <i>7.6</i>		
pH eingestellt mit	Name: <i>1204</i>	Konz.: <i>5N</i>	Menge: <i>50</i> ml	

Sterilisation:

Steril. Gleitringdichtung	Datum: <del>20.08.00</del>	Uhrzeit: <i>9:35</i>	Dauer: <i>45</i> min
1. Sterilisation Fermenter	Datum: <del>20.08.00</del>	Uhrzeit: <i>12:20</i>	Dauer: <i>60</i> min
2. Sterilisation Fermenter	Datum:	Uhrzeit:	Dauer: min
pH nach Sterilisation	<i>7.08</i>	Reaktorgewicht nach St.	<i>82</i> kg

## Substrat und Hilfsmittel Zugabe: (nach Sterilisation)

Art	Herkunft	Vol. [ml]	Datum	Zeit	Gew. <sub>gesamt</sub> (KG)
	Flasche Nr. _____				
	Flasche Nr. _____				
	Flasche Nr. _____				
	Flasche Nr. _____				
	Flasche Nr. _____				
	Flasche Nr. _____				

## Vorlagen und Korrekturmittel:

Lauge 1: 100% 10%	Vol. <sub>Anfang</sub> : 1500	Dat./Zeit: 27.7/10 <sup>10</sup>	Herk.: Flasche Nr. 533
Lauge 2:	Vol. <sub>Anfang</sub> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Lauge 3:	Vol. <sub>Anfang</sub> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Säure 1:	Vol. <sub>Anfang</sub> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Säure 2:	Vol. <sub>Anfang</sub> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Säure 3:	Vol. <sub>Anfang</sub> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Antischaum 1: Tegobipon	Vol. <sub>Anfang</sub> : 500	Dat./Zeit: 27.7/10 <sup>10</sup>	Herk.: Flasche Nr. 554
Antischaum 2:	Vol. <sub>Anfang</sub> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Zufütterung 1 Art:	Vol. <sub>Anfang</sub> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Zufütterung 2 Art:	Vol. <sub>Anfang</sub> :	Dat./Zeit:	Herk.: Flasche Nr. _____

## Regelung und Fermentationsstrategie, Startwerte:

pH-Sollwert:	eingestellt mit :		pH-Regelung von 7.0 bis .....	
pO <sub>2</sub>	Messung	nein o ja <input checked="" type="checkbox"/>	Regelung	nein <input checked="" type="checkbox"/> ja o
pO <sub>2</sub> Sollwert:	Strategie: Drehzahl o Zuluft o sonstige o _____			
Temperatur 30 [°C]	Druck	[mbar]	Drehzahl 200	[rpm]
Parameter:	Sollwert:	[.....]	Strategie:	
Parameter:	Sollwert:	[.....]	Strategie:	
Parameter:	Sollwert:	[.....]	Strategie:	
Begasung: Luft	_____ 10	l/min	_____ 0,1	vvm
andere: _____	_____	l/min	_____	vvm
_____	_____	l/min	_____	vvm
_____	_____	l/min	_____	vvm
Überlagerung GLRD	Luft <input checked="" type="checkbox"/>	Dampf o		
Abgasmessung	nein o	ja <input checked="" type="checkbox"/>	Kanal: 2	
Rechnerfassung nein o	Exp.: A6453	Start-Datum: _____	Zeit: 10 <sup>10</sup>	

4-25

Fermenter: Blatt 3

Kostenstelle: 103310

Vers.Nr.: 96/145702/03

Inokulation:

Inokulum 1	Herk.: Nutzer 0 Protokoll-Nr.: 02/04 Flasche Nr. 592	Volumen: 9 [l]
Fermentation Beginn	Datum: [redacted] Uhrzeit: 1025	
Inokulum 2	Herk.: Nutzer 0 Protokoll-Nr.: _/ _/ _ Flasche Nr. _	Volumen: [l]
Inokulum 2 Zeitpunkt	Datum: _/ _/ _ Uhrzeit: _	
Fermentergewicht nach	Inokulierung 1: 91 [kg]	Inokulierung 2: [kg]

Fermentation-Ende:

Fermentation-Ende	Datum: [redacted] Uhrzeit: 1310	
Fermenter-Gewicht	90 kg	
Korrekturmittel: Volumen nach der Fermentation	Säure 1: 1400 Lauge 1: 1400 Antischaum 1: 1400	Säure 2: 1400 Lauge 2: 1400 Antischaum 2: 1400
Volumen nach Ferm. von	Zufütterung 1: 1400	Zufütterung 2: 1400
wie geplant	<input checked="" type="checkbox"/>	
Kontamination	<input type="checkbox"/> Zeitpunkt: Vor den Animpfen <input type="checkbox"/> Vorkultur <input type="checkbox"/> Nach dem Animpfen <input type="checkbox"/>	
Defekt	<input type="checkbox"/> Art: 1400	
übergeschäumt	<input type="checkbox"/> Zeitpunkt: Sterilisation: <input type="checkbox"/> Kultivierung: <input type="checkbox"/> Aufheizphase <input type="checkbox"/> Vor den Animpfen <input type="checkbox"/> Haltephase <input type="checkbox"/> während der Kultivierung <input type="checkbox"/> Abkühlphase <input type="checkbox"/> am Ende der Kultivierung <input type="checkbox"/>	
sonstiges		

Weiterverarbeitung:

Transferleitung Sterilisat.	Datum: [redacted] Uhrzeit: 1400 Dauer: 120 min	
Ablasseleitung Sterilisat.	Datum: [redacted] Uhrzeit: 1400 Dauer: 120 min	
Nächster Schritt der Weiterverarbeitung:	Aufarbeitung 0 Übergeimpft auf einen Fermenter 0 An Nutzer übergeben 0 Übergeimpft auf mehrere Fermenter 0	
Volumen [l]	100	
Protokoll-Nr. der nächsten Schritte	02/06	

Entsorgung:

Sterilisation Abluftfilter	Datum: [redacted] Zeit: 1400 Dauer: 120 min	
Inaktivierung Fermenter	gesamter Inhalt <input type="checkbox"/> restl. Inhalt <input type="checkbox"/> Vol: 10 [l] Überstand <input type="checkbox"/> Datum: [redacted] Uhrzeit: 1400 Dauer: 120 min Temp.: 1400	
Besonderheiten		
Betriebs-Ende	Datum: [redacted] Uhrzeit: 1500	



# Formulations- und Anlaufprotokoll

4-27

Technikumsteilung :	De. A. Roll	Tel. 130	priv. (0 53 1)	34 35 49
Formulations :	H. Schiller	Tel. 131	priv. (0 53 71)	79 48
Anlaufsteilung :	R. Krüger	Tel. 137	priv. (0 53 07)	45 62
Technik :	10 43 + D	Tel.	priv. 0	

Anlaufnummer: 0005.0000 Reaktor-Nr.: 0003.0 Auslaufdatum: 00.00.00

Name: Fischer Bericht/Form: NBI

Dienststelle: 465 Privatadresse:

Stamm/Medium: Soce 90 o Stammzucht liegt vor ☒ liegt bei

Zu: Produktion von Epokuiton

Prozentregie am 10<sup>12</sup> Uhr Prozessende am CC am 10<sup>12</sup> Uhr

Startvolumen: 750 l Volumen der Vorkeultur + sonst. Zugaben: 70 l

Vorbereitung: Schmelzkultur o Anforders o Biotechnikum o Reaktion/Exp.Nr.

Medium: Nr. E o trocknet o gelöst ca. kg/l AS

o wird vom Biotechnikum angesetzt o wird gelöst von am

Vorlage: Art Inhalt / Konz. / Menge (oder kg) Pumpentyp Rate (max.)

1. Lauge, KOH 10 l 1 1 1

2. A.S. Tegospon 1 1 1 1

3. 1 1 1 1 1

4. 1 1 1 1 1

5. 1 1 1 1 1

Wagen o 1 o 2 o 3 o 4 o 5 Timer o 1 o 2 o 3 o 4 o 5

o pH-Einstellung vor Sterilisation auf 7,6 mit ca. ml KOH

Sterilisation bei 121°C für min / festschüttet h / Sterilisiert h

Startwerte für die Kultivierung:

Temperatur: 30 °C Belüftung: 0,1 von No<sup>2</sup>

Drehzahl: 200 rpm pH-Wert: > 7,0 konstant

Druck: mbars

pO<sub>2</sub>-Messung o nein ja

Abgemessung o nein o ja/Kanal 1

pO<sub>2</sub>-Regelung o nein o ja/Sollwert % Sättigung

Druckregelung o nein o ja/Sollwert mbars

Rechnererkennung o nein o ja, Exp.Nr. 1

Parameter ändern

nach h -> nach h ->

nach h -> nach h ->

nach h -> nach h ->

weitere Angaben siehe Übersicht ->

GVO o ja

Das Formulationsprotokoll sollte in der der Formulation vorangehenden Kalenderwoche fröhlich vorliegen, spätestens jedoch zwei Tage vor Beginn der Formulation. Mündliche Formulationsvereinbarungen werden nur bis zu diesem Zeitpunkt berücksichtigt. Der Nutzer verpflichtet sich, nicht abgesprochene Manipulationen an Geräten zu unterlassen und im Todesfall die Sicherheitsvorrichtungen (z.B. UVV 102) Gasschutz.

4-28

Anmerkung/Besonderheiten zur Fermentation: Mischkultur mit Citratkinase Suspension  
250 ml Tegosipon, XAD-Erzuge

### Aufarbeitung

Zielfestlegung: Nach Rücksprache mit H. Steinmetz

### Feststoffabtrennung:

- ☐ Zentrifugation      ☐ Mikrofiltration      ☐ Dead-end-Filtration  
☐ Adsorberharzabtrennung

### Benötigt werden -->

- ☐ Filtrat/Überstand      ☐ Feststoff

### Lyophilisation

- ☐ Ultrafiltration

Verdampfung gewünschtes Endvolumen : ..... (L/ml)  
 max. Temp. : ..... (°C)

### Extraktion:

- ☐ Kulturbühe      ☐ Überstand      ☐ Feststoff

Verteilungskoeffizient: .....

Lösungsmittel/Zusätze: .....

Phasenverhältnis: ..... Stufenzahl: .....

Zusatzprotokolle: .....

Produktspezifische Besonderheiten/weitergehende Aufarbeitungsschritte/Analytik:

Toxische Eigenschaften/Sicherheitsmaßnahmen: .....

Besonderheiten der Entsorgung/Dekontamination von Mikroorganismen bzw. toxischen Produkten:

ACHTUNG!! Lagerzeiten von Kühlgut max. 3 Arbeitstagen, von Gefriergut max. 3 Monate! Nach Terminüberschreitung erfolgt Entsorgung!!

Datum/Unterschrift: .....

CFS



FERMENTER: Blatt 1

Kostenstelle: 20330

Vers.Nr.: 96/111/0206

Betreiber: K. Jule

Betreuer: S. Lisski

Organismus: S. cerevisiae

Kulturführung: Aerob: ☐ Anaerob: ☐ Phototroph: ☐Prozeführung: Batch: ☐ Feed-Batch: ☐ Konti: ☐

Fermenteraufbau:

Fermenter Nr. 901	Verwendung: Fermentation <input type="radio"/> d Vorlage <input type="radio"/> o	Steriltest <input type="radio"/> o für Protokoll-Nr. 1
Sicherheitsmaßnahmen	Abluftfilter: Nein <input type="radio"/> Ja <input type="radio"/> o Handschuhe tragen: Nein <input type="radio"/> Ja <input checked="" type="radio"/>	
Betrieb-Beginn	Datum: [redacted] Uhrzeit: 10:00	
Rührerart	2x 3-Blatt	
Sondergeräte		
Pumpe für Lauge	Typ:	Pumprate: Durchmischschub:
Pumpe für	Typ:	Pumprate: Durchmischschub:
	Medium mit Aufhänger	

Elektroden:

pH-Elektrode	Nr.: 200.6	Puffer 1: 7 Poti/ mV: -5,1	Puffer 2: 4 Poti/ mV: 5,5, 7
pH-Elektrode	Nr.:	Puffer 1: Poti/ mV:	Puffer 2: Poti/ mV:
pO <sub>2</sub> -Elektrode	Nr.: 150.16	Nr.: 150.15	

Reaktorgewicht:

Gesamtgewicht

Sollgewicht	620		[KG]
leer			[KG]
Wassermenge	580 (l)		[KG]
Medium-Zugabe	Name:	Herk.: Nutzer 0 SE: 03/04	680 [KG]
	XAD Zugabe:	Ja <input checked="" type="radio"/> o Nein <input type="radio"/>	
Antischaum	Art: 0.1mpe	Volumen: 200	[ml]
pH vor Sterilisation	Ist: 6,18	Soll: 7,0	
pH eingestellt mit	Name: 1204	Konz.: 5N	Menge: 360 ml

Sterilisation:

Steril. Gleitringdichtung	Datum: [redacted]	Uhrzeit: 9:50	Dauer: 50 min
1. Sterilisation Fermenter	Datum: [redacted]	Uhrzeit: 11:10	Dauer: 60 min
2. Sterilisation Fermenter	Datum:	Uhrzeit:	Dauer: min
pH nach Sterilisation	6,79	Reaktorgewicht nach St.	kg



## Substrat und Hilfsmittel Zugabe: (nach Sterilisation)

Art	Herkunft	Vol. [ml]	Datum	Zeit	Gew. <small>procentum</small> (KG)
AS	Flasche Nr. 96/0537	300		7:25	
	Flasche Nr. _____				
	Flasche Nr. _____				
	Flasche Nr. _____				
	Flasche Nr. _____				
	Flasche Nr. _____				

## Vorlagen und Korrekturmittel:

Lauge 1: KOH 10%	Vol. <small>Auftrag</small> : 400	Dat./Zeit: 13:45	Herk.: Flasche Nr. 539
Lauge 2:	Vol. <small>Auftrag</small> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Lauge 3:	Vol. <small>Auftrag</small> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Säure 1:	Vol. <small>Auftrag</small> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Säure 2:	Vol. <small>Auftrag</small> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Säure 3:	Vol. <small>Auftrag</small> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Antischaum 1: Tego 1000	Vol. <small>Auftrag</small> : 1500	Dat./Zeit:	Herk.: Flasche Nr. 534
Antischaum 2:	Vol. <small>Auftrag</small> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Zufütterung 1 Art:	Vol. <small>Auftrag</small> :	Dat./Zeit:	Herk.: Flasche Nr. _____
Zufütterung 2 Art:	Vol. <small>Auftrag</small> :	Dat./Zeit:	Herk.: Flasche Nr. _____

## Regelung und Fermentationsstrategie, Startwerte:

pH-Sollwert:	eingestellt mit :		pH-Regelung von ..... bis 7.0	
pO <sub>2</sub>	Messung	nein o ja <input checked="" type="checkbox"/>	Regelung	nein o ja o
pO <sub>2</sub> Sollwert: 30%	Strategie: Drehzahl- <input checked="" type="checkbox"/> Zuluft o sonstige o			
Temperatur 30 (°C)	Druck 300	(mbar)	Drehzahl 100	(rpm)
Parameter:	Sollwert:	[.....]	Strategie:	
Parameter:	Sollwert:	[.....]	Strategie:	
Parameter:	Sollwert:	[.....]	Strategie:	
Begasung: Luft	70	l/min	0.9	vvm
andere:		l/min		vvm
		l/min		vvm
		l/min		vvm
Überlagerung GLRD	Luft <input checked="" type="checkbox"/>	Dampf o		
Abgasmessung	nein o	ja <input checked="" type="checkbox"/>	Kanal: 2	
Rechnererfassung nein o	Exp.: P61456	Start-Datum:	Zeit: 13:45	

Fermenter: Blatt 3

Kostenstelle: 203210

Vers.Nr.: 96/145/02/06

**Inokulation:**

Inokulum 1	Herk.: Nutzer 0	Protokoll-Nr.: 02103	Flasche Nr. _____	Volumen: 100 [l]
Fermentation Beginn	Datum: _____	Uhrzeit: 13:40		
Inokulum 2	Herk.: Nutzer 0	Protokoll-Nr.: _____	Flasche Nr. _____	Volumen: [l]
Inokulum 2 Zeitpunkt	Datum: _____	Uhrzeit: _____		
Fermentergewicht nach	Inokulierung 1: 780 [kg]	Inokulierung 2: _____	[kg]	

**Fermentation-Ende:**

Fermentation-Ende	Datum: <span style="background-color: black; color: black;">XXXXXXXXXX</span>		Uhrzeit: 08:55	
Fermenter-Gewicht				
Korrekturmittel: Volumen nach der Fermentation	Säure 1: Lauge 1: 3000 Antischaum 1: 1000	Säure 2: Lauge 2: Antischaum 2:	Säure 3: Lauge 3:	
Volumen nach Ferm. von	Zufütterung 1:		Zufütterung 2:	
wie geplant	o			
Kontamination	o	Zeitpunkt: Vor den Animpfen Nach dem Animpfen	o	Vorkultur o
Defekt	o	Art:		
überschäumt	o	Zeitpunkt: Sterilisation: Aufheizphase Haltephase Abkühlphase	Kultivierung: Vor den Animpfen während der Kultivierung am Ende der Kultivierung	 o o o
sonstiges				

**Weiterverarbeitung:**

Transferleitung Sterilisat.	Datum: _____	Uhrzeit: 10:55	Dauer: _____
Ablassleitung Sterilisat.	Datum: _____	Uhrzeit: _____	Dauer: _____
Nächster Schritt der Weiterverarbeitung:	Aufarbeitung	Übergemipft auf einen Fermenter	0
	An Nutzer übergeben	Übergemipft auf mehrere Fermenter	0
Volumen [l]	776		
Protokoll-Nr. der nächsten Schritte	031		

**Entsorgung:**

Sterilisation Abluftfilter	Datum: _____	Zeit: _____	Dauer: _____
Inaktivierung Fermenter	gesamter Inhalt o	restl. Inhalt o	Vol: _____ [l] Überstand o
	Datum: _____	Uhrzeit: _____	Dauer: _____ Temp.: _____
Besonderheiten			
Betriebs-Ende	Datum: _____	Uhrzeit: 15:00	

Verlaufs-Protokolle: Fern Nr.: -----

Kostenstelle: -----

Vers.Nr.: 96/-----/02/-----

Organismus: -----

Betreiber: -----

Datum	Zeit	Probe Vol.							Zugabe	Parame-ter	Wert alt	Wert neu	Bemerkungen
8.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
15.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
16.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
17.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
18.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
19.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
20.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
21.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
22.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
23.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
24.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
25.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
26.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
27.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
28.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
29.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
30.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar
31.12	200.1	180								Druck	500 mm	300 mm	Druck auf 300 mm = 0,1 bar Druck auf 300 mm = 0,1 bar

8.12 300  
15.12 300  
16.12 300

Grammatische Form

Socce 90 A4 27.12

Socce 90 A3 27.12

Socce 90 A2 27.12

Socce 90 W20 27.12

Socce 1275 27.12

Socce 1298 AS 27.12

Socce 1300 27.12

Bestellungen

Pegasporn nach

Wohn 7-30 Socce 90.00.00

P76 Entledigt

Prahe F 900 7700

Wohn 7-30

9.70

P78 Erneut V

800 F900 Prahe V

Hofen 2. Gang

FIPIC

## Dead-End-Filtration

Kostenstelle: 703390

Vers.Nr.: 96/0747/03/06

Bearbeiter: Prozeß: Risth

Analyse:

Analysen-Protokoll: \_/ \_/ \_

Stamm / Medium: Faden Girth Mer

Besondere Sicherheitsmaßnahmen: Hand waschen

Zielsetzung: x.a.d. Gewinn

## Grunddaten

Anlagentyp	Prozessfilter Wiga EFT 60/180		
Modifikationen	Process filter		
Betriebsbeginn	Datum: [redacted]	Uhrzeit: 08:00	
Prozessbeginn	Datum: [redacted]	Uhrzeit: 08:20	

## Bearbeitetes Material

Art:	Firmeninternes Produkt				
Vol.: 2 l	[l]	Temp.	[°C]	Herk.: Nutzer o	Protokoll-Nr.: 02/06
pH	[-]	oD Medium	[-]	Feststoffanteil	[g/l]

## Filterhilfsmittel

Art:	eingewogen	[kg]	gelöst in	[l]
Konz. Filterhilfsmittel	[g/l]	konti. Dosierung	[l/h]	Pumpentyp:

## Geräteparameter

Eingesetzte Filtermedien/Siebewebe:	2 x 0,1 µm
-------------------------------------	------------

## Produkte

Gesamtlaufzeit	5,5	[h]	mittlerer Flux	ca. 120	[l/h]	oD <sub>Klarauf</sub>	[-]
Feststoff <sub>Klarauf</sub>		[mg/l]	Endvol <sub>Klarauf</sub>		[l]	ProdKonz <sub>Klarauf</sub>	[.../ml]
Feststoff <sub>Konzentrat</sub>		[mg/l]	Endvol <sub>Konzentrat</sub>		[kg/l]	ProdKonz <sub>Konzentrat</sub>	[.../ml]
Konz. grad		[%]	Konz. faktor		[-]		

## Verbleib der Produkte

	Klarauf	Konzentrat	x.a.d.
Weiterverarbeitung	Protokoll-Nr. 1	Protokoll-Nr. 03	
An/Für Nutzer	übergeben o	eingelagert o	übergeben o
Inaktivierung (Art)			
Entsorgung (Art)	x		



Feststoffextraktion / Desorption

Kostenstelle: 703110

Vers.Nr.: 96/0741/03/03

Bearbeiter: Prozeß: R. Roth

Analysen: .....

Analysen-Protokoll: \_/ \_/ \_

Stamm / Medium: F. 990 G. Roth M. K. T. Sp. K. H. L. a. n.

Besondere Sicherheitsmaßnahmen: .....

Zielsetzung: .....

Grunddaten

Anlagentyp	Sitz Prozeßführ EFT 601785		
Modifikationen			
Betriebsbeginn	Datum: .....	Uhrzeit: 14: 50	
Prozeßbeginn	Datum: .....	Uhrzeit: 14: 50	

Bearbeitetes Material

Art:	12 g Prodn. etw. Ant.		
Vol.: .....	[l]	Menge: .....	[g] Herk.: Nutzer o
			Protokoll-Nr.: 1

Extraktions- / Desorptionsverlauf

Probe Nr.	Menge [kg] ; [l]	Lösungsmittel		Kontaktzeit [min] ; [h]	Produkt [mg] ; [g]	Phasentrennung $Q_m$ [l/h]
		Art	Menge [l]			
Rinigung ca. 25		Methanol <sup>2)</sup>	45	nur Wassert		
1. El.	15 kg	Methanol	15	3 h		
2. El.	15 kg	Methanol	15	nur das Wassert		
3. El.	15 kg	Methanol	15	3 h		
4. El.	15 kg	Methanol	30 L	3 h		
5. El.	15 kg	Methanol	30 L	n. Wassert		
6. El.	15 kg	Methanol	30 L	3 h		
7.	15 kg	Methanol	15 L	2 h		

1.) Methanol + H<sub>2</sub>O Gemische 12 g 2 !

## Verbleib der Produkte:

	Wässrige Phase	Organische Phase
Weiterverarbeitung	Protokoll-Nr.: /	Protokoll-Nr.: 03 / 08
An/Für Nutzer	übergeben o                      eingelagert o	übergeben o                      eingelagert o
Inaktivierung (Art)		
Entsorgung (Art)	bc	

## Versuchsende

Prozessende	Datum: [REDACTED]	Uhrzeit: 17:00
Betriebsende	Datum: [REDACTED]	Uhrzeit: 17:30

Bemerkungen



### Verdampfung

Kostenstelle: 1033-10

Vers.Nr.: 96/0141/03/C 2

Bearbeiter: Prozeß: Perruth

Analysen.....

Analysen-Protokoll:          /

Stamm / Medium

F. 200- Girth Epithyllum

Besondere Sicherheitsmaßnahmen:

Handwritten: Handwritten

**Zielsetzung:**

Fluorkonzentrationen der Mithrasnigales

## Grunddaten

Verdampfertyp	Luft-Dünnschichtverdampfer	
Modifikationen Besonderheiten	thin film evaporator	
bei Dünnschicht- verdampfer	Starrflügelrotor <input checked="" type="checkbox"/>	Schwingflügelrotor <input type="checkbox"/>
Betriebsbeginn	Datum: <input type="text"/>	Uhrzeit: <input type="text"/>
Prozessbeginn	Datum: <input type="text"/>	Uhrzeit: <input type="text"/>

### Bearbeitetes Material

Art: <u>Mathematische Logik</u>			
Vol. <u>170</u> +	[1]	Konz. <u>Schönheits</u>	[2]
Herk.: Nutzer o		Protokoll-Nr: /	

### Rotationsverdampfer

Vakuum	14,6	[hPa]	Brüdentemperatur	[°C]
Badtemperatur		[°C]		

### Dünnschichtverdampfer

Vakuum	250 (120)	[hPa]		
Rohproduktflux		[l/h]	Rohproduktpumpe	46 (48) [%]
Destillatleistung	53	[l/h]	Konzentratflux	
Eindampfverhältnis		[-]	Dampfdruck	0,1 bar abs. (2) $\times 10^3$ [hPa]
Konzentrattemperatur	30,5	[°C]	Brüdentemperatur	23 [°C]
Wärmeträger Zufuhr	100	[°C]	Wärmeträger Abfuhr	22 [°C]

## Rektifikation

Vakuum	[hPa]		
$T_{Destillat}$	[sec.]	$T_{Nachlauf}$	[sec.]
Destillatleistung	[l/h]	Dampfdruck	$\times 10^3$ [hPa]
Destillatmenge	[l]	Sumpfschlamm	[l]

(x) Sechsmal stückelg an, (zudem korrigiert).

② Dampf verdichtet auf 0,4 Bar gesätt.

## Batch-Reaktor

Vakuum	Konzentrattemp. [°C]	
Destillatleistung	Heizmedium [°C]	
Direkt-	Dampfdruck	$\times 10^3$ [hPa]
bedampfung	Destillatleistung [l/h]	
		Konzentrattemp [°C]

## Produkte

End-Werte	Endvolumen [l]	Konz. <sub>Produkt</sub> [ ]	Bemerkungen
Konzentrat	26 L		
Sumpf	130 L		

Ausbeute: Produktmenge Konzentrat/Menge Rohprodukt  $\times 100 =$

[%]

## Verbleib der Produkte

	Konzentrat	Sumpf
Weiterverarbeitung	Protokoll-Nr.: 031	Protokoll-Nr.: 1
An/Für Nutzer	übergeben o eingelagert o	übergeben o eingelagert o
Inaktivierung (Art)		
Entsorgung (Art)		aufgefrieren

## Versuchsende

Prozeßende	Datum: [redacted]	Uhrzeit: 14:20
Betriebsende	Datum: [redacted]	Uhrzeit: 16:20

Bemerkungen: Konzentrat über Vordampfer in Reaktor wargeführt, in Reaktor  
mischend abdestilliert.  
Wasserbadtemp. 28°C, Max. Vakuum 11 m.B.r.

Analysen-Protokoll: /

Besondere Sicherheitsmaßnahmen:

Zielsetzung: Gegenstrategie zur Wirtsebene

Extraktortyp	Gieseler dVf / SAN Separator	
Modifikationen		
Betriebsbeginn	Datum: <u>          </u>	Uhrzeit: <u>14:20</u>
Prozessbeginn	Datum: <u>          </u>	Uhrzeit: <u>13:00</u>

An: <u>Konwert-qt Dümmelversteht-Ratet-versteht</u>	
Vol.: <u>26</u>	Herkunft: Nutzer <u>o</u> Protokoll-Nr: <u>1</u>
Temp.: <u></u> [°C]	pH <u></u> [-] Konz. Produkt <u></u> [mg/...]

Zusatzstoffe	Art: Ammoniak 1202 PH2
pH-Einstellungen	mit: 1204 Essigsäure conlauf: 6,9
Lösungsmittel	Art: Ethylacetat

Durchfluß Phase <sub>Wasser</sub>	[l/h]	Durchfluß Phase <sub>Öl</sub>	[l/h]	Phasen- verhältnis	12:1 [-]
--------------------------------------	-------	----------------------------------	-------	-----------------------	----------

Probe Nr.	Datum Uhrzeit	Stufe	Konz. [mg/l]		Vol. [l]		Bemerkungen
			Phase <sub>Wasser</sub>	Phase <sub>Öl</sub>	Phase <sub>Wasser</sub>	Phase <sub>Öl</sub>	
16.6.80		1.			20	20	sch. d. s. u. t.
2.6.80		2.					
		3.					
Start	8.4.80	4.			ca. 20% Commission		
		5.					
		6.					

Dekantierung	o	Filtration (Koaleszenz)	o	Zentrifugation	b
--------------	---	-------------------------	---	----------------	---

4-42

# Volumen der Produkte

Phase <sub>Wässrig</sub>	SA1 Emulsi: 43	(l)	Phase <sub>Organisch</sub>	Emulsi SA1 46 L	(l)
--------------------------	----------------	-----	----------------------------	-----------------	-----

## Konditionierung der Produkte

Phasen	Art	Zusatzstoffe (z.B. Na <sub>2</sub> SO <sub>4</sub> )	pH-Einstellung	
			Menge [g], (l)	mit auf
Wässrige				
Organische				

## Verbleib der Produkte:

	Wässrige Phase	Organische Phase
Weiterverarbeitung	Protokoll-Nr.: /	Protokoll-Nr.: 03 / 10
An/Für Nutzer	übergeben o eingelagert o	übergeben o eingelagert o
Inaktivierung (Art)		
Entsorgung (Art)	α	

## Versuchsende

Prozeßsende	Datum: [redacted]	Uhrzeit: 13:30
Betriebsende	Datum: [redacted]	Uhrzeit: 15:50

Bemerkungen: Auf Grund ungenügender Trennungverhältnisse wurde wäsr.

25 L Ethylacetat + 25 L H<sub>2</sub>O hinzugefügt (16 ml). 80 L Gesamtvol.

Dekantierung nicht erfolgreich.

Emulsion Pkt instabil, Trennung über Separator SA1.

Verdampfung

Kostenstelle 103320

Vers. Nr.: 96049 E / 03 / 10

Bearbeiter: Prozeß: Rerath

Analysen: \_\_\_\_\_

Analysen-Protokoll: \_/ \_/ \_

Stamm / Medium: Ethylacetat Extrakt Ess. Gith. Epithel

Besondere Sicherheitsmaßnahmen: \_\_\_\_\_

Zielsetzung: Konservierung zum Produkt

Grunddaten

Verdampfertyp	Reinheitsverdampfer SVF RZD EX		
Modifikationen Besonderheiten			
bei Dünnschicht- verdampfer	Starrflügelrotor 0		Schwingflügelrotor 0
Betriebsbeginn	Datum: _____	Uhrzeit: 07:25	
Prozeßbeginn	Datum: _____	Uhrzeit: 07:50	

Bearbeitetes Material

Art:	Ethylacetat - Extrakt		
Vol.: 46 [l]	Konz. Rohprodukt [g/l]	Herk.: Nutzer o	Protokoll-Nr.: 1

Rotationsverdampfer

Vakuum	90 [hPa]	Brüdentemperatur	27,2 [°C]
Badtemperatur	27,7 [°C]		

Dünnschichtverdampfer

Vakuum	[hPa]		
Rohproduktflux	[l/h]	Rohproduktpumpe	[%]
Destillatleistung	[l/h]	Konzentratflux	[l/h]
Eindampfverhältnis	[-]	Dampfdruck	$\times 10^3$ [hPa]
Konzentrattemperatur	[°C]	Brüdentemperatur	[°C]
Wärmeträger Zufuhr	[°C]	Wärmetr., Abfuhr	[°C]

Rektifikation

Vakuum	[hPa]		
$T_{\text{Destillat}}$	[sec.]	$T_{\text{Rektifikat}}$	[sec.]
Destillatleistung	[l/h]	Dampfdruck	$\times 10^3$ [hPa]
Destillatmenge	[l]	Sumpfprodukt	[l]

## Batch-Reaktor

Vakuum		Konzentrattemp.	[°C]
Destillatleistung		Heizmedium	[°C]
Direkt-	Dampfdruck	$\times 10^3$ [hPa]	
bedampfung	Destillatleistung		
	[l/h]	Konzentrattemp.	[°C]

## Produkte

End-Werte	Endvolumen	[l]	Konz. <sub>Produkt</sub>	[ ]	Bemerkungen
Konzentrat	ca. 4 L		ca. 4 L		
Sumpf	52 L				

Ausbeute: Produktmenge Konzentrat/Menge Rohprodukt  $\times 100 =$  [%]

## Verbleib der Produkte

	Konzentrat	Sumpf
Weiterverarbeitung	Protokoll-Nr.: /	Protokoll-Nr.: /
An/Für Nutzer	übergeben o eingelagert o	übergeben o eingelagert o
Inaktivierung (Art)		
Entsorgung (Art)		

## Versuchsende

Prozeßende	Datum: <del>          </del>	Uhrzeit: 09:34
Betriebsende	Datum: <del>          </del>	Uhrzeit: 11:40

Bemerkungen:

# EPOTHILON - Aufarbeitung 900L (750L AV)

XAD: ca 15L

4-45

Analytik


Integral 2500  $\hat{=}$  41  $\mu$ g EPOB

XAD-Elution

			EPOTHILON AB-freiset	(g)
1	MeOH/Wasser 1:2 (ca 80L)			
2	MeOH	15L	2,60	1,40
3	"	15L	2,10	1,23
4	"	15L	2,95	1,80
5	"	30L	2,63	1,58
6	"	30L	1,37	0,80
7	"	30L	0,50	0,32
8	"	15L	0,22	0,14
			12,37	7,27

Gesamtelutionsvolumen: 150L  $\hat{=}$  10 BV

Gehalt  
EPOA  
[g]



Data File name: C:\HPCHEM\1\DATA\ANTJE\EP000014.D

Method name: C:\HPCHEM\1\METHODS\SCREEN1.M

Sample Name: ~~990014.D~~ 990014.D

Sample Info: HPLC\_MS\_ -&gt; 4-26

Injection Time: 10:36:36 AM

Sequence Name:


Report Style: screen1

data acquired by: Antje


on: ~~XXXXXXXXXX~~

10:36:36 AM


vial:1




23.04 17886.2




23.79 9602.7



25.38 439.0



26.10 1218.6







Data File name: C:\HPCHEM\1\DATA\ANTJE\EPO00014.D

Method name: C:\HPCHEM\1\METHODS\SCREEN1.M


26.92 324.4



28.64 519.7



29.87 367.6



4-47

## Integration Results


4-48

Signal 1: DAD1 A, Sig=210,4 Ref=550,100


5 $\mu$ L

Peak#	Time [min]	Type	Area [mAU*s]	Height [mAU]	Width [min]	Start [min]	End [min]
1	23.043	PV	17886.182	1359.741	0.201	22.614	23.457
2	23.791	VV	9602.701	705.784	0.206	23.457	24.265
3	25.383	PV	438.981	17.453	0.335	24.965	25.738
4	26.101	VV	1218.557	71.913	0.252	25.738	26.433
5	26.919	VV	324.419	11.990	0.364	26.720	27.240
6	28.637	PV	519.701	26.924	0.279	28.245	29.056
7	29.872	VV	367.567	23.116	0.235	29.647	30.264


Plot of TIC from Epo 900L pos




Plot of "Device A" from Epo 900L pos




Plot of Spectrum from 22.85 min (7 scans) from Epo 900L pos, subtracted




Plot of Spectrum from 23.71 min (8 scans) from Epo 900L pos, subtracted



Plot of Spectrum from 28.85 min (7 scans) from Epo 900L pos, subtracted



Plot of Spectrum from 29.82 min (7 scans) from Epo 900L pos, subtracted



XAD- Quate 1-8 über Eiderndampf konzentriert  
und anschließend mit EE verbleibt

Wasserphase 42 l

Ca 280 mg EPD in H<sub>2</sub>O-Phase

EE-Phase 46 l

- Wasserphase wurde nur 1 mal extrahiert
- EE-Phase wurde im Roti konzentriert und von NCH übernommen.
- EE-Extrakt war sauer pH 5.0 und wurde mit 1M  $\text{NH}_4\text{COOCH}_3$  gepuffert. Schwierigkeiten bei der Pufferanstellung.
- Nachteil bei EE-Konzentrierung dampft  $\text{NH}_3$ -Gas ab. Das Quat wird sauer.
- Erreichte Pufferung mit 0,5M  $\text{KPO}_4$ -Puffer
- Extraktion ist neutral!
- EE-gesamt- Cetrakt 246g 407.  
 Gehalt EPD A = 13,82g A  
 " " B = 8,40g B
- von den 246g Rohextrakt wurden 80g entnommen und einmal mit n-Heptan ausgeschüttelt!
- n-Heptanphase: 20g  
 MeOH-Phase: 60g 408.

flüssigster Extrakt 407

$\left( \frac{2}{3} \text{ davon} \right)$   
 $\left( \frac{1}{3} \text{ s. 408} \right)$

$\gamma = 5.1$

wurden mit Heptan - verteilt

413. Auswage:

Heptanphase: 20.4 g

EPO A

30 mg verwerfen


" B

19 mg "


LH20 - Chromatographie von So 90. 408

900 L 4-52

Teil 1 60g Rohextrakt



Spinnung  
Spots for epo-  
Kilone faded



Fractionierung

1-3

4+5

6-12

13- Rest (19)

Spinnung

Spinnung + EPO

~~409.~~ 409

410.

411.


412.

Data File name: C:\HPCHEM\1\DATA\MITTWOCH\A000000->  
 Method name: C:\HPCHEM\1\METHODS\SCREEN1.M  
 Sample Name: Fr.6-12  
 Injection Time: 4:02:31 PM  
 Sequence Name:  
 Report Style: screen1  
 data acquired by: Antje  
 vial: 1


Sample Info:  
 LH20

4-53


on: [REDACTED] 4:02:31 PM




19.63 15304.8




20.53 7617.5



23.25 894.8




23.65 648.1



Data File name: C:\HPCHEM\1\DATA\MITTWOCH\A000000->


Method name: C:\HPCHEM\1\METHODS\SCREEN1.M

26.40 1092.9




4-54


27.89 956.6




28.91 706.5




30.42 1476.6




31.59 640.9




32.60 4815.9



33.04 2642.5



33.41 1459.5







Data File name: C:\HPCHEM\1\DATA\MITTWOCH\A000000->

Method name: C:\HPCHEM\1\METHODS\SCREEN1.M


34.85 3627.0



36.17 2105.6



38.56 4021.5



4-55

Integration Results

4-56

Signal 1: DAD1 A, Sig=210,4 Ref=550,100

Peak#	Time [min]	Type	Area [mAU*s]	Height [mAU]	Width [min]	Start [min]	End [min]
1	19.635	VV	15304.782	955.700	0.241	18.503	20.154
2	20.529	VV	7617.517	457.590	0.249	20.154	21.403
3	22.436	VV	533.199	14.543	0.483	21.932	22.681
4	23.254	VV	894.821	30.803	0.393	22.681	23.520
5	23.651	VV	648.111	19.969	0.421	23.520	24.170
6	26.398	VV	1092.884	30.130	0.485	25.898	26.916
7	27.892	VV	956.623	28.627	0.448	27.530	28.423
8	28.909	VV	706.516	16.989	0.574	28.423	29.178
9	30.425	VV	1476.579	27.183	0.694	29.676	31.044
10	31.586	VV	640.901	16.239	0.506	31.044	31.743
11	32.604	VV	4815.902	130.967	0.544	31.743	32.884
12	33.035	VV	2642.511	127.065	0.294	32.884	33.321
13	33.407	VV	1459.489	68.039	0.298	33.321	33.810
14	34.846	VV	3626.960	57.609	0.901	34.234	35.738
15	36.168	VV	2105.642	36.447	0.792	35.738	37.210
16	38.556	VV	4021.517	61.308	0.907	38.050	40.871

A  
B

C  
D

5.2  
7.2

400 mg  
400 mg

5800 - 2 µg

1000

4.1 mg/ml

5 µl

2.0 µg


2000 + 200 + 5500

5800 + 1000


400 mg

>


Plot of TIC from Fr.6-12 pos




Plot of "Device A" from Fr.6-12 pos




Plot of Spectrum from 19.55 min (7 scans) from Fr.6-12 pos, subtracted



Plot of Spectrum from 20.48 min (9 scans) from Fr.6-12 pos, subtracted



Plot of Spectrum from 26.38 min (12 scans) from Fr.6-12 pos, subtracted



# Präp. RP-18 Chromatographie (Merck Prep-bar)

4-5P

Soce 90.411 ca 30 g

Probe wurde nicht getrocknet, da sie mit ein 100% Saltsäure löst.

LM M/W 6:4

Fraktion 1-30 mit Gradientenpumpe auf M/W=67/33

1 verworfen

2 150 mg 414.

3

4 verworfen

5

6 0,521 g 415.

7 1,892 g ~~416.~~

8 1,850 g 417.

9 1,847 g 418.

10 1,486 g 419.

11 ca 940 g 420.

12 98 mg 421.

13 verworfen

14 334 mg 422.

15 Gewicht= 232 mg „Exp. E“ 423.

16 500 mg 424.

17

18

19

20

21

22

(250 mg Kristall  
200 mg Boehringer  
Fraktion verbraucht 1,3 g Siebe)

Fraktion:

4-5g

22

23

172 mg ~~522 mg~~ 425.

24

Gewicht: 153 mg Epo C 426.

25

verworfen

26

27

257 mg 427.

28

Gewicht: 150 mg Epo D 428.

29

Gewicht: 103 mg 429.

30

verworfen

## RP18 Chromatography

So 90.411 ~ 1. Teil cc 50 g Relativität

R. 128

L: M/W 6.4

→ ~ 160 ml/min

180

R256.

A

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372


373

374

4-61

LC A 254,4 450,80 of AK1.D  
DATA:AK1.D

Peak#	Ret Time	Type	Width	Area	Start Time	End Time
1	3.572	BV	0.234	13828	2.544	3.977
2	4.056	VV	0.255	1568	3.977	5.115




1,454gA

0,164gB

4-62

LC A 254,4 450,80 of AK1.D  
DATA:AK1.D

Peak#	Ret Time	Type	Width	Area	Start Time	End Time
1	3.585	BV	0.227	5375	3.079	3.892
2	4.103	VB	0.274	4495	3.892	5.447



0,566g A


0,474g B




4-63

LC A 254,4 450,80 of AK1.D  
DATA:AK1.D


Peak#	Ret Time	Type	Width	Area	Start Time	End Time
1	4.101	UV	0.275	3461	3.795	5.254




Original-File: Spectra.FRP  
 Data File name: C:\HPCHEM\1\DATA\ANTJE\EP000004.D  
 Method name: C:\HPCHEM\1\METHODS\SCREEN1.M  
 Sample Name: Fr.24 20 µl  
 Injection Time: 2:40:26 PM  
 Sequence Name:  
 Report Style: screen1  
 data acquired by: Antje  
 vial:1  
 Sample Info: HPLC\_MS\_ ->  
 Screening gradient  
 5090.426  
 on: [REDACTED] 2:40:26 PM




23.30 132.3




27.27 66.4




28.00 83.1




28.54 2561.2




Plot of TIC from Fr.24 pos




Plot of "Device A" from Fr.24 pos



Plot of Spectrum from 29.22 min (7 scans) from Fr.24 pos, subtracted




Plot of Spectrum from 28.42 min (9 scans) from Fr.24 pos, subtracted




4-65


Original File: Spectra.FRP  
 Data File name: C:\HPCHEM\1\DATA\ANTJE\EPO00005.D  
 Method name: C:\HPCHEM\1\METHODS\SCREEN1.M  
 Sample Name: Fr.28  
 Injection Time: 3:27:54 PM  
 Sequence Name:  
 Report Style: screen1  
 data acquired by:Antje  
 vial:1  
 on: XXXXXXXXXX 3:27:54 PM  
 So 90.428




23.35 607.2




24.08 573.3




29.80 3346.7




31.94 906.1




Plot of TIC from Fr:28 pos




Plot of "Device A" from Fr:28 pos




Plot of Spectrum from 23.38 min (20 scans) from Fr:28 pos




Plot of Spectrum from 27.58 min (14 scans) from Fr:28 pos




Plot of Spectrum from 29.79 min (10 scans) from Fr:28 pos



Plot of Spectrum from 31.99 min (8 scans) from Fr:28 pos



RP-Trennung von SO<sub>2</sub>O<sub>4</sub> 411



46

RP-Trennung von RP-Fl. 24 (Fang) von 153 g 4-69

Säule = Unischalt C18, 7 µm 20 x 250 mm

LM = 20 µmol  
30 %  $H_2PO_4$ , 0,01 M,  $NH_2O$  → umstellen auf 73 µmol  
27  $Na_2HPO_4$ , 0,01 M, 1970

Temperatur = 200 1. Phase: Simultane

$\lambda$  = 254 nm Range = 0.66 - 1.0

Fraktionierung bis zur  $H_2O$ -Phase injiziert, 2x mit EE extrahiert, EE-Phase mit  $H_2O$  gewaschen und mit  $MgSO_4$  getrocknet.

Fraktionierung:

RP-Fl. 24/EP-① - Proben: Gewicht: 2 mg → Analyse Ergebnis (117)

426.11

RP-Fl. 24/EP-② - Proben:  $C$

26.7 mg, NMR 004033,  $\mu$  132 g/L

$^{13}C$  → V6-Filtration (5.11.196)


↓  
Filtrat

RP-Fl. 24/EP-③ - Proben: 5 µmol

Leopold: RP-① = 19.3364g  
RP-② = 22.3223g

4-70

RP 18 Chromatograms





aktive gel

KG-Filtration von So 90.411 IRP-Fl.24 IRP ② = C

4.7.1

So 90.411 IRP-Fl.24 IRP ② = 26.7 mg in CH<sub>2</sub>Cl<sub>2</sub> auftragen

offene Säule = Material = KG.60, 0.063 mm - 0.300 mm

18 cm Höhe, Ø 0.9 cm

→ Kopf gepackt in 97 CH<sub>2</sub>Cl<sub>2</sub> / 3 EtOH, eluiert mit

97 Et<sub>2</sub>O / 3 EtOH




Epo C

angereichert mit Vanillin / H<sub>2</sub>SO<sub>4</sub>

Fraktionierung:

So 90.411 IRP-Fl.24 IRP ② 1 KG = Gewicht: 12.6 g  
426.2 C



Epo C

MFC = 50 g/L

Lager-Vst = 14, 4406 g

RP-Trennung von RP-Fr. 28 (90mg von 159mg)

4-42

So 90.4M RP-Fr. 28 = 90mg von 159mg in 3 Läufen getrennt

Säule = Wüchink (C<sub>18</sub>, 9µm), 20 x 250mm

LM = 75 NaOH / 25 Na<sub>2</sub>HPO<sub>4</sub> 0.01M, pH 7.0

Temperatur = 200, Flussrate = 1.0ml/min

k = 25min, Range = 0.64 - 0.8


Fractionen mit zw. H<sub>2</sub>O-Phase eingeleitet, 3x mit EE extrahiert, EE-Phase mit H<sub>2</sub>O gewaschen und mit MgSO<sub>4</sub> getrocknet.

Fraktionierung:

So 90.4M RP-Fr. 28 / RP-① = 31.2mg, NMR 004045, Mr. 145g/g  
15C Wd-Filtration (S.M. 96)

So 90.4M RP-Fr. 28 / RP-② = 14.6mg, NMR 004046, Mr. 146g/g  
? ④28.1

So 90.4M RP-Fr. 28 / RP-③ = 17.8mg  
④28.2 Reduktion




Langzeitstabilität: RP-① = 22, 18.8g

RP-② = 12, 9.16g



RP-③ = 10, 9.31g

4-73



D

RP18 chromatogr.



Silica gel

KG-Fraktion von So 90.4.11 IRP. FL 28 IRP - ① = ① D'

9-28

So 90.4.11 IRP. FL 28 IRP - ① = 34,2 g in  $CH_2$  aufgetragen


offene Säule: Material = 4660 10,063 mm - 0,2 mm

19 mm Höhe, 0,9 mm

→ nach gespalten in 97  $CH_2$  13 MeOH, eluiert mit

97% 13 MeOH

Sp. D



Ergebnis = 1 Varietät / Hetero

Fraktionierung =

So 90.4.11 IRP. FL 28 IRP - ① 146 ① = 14,1-2 = Gewicht: 14,2 mg  $CH_2$  100% 100%  
 428.3 ① qly Teil Wasser 100% 100%  
 2 mg Spalte 5 g 2 mg 100% 100%

So 90.4.11 IRP. FL 28 IRP - ① 146 ② = 61.3 - Gewicht: 5,9 mg → Verunreinigen  
 428.4 ①

EW ① = MeC = 15 mg / ml

Leergewicht: 17,74 g 40-7  
 4,784 g 100%

Einlieferungsdatum:                     Spektrum-Nr.: 004033**NMR-ANTRAG**

GBF — Abt. Molekulare Strukturforschung

**132.**

4-78

Substanz-Bez.: S 90.411 IRP-Flz4 IRP-(2) 1°CSummenformel:                     Substanzhersteller: PohlauAbteilung: NC (1.1.7) Tel.: 343Kernart ( $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{31}\text{P}$ , andere?)                     Substanz-Menge: 20 mg, Molmasse:                     geeignetes Lösungsmittel:  $\text{CD}_3\text{OD}$  weitere Messung nach Zugabe von                     Substanz zurück: ja ☒  
nein ☐Strukturvorschlag:                     Radioaktiv ☐Toxisch ☐**Allgemeine Angaben**Probe lagern im Kühlschrank ☒  
im Tiefkühlfach ☐  
im Dunkeln ☐  
Probe auf Abruf beim Hersteller ☐Signale erwartet zwischen  $\delta =$  0 und 9  
Gewünscht: nur Spektrum ☒  
plus Integral ☒  
Interpretation ☐  
Zahl der Akkumulationen (falls > 104):                     **Art des Experiments** $^1\text{H}$  Standardspektrum ☒  
Entkopplung ☐ Differenz-NOE ☐  
Differenz-Entkopplung ☐  
Entkoppler-Frequenz(en):                      $^{13}\text{C}$   $^1\text{H}$ -Entkopplung:  
Breitband ☒ selektiv ☐  
DEPT ☒ ohne ☐**Plot und Datenmanipulation**Gauss-Multiplikation ☐Linienausdruck ☐ $^1\text{H}$   
 $\delta =$  8.9 bis -0.1 (0.15 ppm/cm) ☒  
11.9 bis -0.1 (0.2 ppm/cm) ☐Drehungen:  
10 Hz/cm ☐ von  $\delta =$                       bis                      $^{13}\text{C}$  normal ( $\delta = 220$  bis 0) ☒anderes Format:                     Sonderwünsche: COSY ☐ $^{13}\text{C}$  —  $^1\text{H}$  Korrel. Direkt ☐ Long-range ☐

(Nicht vom Antragsteller auszufüllen)

gemessen auf ☒ AM-300  
☐ ARX-400  
☐ DMX-600gespeichert unter Nr. SPE 4033/10  
                    , 121  
                    , 120Bitte um Rücksprache ☐Kommentar:                     

(Unterschrift)


Epoxidation

So 90.644 187-FL-24 (177-2)

1215

20mg -> 267mg

SIPZ4033 10 1 Ponlan



Current Data Parameters  
NAME SIPZ4033  
EXPNO 10  
PROCNO 1

F2 - Acquisition Parameters


Date\_ 1215  
Time\_ 1215  
INSTRUM spect  
PROBHD 5 mm QNP 1H  
PULPROG zgpg30  
SOLVENT H2O  
NS 819  
DS 4  
SWH 6172.1858 Hz  
FIDRES 0.152599 Hz  
AQ 2.6542590 sec  
RG 320  
TE 300.2 K  
DE 81.000 usec  
EC 1.000 usec  
TE 300.0 K  
D1 1.00000000 sec  
DE 12.00 usec  
EC 1.000 usec  
SPF1 300.1310524 MHz  
NUC1 1H  
PL1 -4.00 dB

F2 - Processing parameters

SF 300.1310524 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00  
10 MHz plot parameters  
CX 30.00 cm  
F2 4.400 gpa  
F1 120.000 Hz  
F3P -0.100 Hz  
F2 -30.01 Hz  
PROCK 6.10000 gpa/cm  
HSCN 45.01805 Hz/cm

4-79

SPZ4033 10 1 Ponlan



4-80



So 90.44 RP - F1.24 RP. (2)


1426

2011.11.23

;

SIPZ4033 20 1 Pohlan

4-81



DU=u, USER=chk, NAME=SIPZ4033, EXPNO=20, PROCNO=1  
 F1=230.000ppm, F2=0.000ppm, MI=0.00cm, MAXI=10000.00cm, PC=1.400

4-82

#	ADDRESS	FREQUENCY [Hz]	INTENSITY [PPM]
1	6711.5	16634.855	220.4237 c 5 2.95
2	11729.2	12988.931	172.1126 c 1 3.44
3	12268.5	12597.046	166.9198 - 20 1.71
4	13677.1	11573.543	153.3577 - 18 2.70
5	15059.4	10569.200	140.0494 - 16 3.46
6	15615.0	10165.478	134.6998 0.86
7	15640.6	10146.885	134.4534 5.61
8	16421.5	9579.455	126.9346 0.70
9	16539.5	9493.721	125.7986 5.35
10	17145.8	9053.167	119.9609 - 14 5.34
11	17174.2	9032.517	119.6873 0.84
12	17398.9	8869.258	117.5240 0.88
13	17411.1	8860.417	117.4068 - 19 5.22
14	21268.5	6057.571	80.2671 5.41
15	21435.0	5936.585	78.6640 1.22
16	21589.0	5824.736	77.1819 - 15 4.28
17	22074.7	5471.765	72.5048 5.04
18	22109.2	5446.690	72.1725 0.87
19	23214.8	4643.369	61.5279 1.35
20	23911.4	4137.193	54.8208 - 4 4.02
21	24427.1	3762.479	49.8555 11.90
22	24456.7	3741.021	49.5712 34.54
23	24486.1	3719.640	49.2879 70.13
24	24515.7	3698.156	49.0032 80.32
25	24545.1	3676.791	48.7201 69.03
26	24574.6	3655.367	48.4362 34.30
27	24604.0	3633.971	48.1527 12.04
28	24859.0	3448.694	45.6977 0.72
29	24909.2	3412.198	45.2141 - 6 4.38
30	25330.7	3105.970	41.1563 0.62
31	25423.8	3038.285	40.2594 - 2 4.95
32	25580.7	2924.324	38.7494 - 8 5.13
33	25632.7	2886.490	38.2481 0.92
34	25754.1	2798.305	37.0795 0.73
35	26126.9	2527.458	33.4906 0.74
36	26224.1	2456.771	32.5540 4.97
37	26298.1	2403.007	31.8416 4.80
38	26550.6	2219.588	29.4111 0.72
39	26578.0	2199.672	29.1472 5.24
40	26607.5	2178.218	28.8629 5.45
41	26699.7	2111.245	27.9755 0.68
42	27183.1	1760.011	23.3214 - 23 4.69
43	27335.5	1649.258	21.8538 0.63
44	27438.5	1574.374	20.8616 0.96
45	27497.0	1531.911	20.2989 0.76
46	27551.4	1492.387	19.7752 - 12 5.09
47	27665.8	1409.260	18.6737 - 24 4.97
48	27735.3	1358.757	18.0045 0.76
49	27819.7	1297.446	17.1921 - 24 4.98
50	27855.0	1271.734	16.8514 0.80
51	27928.3	1218.500	16.1460 0.88
52	27951.2	1201.869	15.9256 5.26
53	27965.0	1191.823	15.7925 5.81
54	28102.7	1091.776	14.4668 2.05

4-83

Einlieferungsdatum: [REDACTED]

Spektr-Nr.: 004069

167.

NMR-ANTRAG  
GBF — Abt. Molekulare Strukturforschung

4-84

Substanz-Bez.: Jo 90.4.11 RP-Fl. 24 / RP-2 / KG = C

Strukturvorschlag:

Summenformel:

Substanzhersteller: Polyan

Abteilung: N (1.1.2) Tel.: 343

Kernart (<sup>1</sup>H), <sup>13</sup>C, <sup>31</sup>P, andere?)

Substanz-Menge: 17.6 mg, Molmasse:

geeignetes Lösungsmittel: CD<sub>3</sub>OD weitere Messung nach Zugabe vonSubstanz zurück: ja ☒  
nein ☐Radioaktiv ☐Toxisch ☐

## Allgemeine Angaben

Probe lagern im Kühlschrank ☒im Tiefkühlfach ☐im Dunkeln ☐Probe auf Abruf beim Hersteller ☐

Signale erwartet zwischen

 $\delta = 0$  und 9Gewünscht: nur Spektrum ☒plus Integral ☒Interpretation ☐

Zahl der Akkumulationen (falls &gt; 104):

## Art des Experiments

☒ <sup>1</sup>H StandardspektrumEntkopplung ☐ Differenz-NOE ☐Differenz-Entkopplung ☐

Entkoppler-Frequenz(en):

☐ <sup>13</sup>C <sup>1</sup>H-Entkopplung:Breitband ☐ selektiv ☐DEPT ☐ ohne ☐

## Plot und Datenmanipulation

Gauss-Multiplikation ☐☒ <sup>1</sup>HLinienausdruck ☐ $\delta = 8.9$  bis  $-0.1$  (0.15 ppm/cm) ☒11.9 bis  $-0.1$  (0.2 ppm/cm) ☐

Drehungen:

10 Hz/cm ☐ von  $\delta =$  bis☐ <sup>13</sup>C normal ( $\delta = 220$  bis 0) ☐

anderes Format:

Sonderwünsche: COSY ☐<sup>13</sup>C — <sup>1</sup>H Korrel.Direkt ☐Long-range ☐

(Nicht vom Antragsteller auszufüllen)

gemessen auf ☒ AM-300

gespeichert unter Nr. SIP 24069/10


☐ ARX-400☐ DMX-800Bitte um Rücksprache ☐

Kommentar:

(Unterschrift)

So 90.44 MR-78.24 (EP-Q) 146  
 [426.2]  
 E110 C

SIPZ4069 10 1 Pohlman



Current Data Parameters  
 NAME SIPZ4069  
 EXPNO 10  
 PROCNO 1

F2 - Acquisition Parameters

Date\_ 17.6.89  
 Time 16.18  
 PULPROG zgpg30  
 SFO 500.1360  
 PULPROG 500.1360  
 TD 32768  
 SFO 500.1360  
 DS 4  
 SMH 6172.839 Hz  
 FIDRES 0.188300 Hz  
 AQ 2.5542980 sec  
 RG 81.000 uHz  
 DE 4.50 uHz  
 TE 300.0 K  
 D1 1.00000000 sec  
 P1 15.00 uHz  
 DE 4.50 uHz  
 D1 300.118034 MHz  
 SFO 500.136034 MHz  
 PL1 -4.00 dB

F2 - Processing parameters

SI 32768  
 SF 500.123827 MHz  
 NDM 76  
 SSB 0  
 GB 0  
 PC 1.00


1D MPR plot parameters

SI 32768  
 FAP 4.000 cm  
 F1 1320.57 Hz  
 F2 -0.100 dB  
 F3 1320.57 Hz  
 PRACH 0.15000 Hz/cm  
 MZEN 45.01000 Hz/cm

4-85

4-86

SIPZ4069 10 1 Pohlan



Einlieferungsdatum:                     Spektren-Nr.: 004174

273.

## NMR-ANTRAG

GBF — Abt. Molekulare Strukturforschung

4-87

Substanz-Bez.: Epo C / So 90.426.2Summenformel:                     Substanzhersteller: PoldanAbteilung: NC (1.A.2)Tel.: 343Kernart: (<sup>1</sup>H/<sup>13</sup>C, <sup>31</sup>P, andere?)                     Substanz-Menge: 5 mg, Molmasse:                     

geeignetes

Lösungsmittel: DMSO-d<sub>6</sub> weitere Messung  
nach Zugabe von                     Substanz zurück: ja ☒nein ☐Strukturvorschlag:                     Radioaktiv ☐Toxisch ☐

## Allgemeine Angaben

Probe lagern im Kühlschrank ☒im Tiefkühlschrank ☐im Dunkeln ☐Probe auf Abruf beim Hersteller ☐

Signale erwartet zwischen

 $\delta =$  0 und 9Gewünscht: nur Spektrum ☒plus Integral ☒Interpretation ☐Zahl der Akkumulationen (falls > 104):                     

## Art des Experiments

☒ <sup>1</sup>H Standardspektrum ☒Entkopplung ☐ Differenz-NOE ☐Differenz-Entkopplung ☐Entkoppler-Frequenz(en):                     ☐ <sup>13</sup>C <sup>1</sup>H-Entkopplung:Breitband ☒ selektiv ☐DEPT ☒ ohne ☐

## Plot und Datenmanipulation

Gauss-Multiplikation ☐☒ <sup>1</sup>HLinienausdruck ☐ $\delta = 8.9$  bis  $-0.1$  (0.15 ppm/cm) ☒ $11.9$  bis  $-0.1$  (0.2 ppm/cm) ☐

Drehungen:

10 Hz/cm ☐ von  $\delta =$                       bis                     ☒ <sup>13</sup>C normal ( $\delta = 220$  bis 0) ☒anderes Format:                     Sonderwünsche: COSY ☒<sup>13</sup>C—<sup>1</sup>H Korrel.Direkt ☒Long-range ☐

(Nicht vom Antragsteller auszufüllen)

gemessen auf

☐ AM-300☐ ARX-400☐ DMX-600Bitte um Rücksprache ☐Kommentar:                     gespeichert unter Nr. 8102 11/11/16


(Unterschrift)

5030 426.2  
 Epistemon C  
 R-5

DSH

4-88


SIP24174 10.1





SI224174 10 1

DK50



4-89



/u/data/chk/nmr/SIPZ4174/32/pdata/1/screen

Fri 1988.05.32

DU=u, USER=chk, NAME=SIPZ4174, EXPNO=32, PROCNO=1  
 F1=220.000ppm, F2=0.000ppm, M1=0.00cm, MAXI=10000.00cm, PC=1.400

#	ADDRESS	FREQUENCY	INTENSITY
		[Hz]	[PPM]
1	6816.6	16416.988	217.5364
2	11741.3	12838.661	170.1211
3	12351.2	12395.488	164.2487
4	13595.5	11491.410	152.2691
5	15141.4	10368.112	137.3846
6	15584.0	10046.493	133.1229
7	16473.1	9400.500	124.5631
8	17077.2	8961.576	118.7470
9	17205.5	8868.332	117.5115
10	21259.5	5922.664	78.4794
11	21602.4	5673.510	75.1779
12	22047.1	5350.393	70.8964
13	23883.2	4016.285	53.2185
14	24807.3	3344.793	44.3208
15	25221.4	3043.879	40.3335
16	25250.1	3023.054	40.0575
17	25278.9	3002.137	39.7804
18	25307.6	2981.238	39.5034
19	25336.4	2960.312	39.2262
20	25365.2	2939.395	38.9490
21	25394.1	2918.407	38.6709
22	25613.2	2759.223	36.5616
23	26182.3	2345.693	31.0820
24	26292.8	2265.400	30.0181
25	26542.5	2083.948	27.6137
26	27070.1	1700.635	22.5346
27	27306.2	1529.078	20.2613
28	27448.7	1425.549	18.8895
29	27601.3	1314.677	17.4204
30	27743.0	1211.706	16.0559
31	27885.2	1108.357	14.6865

78.5  
75.2  
76.9

9 + 11

EPO C

in DMSO

Einlieferungsdatum:                     Spektren-Nr.:                     

004045

4-92

145.

## NMR-ANTRAG

GBF — Abt. Molekulare Strukturforschung

Substanz-Bez.: 690.411 RP-Fl. 28 IRP-①Summenformel:                     (?)Substanzhersteller: PolymerAbteilung: NC (A.1-2) Tel.: 343Kernart: <sup>1</sup>H <sup>13</sup>C <sup>31</sup>P, andere?Substanz-Menge: 10.5 mg, Molmasse:                     geeignetes  
Lösungsmittel: CD<sub>3</sub>OD weitere Messung  
nach Zugabe von                     Substanz zurück: ja ☒nein ☐Strukturvorschlag:                     Radioaktiv ☐Toxisch ☐

## Allgemeine Angaben

Probe lagern im Kühlschrank ☒im Tiefkühlfach ☐im Dunkeln ☐Probe auf Abruf beim Hersteller ☐

Signale erwartet zwischen

 $\delta$  = 0 und 9Gewünscht: nur Spektrum ☒plus Integral ☒Interpretation ☐Zahl der Akkumulationen (falls > 104):                     

## Art des Experiments

☒ Standardspektrum ☒Entkopplung ☐ Differenz-NOE ☐Differenz-Entkopplung ☐Entkoppler-Frequenz(en):                     ☒ <sup>1</sup>H-Entkopplung:Breitband ☒ selektiv ☐DEPT ☒ ohne ☐

## Plot und Datenmanipulation

Gauss-Multiplikation ☐☒ <sup>1</sup>HLinienausdruck ☐ $\delta$  = 8.9 bis — 0.1 (0.15 ppm/cm) ☒11.9 bis — 0.1 (0.2 ppm/cm) ☐

Drehungen:

10 Hz/cm ☐ von  $\delta$  =                      bis                     ☒ <sup>13</sup>C normal ( $\delta$  = 220 bis 0) ☒anderes Format:                     Sonderwünsche: COSY ☐<sup>13</sup>C — <sup>1</sup>H Korrel.Direkt ☐Long-range ☐

(Nicht vom Antragsteller auszufüllen)

gemessen auf

☒ AM-300☐ ARX-400☐ DMX-600Bitte um Rücksprache ☐Kommentar:                     

gespeichert unter Nr.

51P24045/10

130

131


(Unterschrift)

Epothilone

503044 189-7228 187-1

195mg → 242mg


SIPZ4045 10 1 Pohlman



Current Data Parameters  
 Date\_ 10.13  
 Time\_ 10:13  
 INSTRUM spect  
 PROCESSOR 5 mm QNP 1H  
 PULPROG zgpg30  
 TO 32768  
 SOLVENT MECH  
 NS 8  
 DS 0  
 SHW 6172.639 Hz  
 FIDRES 0.188300 Hz  
 AQ 2.6542500 sec  
 RG 655.357  
 DM 81.000 usec  
 DE 4.50 usec  
 TE 300.2 K  
 D1 1.00000000 sec  
 P1 13.00 usec  
 DE 4.50 usec  
 SF 300.136034 MHz  
 F2 - Processing parameters  
 SF 300.136034 MHz  
 SF 300.136034 MHz  
 XN1 no  
 SSB 0  
 B 0.00 Hz  
 BR 0  
 PC 1.00  
 1D NMR plot parameters  
 CP 4096 pts  
 F2 4.400 usec  
 F1 1320.57 Hz  
 F2 -30.000 ppm  
 SFO 0.001 Hz  
 PRACH 0.35000000/cm  
 HZCN 45.01550 Hz/cm

4-93

SIPZ4045 10 1 Pohlman



4 - 94


SIP24045 20 1 Pohlen

5090.911 20.11.21 10.11.21

1438

M.S.

4-5



DU=u, USER=chk, NAME=SIP24045, EXPNO=20, PROCNO=1

F1=285.042ppm, F2=-30.451ppm, M1=0.00cm, MAX1=10000.00cm, PC=1.000

4-96

#	ADDRESS	FREQUENCY [Hz]	INTENSITY [PPM]
1	6727.1	16623.523	220.2735
2	11639.8	13053.866	172.9730
3	11728.8	12989.188	172.1160
4	12268.2	12597.304	166.9232
5	13675.7	11574.554	153.3711
6	15038.5	10584.390	140.2507
7	15046.4	10578.604	140.1740
8	15482.8	10261.529	135.9726
9	15633.7	10151.841	134.5191
10	15860.8	9986.855	132.3329
11	16164.2	9766.376	129.4114
12	16979.5	9174.034	121.5625
13	17026.3	9139.974	121.1112
14	17142.8	9055.376	119.9902
15	17413.0	8859.035	117.3885
16	19273.8	7506.939	99.4723
17	21223.3	6090.396	80.7021
18	21426.0	5943.124	78.7506
19	21563.9	5842.914	77.4228
20	21672.9	5763.763	76.3740
21	21702.0	5742.604	76.0936
22	21782.6	5684.032	75.3175
23	22079.0	5468.641	72.4634
24	22226.1	5361.791	71.0475
25	22380.5	5249.614	69.5611
26	23214.8	4643.351	61.5277
27	23532.2	4412.754	58.4721
28	23849.3	4182.324	55.4188
29	23899.7	4145.718	54.9337
30	24427.1	3762.483	49.8556
31	24456.7	3741.021	49.5712
32	24486.1	3719.649	49.2880
33	24515.7	3698.168	49.0034
34	24545.1	3676.783	48.7200
35	24574.6	3655.310	48.4355
36	24604.1	3633.926	48.1521
37	24831.9	3468.352	45.9581
38	24886.7	3428.535	45.4305
39	25410.1	3048.276	40.3918
40	25435.5	3029.783	40.1468
41	25569.3	2932.605	38.8591
42	25601.9	2908.881	38.5447
43	25693.4	2842.427	37.6642
44	25729.8	2815.970	37.3136
45	25834.2	2740.097	36.3082
46	25910.7	2684.506	35.5716
47	25932.5	2668.660	35.3616
48	26078.1	2562.849	33.9596
49	26144.2	2514.872	33.3238
50	26188.5	2482.672	32.8972
51	26319.9	2387.194	31.6320
52	26484.0	2267.948	30.0519
53	26750.9	2074.054	27.4827
54	26942.3	1934.968	25.6397
55	27169.2	1770.080	23.4548
56	27172.5	1767.651	23.4226
57	27303.7	1672.336	22.1596
58	27438.6	1574.322	20.8609



59	27582.0	1470.167	19.4808	6.62
60	27666.0	1409.089	18.6714	5.77
61	27735.5	1358.635	18.0029	0.80
62	27784.2	1323.231	17.5338	6.44
63	27929.8	1217.439	16.1319	6.08
64	27959.4	1195.924	15.8468	2.67
65	27973.0	1186.054	15.7161	7.35
66	28015.2	1155.338	15.3090	1.07
67	28070.7	1115.056	14.7753	1.22
68	28102.7	1091.755	14.4665	4.71
69	28199.8	1021.210	13.5318	1.65
70	28503.1	800.822	10.6115	0.73
71	28571.0	751.523	9.9582	1.60
72	28776.3	602.322	7.9812	0.91
73	29178.2	310.304	4.1118	1.55

4-97

Einlieferungsdatum: [REDACTED]

Spektrum-Nr.: 004070

168.

NMR-ANTRAG  
GBF — Abt. Molekulare Strukturforschung

4-98

Substanz-Bez.: Jo 90.411/2P-Fl.28RP-D (K6-f)

Summenformel: = 1

Substanzersteller: Pohlen

Abteilung: NC (1.1.2) Tel.: 343

Kernart ( $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{31}\text{P}$ , andere?)

Substanz-Menge: 11.2 mg, Molmasse:

geeignetes Lösungsmittel:  $\text{CDCl}_3$  weitere Messung nach Zugabe vonSubstanz zurück: ja ☒  
nein ☐

Strukturvorschlag:

Radioaktiv ☐ Toxisch ☐

## Allgemeine Angaben

Probe lagern im Kühlschrank ☒im Tiefkühlfach ☐im Dunkeln ☐Probe auf Abruf beim Hersteller ☐

Signale erwartet zwischen

 $\delta = 0$  und 9Gewünscht: nur Spektrum ☒plus Integral ☒Interpretation ☐

Zahl der Akkumulationen (falls &gt; 104):

## Art des Experiments

 $^1\text{H}$  Standardspektrum ☒Entkopplung ☐ Differenz-NOE ☐Differenz-Entkopplung ☐

Entkoppler-Frequenz(en):

 $^{13}\text{C}$   $^1\text{H}$ -Entkopplung:Breitband ☐ selektiv ☐DEPT ☐ ohne ☐

## Plot und Datenmanipulation

Gauss-Multiplikation ☐ $^1\text{H}$  $\delta = 8.9$  bis  $-0.1$  (0.15 ppm/cm) ☒11.9 bis  $-0.1$  (0.2 ppm/cm) ☐

Drehungen:

10 Hz/cm ☐ von  $\delta =$  bis $^{13}\text{C}$  normal ( $\delta = 220$  bis 0) ☐

anderes Format:

Sonderwünsche: COSY ☐ $^{13}\text{C}$ - $^1\text{H}$  Korrel. Direkt ☐ Long-range ☐

(Nicht vom Antragsteller auszufüllen)

gemessen auf ☒ AM-300  
☐ ARX-400  
☐ DMX-600

gespeichert unter Nr. 5182.407070

Bitte um Rücksprache ☐

Kommentar:

(Unterschrift)

E10

D

SIPZ4070 10 : Pohlen

609044177.77.281RP-01660  
11.2-8

428.3

Current Data Parameters  
NAME SIPZ4070  
EXPNO 10  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 9.28  
Time 9.28


INSTRUM spect  
PROBHD 5 mm QNP 1H  
PULPROG zgpg30  
TD 32768  
SOLVENT H<sub>2</sub>O  
NS 64  
DS 4

SMH 6572.630 Hz  
FIDRES 0.188880 Hz  
AQ 2.6542500 sec  
RG 81.000 uspc  
DE 4.50 uspc  
TE 300.0 K  
D1 1.00000000 sec  
P1 15.00 uspc  
DE 4.50 uspc  
SFO 300.131834 MHz  
NUC1 1H  
PC 1.00

PL1 -4.00 dB


F2 - Processing parameters  
SI 32768  
SF 300.1250627 MHz  
WDW 0  
SSB 0  
GB 0  
PC 1.00

GD NMR plot parameters  
CX 0.00000000  
CY 0.00000000  
FIP 4.40000000  
F1 1320.27 Hz  
F2 -0.10000000  
F3 0.00000000  
PRG00 0.15000000 Hz/c  
MECN -45.019500 Hz/c



4 - 99

SIP24070 10 1 Pontian



4 - 1000

Einfieferungsdatum:                     Spektr-Nr.: 004175

274.

NMR-ANTRAG  
GBF — Abt. Molekulare Strukturforschung

4-109

Substanz-Bez.: Epo.D1 So 90. 428.3  
Summenformel:                       
Substanzhersteller: Polysar  
Abteilung: NC (1.1.2) Tel.: 363  
Kernart: <sup>1</sup>H, <sup>13</sup>C (P, andere?)                       
Substanz-Menge: 11,2 mg, Molmasse:                       
geeignetes Lösungsmittel: DMSO-d<sub>6</sub> weitere Messung nach Zugabe von                     

Strukturvorschlag:                     

Substanz zurück: ja ☒  
nein ☐

Radioaktiv ☐ Toxisch ☐

## Allgemeine Angaben

Probe lagern im Kühlschrank ☒  
im Tiefkühlfach ☐  
im Dunkeln ☐  
Probe auf Abruf beim Hersteller ☐

Signale erwartet zwischen

 $\delta =$  0 und 9

Gewünscht: nur Spektrum ☒  
plus Integral ☒  
Interpretation ☐

Zahl der Akkumulationen (falls > 104):                     

## Art des Experiments

☒ <sup>1</sup>H Standardspektrum ☒  
Entkopplung ☐ Differenz-NOE ☐  
Differenz-Entkopplung ☐  
Entkoppler-Frequenz(en):                     

☒ <sup>13</sup>C <sup>1</sup>H-Entkopplung:

Breitband ☒ selektiv ☐  
DEPT ☒ ohne ☐

## Plot und Datenmanipulation

Gauss-Multiplikation ☐Linienausdruck ☐

☒ <sup>1</sup>H  
 $\delta = 8.9$  bis  $-0.1$  (0.15 ppm/cm) ☒  
 $11.9$  bis  $-0.1$  (0.2 ppm/cm) ☐

Drehungen:

10 Hz/cm ☐ von  $\delta =$                       bis                     ☒ <sup>13</sup>C normal ( $\delta = 220$  bis 0) ☒anderes Format:                     Sonderwünsche: COSY ☒<sup>13</sup>C—<sup>1</sup>H Korrel.Direkt ☒Long-range ☐

(Nicht vom Antragsteller auszufüllen)

gemessen auf ☐ AM-300  
☐ ARX-400  
☐ DMX-600

gespeichert unter Nr. 5102, 4175, 101Bitte um Rücksprache ☐Kommentar:                     

(Unterschrift)


12.11.10 die

So 90.428.3

Erythronium ①


11,2-2

4-102



Current Data Parameters		T1 Acquisition Parameters		T2 Processing parameters		Non-Pilot parameters	
NAME	52341715	Dec	11.79	T1	300.100001 MHz	HP	4.400 per
UNIT	10	PROB	10	T2	300.100001 MHz	FP	4.400 per
MODE	1	PROB	10	CP	0	1P	1120.57 Hz
		PROB	10	CS	0	2P	-0.100 Hz
		PROB	10	SC	0	3P	-0.100 Hz
		PROB	10	CC	0	4P	-0.100 Hz
		PROB	10	CC	0	5P	-0.100 Hz
		PROB	10	CC	0	6P	-0.100 Hz
		PROB	10	CC	0	7P	-0.100 Hz
		PROB	10	CC	0	8P	-0.100 Hz
		PROB	10	CC	0	9P	-0.100 Hz
		PROB	10	CC	0	10P	-0.100 Hz
		PROB	10	CC	0	11P	-0.100 Hz
		PROB	10	CC	0	12P	-0.100 Hz
		PROB	10	CC	0	13P	-0.100 Hz
		PROB	10	CC	0	14P	-0.100 Hz
		PROB	10	CC	0	15P	-0.100 Hz
		PROB	10	CC	0	16P	-0.100 Hz
		PROB	10	CC	0	17P	-0.100 Hz
		PROB	10	CC	0	18P	-0.100 Hz
		PROB	10	CC	0	19P	-0.100 Hz
		PROB	10	CC	0	20P	-0.100 Hz
		PROB	10	CC	0	21P	-0.100 Hz
		PROB	10	CC	0	22P	-0.100 Hz
		PROB	10	CC	0	23P	-0.100 Hz
		PROB	10	CC	0	24P	-0.100 Hz
		PROB	10	CC	0	25P	-0.100 Hz
		PROB	10	CC	0	26P	-0.100 Hz
		PROB	10	CC	0	27P	-0.100 Hz
		PROB	10	CC	0	28P	-0.100 Hz
		PROB	10	CC	0	29P	-0.100 Hz
		PROB	10	CC	0	30P	-0.100 Hz
		PROB	10	CC	0	31P	-0.100 Hz
		PROB	10	CC	0	32P	-0.100 Hz
		PROB	10	CC	0	33P	-0.100 Hz
		PROB	10	CC	0	34P	-0.100 Hz
		PROB	10	CC	0	35P	-0.100 Hz
		PROB	10	CC	0	36P	-0.100 Hz
		PROB	10	CC	0	37P	-0.100 Hz
		PROB	10	CC	0	38P	-0.100 Hz
		PROB	10	CC	0	39P	-0.100 Hz
		PROB	10	CC	0	40P	-0.100 Hz
		PROB	10	CC	0	41P	-0.100 Hz
		PROB	10	CC	0	42P	-0.100 Hz
		PROB	10	CC	0	43P	-0.100 Hz
		PROB	10	CC	0	44P	-0.100 Hz
		PROB	10	CC	0	45P	-0.100 Hz
		PROB	10	CC	0	46P	-0.100 Hz
		PROB	10	CC	0	47P	-0.100 Hz
		PROB	10	CC	0	48P	-0.100 Hz
		PROB	10	CC	0	49P	-0.100 Hz
		PROB	10	CC	0	50P	-0.100 Hz
		PROB	10	CC	0	51P	-0.100 Hz
		PROB	10	CC	0	52P	-0.100 Hz
		PROB	10	CC	0	53P	-0.100 Hz
		PROB	10	CC	0	54P	-0.100 Hz
		PROB	10	CC	0	55P	-0.100 Hz
		PROB	10	CC	0	56P	-0.100 Hz
		PROB	10	CC	0	57	

STP24175 10 1



4-103





EPO "D"

/u/data/beate/nmr/SIPR4175/20/pdata/1/screen

Thu-11:00:25

DU=u, USER=beate, NAME=SIPR4175, EXPNO=20, PROCNO=1  
 F1=220.000ppm, F2=0.000ppm, M1=0.00cm, MAX1=10000.00cm, PC=1.400

4-105

#	ADDRESS	FREQUENCY [Hz]	[PPM]	INTENSITY
1	7281.0	21874.760	217.4152 - 5	2.07
2	7869.0	21276.707	211.4711	0.67
3	7890.0	21255.285	211.2582	0.75
4	7910.4	21234.568	211.0523	0.74
5	8761.3	20368.973	202.4491	0.63
6	11965.3	17109.715	*170.0550 - 1	2.13
7	12546.3	16518.658	*164.1805 - 20	1.74
8	13727.1	15317.464	*152.2417 - 18	2.20
9	15100.4	13920.527	*138.3574 - 19	2.29
10	15178.4	13841.204	*137.5690 - 16	2.18
11	16887.6	12102.428	*120.2871 - 13	2.50
12	17037.1	11950.432	*118.7764 - 17	2.78
13	17170.7	11814.513	*117.4255 - 19	2.95
14	20978.3	7941.236	*78.9287	2.64
15	21325.2	7588.323	*75.4210 - 7	1.94
16	21783.3	7122.308	*70.7893 - 3	2.42
17	23516.1	5359.594	*53.2695 - 4	3.09
18	23983.1	4884.557	48.5481	0.46
19	24390.8	4469.850	*44.4262 - 6	2.11
20	24816.1	4037.134	40.1254	6.66
21	24836.8	4016.094	39.9163	18.85 +
22	24857.5	3995.087	39.7075	36.05 +
23	24878.1	3974.093	39.4989	42.10
24	24898.8	3953.056	39.2898	35.53
25	24919.4	3932.073	39.0812 - 2	17.61
26	24939.8	3911.324	*38.8750	6.66
27	25192.9	3653.922	*36.3167 - 8	2.51
28	25633.0	3206.134	*31.8661 - 11	2.02
29	25662.2	3176.465	*31.5712 - 14	2.13
30	25827.4	3008.435	*29.9011 - 9	2.36
31	26223.3	2605.679	*25.8981 - 10	2.41
32	26515.7	2308.261	*22.9420 - 26	3.60
33	26556.8	2266.417	*22.5261 - 23	2.95
34	26819.3	1999.370	*19.8719 - 22	3.18
35	26921.3	1895.664	*18.8412 - 21	3.07
36	26945.8	1870.694	*18.5930	0.43
37	27036.9	1778.058	*17.6723 - 25	2.90
38	27182.0	1630.464	*16.2053 - 24	2.54
39	27348.0	1461.631	*14.5273 - 27	3.11

\* können verschoben sein

**Reply to the**  
**Opposition Statement against EP-B-1186606**  
concerning the identity of epothilones C and D

by Gerhard Höfle  
GBF, September 8, 2005

Contributions by Dr. K. Gerth, H. Steinmetz (GBF),  
Prof. D. Schinzer (University of Magdeburg)

1. Introduction.....	p. 2
2. NMR spectroscopy.....	p. 3
3. Production with strain DSM 6773.....	p. 4
4. Statement of Prof. Schinzer.....	p. 6
5. References.....	p. 6
6. Tables.....	p. 7
7. Appendix.....	pdf-file

## Introduction

In 1990/1991 epothilones A and B have been produced for the first time on the gram-scale with *Sorangium cellulosum* So ce90 wild strain. A patent was filed for epothilones A and B November 19, 1991, and the strain was deposited at the German Strain Collection DSMZ under the code DSM 6773. At that time during large scale isolation work more lipophilic epothilones were observed during RP chromatography of epothilones A and B<sup>1)</sup> which however were not isolated because of the small amounts present and, later lack of interest in epothilones.

After the tubulin activity was published by Bollag et al. in 1995 work was resumed, and a number of other *Sorangium cellulosum* strains were identified to produce epothilones A and B. From these strain So cel 198 was selected for further work because of low abundance of other unwanted metabolites which otherwise interfere with isolation. As side products from this strain epothilones C and D were isolated in pure state and the structures elucidated in June 1996 as documented already. In September/October a 350 L fermenter with strain So cel 198 was run for the production of epothilones A and B. From this as side products several hundred milligrams of epothilones C and D were isolated. With this material a complete set of NMR spectra in DMSO-D<sub>6</sub> was obtained, and the chromatographic behavior determined as basis for the patent application November 18, 1996 which represents the first description of epothilones C and D. Later epothilones C and D were obtained by total synthesis by the Danishefsky, Nicolaou and Schinzer groups. Interestingly, in papers by Danishefsky et al. they were named desoxyepothilones A and B<sup>2)</sup>. From natural sources epothilones C and D were re-isolated using So ce90/B2, a mutant with improved epothilone A and B production (Hardt et al.<sup>3)</sup>), and P450 knock-out mutants obtained by UV-irradiation (Gerth et al.<sup>4)</sup>) or genetic engineering (Lau et al.<sup>5)</sup>). To demonstrate feasibility of epothilone A and B total synthesis via C and D, epoxidation using dimethyl dioxirane and *m*-chloroperbenzoic acid were performed in June 1996 and in more detail in November/ December 1996 (Höfle et al.<sup>6)</sup>).

In the present Opposition Statement of Sloan Kettering Institute for Cancer Research it is claimed that the compounds described in the GBF patent EP-B-1186606<sup>(a)</sup> are not epothilones C and D but rather other epothilones of non-defined structure. This conclusion is based on two observations:

1. Certain signals in the proton and carbon NMR spectra taken from MSKCC epothilones C and D differ significantly from those given in EP-B-1186606 (Prof. J. D. Roberts),
2. Attempts to obtain epothilones C and D by cultivation of *Sorangium cellulosum* strain So ce90 obtained as DSM6773 from the DSMZ failed (Dr. P. J. Licari, KOSAN).

In the following it is clearly proven that the compounds isolated in 1996 had the structures claimed in EP-B-1186606, today known as epothilones C and D.

It is further demonstrated that by re-fermentation of strain DSM6773 and isolation as described indeed epothilones C and D are obtained.

Prof. Schinzer confirms that epothilones C and D obtained in 1996 from GBF were identical with his synthetic compounds.

(a) EP 07 129 329 7

with So ce 90 = DSM 6773

## NMR spectroscopy of epothilones C and D

From the first proton NMR spectra recorded in June 1996 (as documented before) and biosynthetic considerations the structures of epothilones C and D were unequivocally derived. When larger amounts of the compounds became available in Oct./Nov. complete sets of 1D and 2D spectra were recorded in DMSO- $D_6$ . The particular solvent was chosen to allow observation of hydroxy proton signals and couplings, and to facilitate comparison with the published data for epothilones A and B (Höfle et al.<sup>7b</sup>). In the appendix NMR Request Forms, shift records and 1D proton and carbon spectra of epothilones C and D are given. In Tab. 1 and 2 carbon shifts, in Tab. 3 and 4 proton shifts determined November 14 and 15, 1996<sup>10)</sup> are compared with those from recent samples measured May 18, 2005 at GBF, and KOSAN (Opposition Statement, p. 54-60).

### <sup>13</sup>C shifts for epothilone C (Tab. 1)

The shifts for all carbons except C1 and C2 are found within +/- 0.1 ppm. C2 deviates by 0.2 ppm due to partial overlap with solvent signals, whereas carbonyl C1 is by 0.5 ppm too high in the KOSAN spectrum. This may be attributed to a solvent induced shift, which is common with carbonyl carbons.

### <sup>13</sup>C shifts for epothilone D (Tab. 2)

The shifts for all carbons except C2 are in excellent agreement within +/- 0.1 ppm. C2 deviates by 0.3-0.4 ppm due to overlap with solvent signals. The values reported by KOSAN are consistently too high by 0.2 ppm which is attributed to an offset of the reference.

### <sup>1</sup>H shifts for epothilone C (Tab. 3)

In general most proton NMR signals of complex natural products are complex because of multiple couplings and signal overlap. Under these circumstances the shift differences of +/- 0.03 ppm between GBF, Nov. 96 and KOSAN measurements indicate excellent Übereinstimmung.

### <sup>1</sup>H shifts for epothilone D (Tab. 4)

The majority of shifts are identical for GBF, Nov. 96 and KOSAN measurements, and only few deviate up to +/- 0.3 ppm.

The above comparison of chemical shift data unequivocally prove that the epothilones isolated in 1996 were indeed epothilones C and D.

How can the deviating values in the table of EP-B-1186606<sup>10)</sup> be explained although they were extracted from the spectra measured November 14/15, 1996 which contain the correct ones?

As basis for writing the table for the patent application Mr. Steinmetz used an existing table with the data for epothilones A and B and replaced the values atom for atom with the corresponding values from the epothilone C and D spectra. Obviously, he started with the signals around the 12,13 double bond and epoxide, respectively, and others differing significantly in the olefin and epoxide series. These values are marked in blue in Tab. 1-4. Later, he apparently forgot to adjust also the slightly deviating values. They are marked in red like those for epothilones A and B in Tab. 1-4. When I checked the table fabricated by Mr. Steinmetz for plausibility before submission of the patent application I had no chance to discover the small differences.

(a) new PLOS DE 19542 886 17.11.1995

Coming back to the claim on p. 39 of the Opposition Statement that the compounds described in the patent were actually isomers of epothilones C and D with the same molecular mass, viz. m/z 477 and 491, respectively. This can be ruled out by comparison of the  $^{13}\text{C}$  shifts for e.g. the known epothilone C isomers, 12E-epothilone C, epothilones D1 and D2. As shown in Tab. 5 shift differences of 2 up to 6.6 ppm are observed which is by far above the (slightly wrong) values in the patent.

Even though the values given in EP-B-1186606 deviate slightly more than is generally observed as experimental error, they are not misleading in a structural assignment. To demonstrate the variability of chemical shifts for complex natural products published data for epothilone C in  $\text{CDCl}_3$  from different authors are summarized in Tab. 6.

### Production of epothilones C and D with *Sorangium cellulosum* DSM 6773

Epothilones C and D are the primary products of epothilone biosynthesis. After release from the polyketide synthase complex they are modified by so-called "decorating enzymes" to the epoxides, epothilone A and B<sup>4,8,9</sup>), and then to the 21-hydroxy derivatives, epothilones E and F<sup>10</sup>).

Thus any *Sorangium* strain capable of epothilone A and/or B synthesis has to produce as intermediates epothilones C and/or D. (Molnar et al.<sup>8)</sup> and Tang et al.<sup>9</sup>). Whether these intermediates can be observed and isolated from a culture depends on a variety of preconditions which are not well defined and mostly unknown. Certainly the harvest time, media composition, export activity of the organism and presence of XAD adsorber resin are essential factors. It is not surprising for the expert that in a single run these compounds may be missed as they are minor side products with wild strains or mutants generated for production of epothilones A and B. Only P450 knock-out mutants produce reliably high amounts of epothilones C and D (Gerth et al.<sup>4</sup>), Lau et al.<sup>5</sup>).

KOSAN ordered strain DSM6673 from DSMZ three times, November 26, 1999, March 9, 2000 and May 18, 2004. From this and data in the Opposition Statement (Appendix 4, p.1-2) it follows that the second shipment of March 9, 2000 was used for the attempt to reproduce the production of epothilones C and D. No information is given whether and how the strain was preserved or kept in culture for several years until the experiments were performed in August-November 2004. It is well known that myxobacteria like other microorganisms change their properties during extended cultivation due to clonal selection or unfavourable conditions for preservation. Thus without an analytical check for epothilone production on the shake flask level it was high-risk to start with a 70 L batch. Even though the procedure in the patent could be reproduced yielding 167 g of crude extract (180 g in the patent). This material was separated on LH-20 under supposedly the same conditions as described in the patent. The fraction eluting between 240-300 minutes was collected without checking the presence of epothilones by TLC or HPLC. The fraction contained only 35 mg instead of 72 g in the patent. From the fact that epothilones A, B, C and D co-elute from Sephadex LH-20 it must be concluded at this point that the right fraction was missed. This is however not too surprising, as it is common experience that retention times are very sensitive to a number of parameters which, particularly in large scale chromatography, cannot be controlled. The expert in the field in such case certainly would have checked adjoining fractions for the presence of epothilones before discarding them and not continued tedious work on a tiny fraction (2,250-times less than expected). In addition, this fraction was not analysed for the presence of epothilones C and D but stupidly processed further without a result. Obviously, this was the actual purpose of the exercise.

It is important to notice at this point that KOSAN reported the isolation of epothilone C and D from a not specified *Sorangium cellulosum* (wild) strain: "They are secreted as minor products during the fermentation process with a combined yield of about 0.4 mg/L" (Lau et al.<sup>5</sup>).

To demonstrate that wild strain DSM 6673 indeed produces epothilones C and D it was newly ordered from DSMZ, and obtained May 24, 2005. The culture (now coded as So ce90wild DSM 6773) on slant agar was propagated on agar plates and taken into liquid culture as described by Gerth et al.<sup>11</sup> and in epothilone A/B patents.<sup>12(a)</sup>

In detail,

1. agar plates with probion medium<sup>13</sup> were inoculated on May 24, and propagated,
2. H medium<sup>12</sup> plus 1.2% HEPES buffer (500 mL) was inoculated on June 16, and the culture propagated
3. 22 shaking flasks with H medium<sup>12</sup> plus 1.2% HEPES buffer (550 mL each) were inoculated on July 26,
4. a 150 L fermentor with H medium<sup>12</sup> (100 L) and 2 Kg of wet XAD-16 adsorber was inoculated with 10 l of the above culture on August 1 (pH adjustment with 10% aq. acetic acid, and 10% aq. KOH, 32°C, 30% oxygen saturation, see also Figure 1),
5. the adsorber resin was harvested by sieving on August 15 and immediately processed further as described below.

When the production of epothilones C and D was determined on the shake flask level a constantly high proportion of spirangiens was observed and only very little of epothilones A-D. This unfavourable production profile may be due to the short time of adaption of the strain to the liquid medium. It was later reproduced with the production fermentor containing 2.4 g of spirangiens A and C, and only 3.1 mg of epothilone A, 1.8 mg of epothilone B, 1.4 mg of epothilone C, and 0.5 mg of epothilone D (Figure 3 - 7). To facilitate the isolation of such small amounts of epothilones in presence of co-eluting spirangiens an additional extraction step with sodium carbonate solution was introduced which removed most of the spirangiens as carboxylic acid salts.

The entire isolation process from wet XAD adsorber resin to pure epothilones C and D is given in Figures 2a and 2b. It should be noted that the presence of epothilones in LH20 and RP-silica gel chromatography fractions was monitored by HPLC/MS. Thus no loss of material occurred, and the expected amounts of 1.4 mg of epothilone C and 0.5 mg of epothilone D were obtained in pure state. From physical data, in particular proton and carbon NMR spectra, the identity of the compounds is equivocally proven (Table 7).

Thus, So ce90wild DSM 6773 (patent strain of DE 4138042) is indeed producing Epothilones C and D.

### Statement from Prof. Schinzer

In 1996 Dieter Schinzer was Professor for Organic Chemistry at the University of Braunschweig and a colleague of mine. Like other synthetic chemists he obtained the absolute configuration of epothilone A and B around November 1995. He developed plans for a total synthesis and discussed certain crucial steps with me. In summer 1996 I mentioned to him the isolation of epothilones A and B and my preliminary experiments on the epoxidation to give preferably the desired stereoisomer. In October he received samples of ca. 5 mg each for comparison purposes. Both were found to be identical with his compounds from total synthesis. This was acknowledged for epothilone C in a paper on epothilone A total synthesis.<sup>14</sup>

From my recent contacts with Prof. Schinzer I know that he is willing to witness this.

### References

- 1) H. Steinmetz, unpublished.
- 2) D.-S. Su et al. *Angew. Chem. Int. Ed.*, 36, 757, 1997.
- 3) I. H. Hardt et al., *J. Nat. Prod.* 2001, 64, 847.
- 4) Gerth, K. et al., *J. Antibiot.*, 54, 144, 2001.
- 5) J. Lau et al., *Biotech & Bioengin.* 78, 280, 2002.
- 6) G. Höfle et al. *Pure Appl. Chem.* 71, 41, 2002.
- 7) Höfle, G. et al *Angew. Chem. Int. Ed.*, 35, 1567, 1996.
- 8) I. Molnar et al. *Chemistry & Biology* 7, 97, 2000.
- 9) L. Tang et al., *Science*, 2000, 287, 640.
- 10) Gerth, K. et al., *J. Antibiot.*, 55, 41, 2002.
- 11) Gerth, K. et al., *J. Antibiot.*, 49, 560, 1996.
- 12) H medium is the production medium used in DE 4138042 (Nov. 19,1991).
- 13) Pradella et al. *Arch Microbiol*, 178, 484, 2002.
- 14) D. Schinzer et al., *Chem. Eur. J.* 5, 2483, 1999

Tab. 1  $^{13}\text{C}$ -NMR chemical shifts of epothilone C in DMSO- $\text{D}_6$ 

C-Atom	Epo A <sup>1</sup>	EP-B-1186606 18.11.96	GBF <sup>3</sup> 15.11.96	GBF <sup>4</sup> 18.5.05	Kosan <sup>5</sup>
1	170.3	170.3	170.1	170.0	170.6
2	38.4	38.4	38.7	38.9	38.8
3	71.2	71.2	70.9	70.8	70.8
4	53.1	53.1	53.2	53.2	53.2
5	217.1	217.1	217.5	217.5	217.5
6	45.4	45.4	44.3	44.2	44.3
7	75.9	75.9	75.2	75.1	75.1
8	35.4	35.4	36.6	36.6	36.6
9	29.6	27.6	27.6	27.5	27.6
10	23.6	30.0	30.0	30.0	30.0
11	27.2	27.6	27.6	27.6	27.6
12	56.6	133.1 <sup>2</sup>	133.1	133.0	133.1
13	54.4	124.6 <sup>2</sup>	124.6	124.6	124.5
14	32.1	31.1	31.1	31.1	31.1
15	76.3	76.3	78.5	78.4	78.4
16	137.3	137.3	137.4	137.4	137.3
17	119.1	119.1	118.7	118.7	118.7
18	152.1	152.1	152.3	152.2	152.3
19	117.7	117.7	117.5	117.4	117.5
20	164.2	164.2	164.2	164.2	164.2
21	18.8	18.8	18.9	18.8	18.9
22	20.8	20.8	20.3	20.1	20.2
23	22.6	22.6	22.5	22.4	22.5
24	16.7	16.7	16.1	15.9	16.0
25	18.4	18.4	17.4	17.3	17.5
26	-	-	-	-	-
27	14.2	14.2	14.7	14.7	14.7

## References and comments:

1. G. Höfle et al. Angew. Chem. Int. Ed. Engl. 1996, 35, 1567-1569.
2. Misalignment corrected.
3. Spectrum taken Nov. 15, 1969 from a sample of epothilone C isolated Oct./Nov. 1996.
4. Recent sample of epothilone C.
5. Opposition Statement, p. 55-56.

## Conclusion:

Chemical shifts for C1-C8 and C15-C27 in EP-B-1186606 are identical with epothilone A (red), those for C9-C14 are identical with epothilone C (blue).



Tab. 2  $^{13}\text{C}$ -NMR chemical shifts of epothilone D in DMSO- $\text{D}_6$ 

C-Atom	Epo B <sup>1</sup>	EP-B-1186606 18.11.96	GBF <sup>2</sup> 14.11.96	GBF <sup>3</sup> 17.5.05	Kosan <sup>4</sup>
1	170.1	170.1	170.1	170.1	170.3
2	38.2	39.0	39.0	38.7	39.1
3	70.0	70.8	70.8	70.8	71.0
4	53.2	53.2	53.3	53.3	53.5
5	217.4	217.4	217.4	217.5	217.6
6	44.9	44.4	44.4	44.4	44.7
7	75.5	75.5	75.4	75.4	75.6
8	35.6	36.3	36.3	36.3	36.5
9	29.6	29.9	29.9	29.9	30.1
10	23.0	25.9	25.9	25.9	26.1
11	32.1	31.6	31.6	31.6	31.8
12	61.0	138.3	138.4	138.4	138.6
13	61.5	120.3	120.3	120.3	120.5
14	33.0	31.9	31.9	31.9	32.1
15	76.6	76.6	78.9	79.0	79.1
16	137.2	137.2	137.6	137.6	137.8
17	119.2	119.2	118.8	118.8	119.0
18	152.1	152.1	152.2	152.3	152.5
19	117.7	117.7	117.4	117.4	117.7
20	164.3	164.3	164.2	164.2	164.4
21	18.9	18.9	18.8	18.9	19.1
22	19.7	19.7	19.9	19.9	20.1
23	22.5	22.5	22.5	22.6	22.7
24	16.4	16.4	16.1	16.2	16.4
25	18.4	18.4	17.7	17.7	17.9
26	22.1	22.9	22.9	23.0	23.2
27	14.1	14.1	14.5	14.6	14.7

#### References and comments:

1. G. Höfle et al. Angew. Chem. Int. Ed. Engl. 1996, 35, 1567-1569.
2. Spectrum taken Nov. 14, 1969 from a sample of epothilone D isolated Oct./Nov. 1996.
3. Recent sample of epothilone D.
4. Opposition Statement, p. 59-60.

#### Conclusion:

Chemical shifts for C7, C15-C25, and C27 in EP-B-1186606 are identical with epothilone B(red), those for C1-C6, C8-C14, and C26 are identical with epothilone D (blue).

Tab. 3  $^1\text{H}$ -NMR chemical shifts of epothilone C in DMSO- $\text{D}_6$ 

H-Atoms	Epo A <sup>1</sup>	EP-B-1186606 18.11.96	GBF <sup>2</sup> 15.11.96	Kosan <sup>3</sup>
2a	2.38	2.38	2.35	2.35
2b	2.50	2.50	2.41	2.43
3	3.97	3.97	4.11	4.14
3OH	5.12	5.12	5.10	-
6	3.07	3.07	3.08	3.10
7	3.49	3.49	3.48	3.51
7OH	4.46	4.46	3.18	-
8	1.34	1.34	1.35	1.38
9a	1.15	1.15	1.03	1.05
9b	1.40	1.40	1.55	1.56
10a	1.15	1.15	1.15	1.19
10b	1.46	1.35	1.35	1.37
11a	1.35	1.90	1.88	1.90
11b	1.66	2.18	2.21	2.22
12	2.84	5.38	5.44	5.48
13	3.06	5.44	5.39	5.40
14a	1.76	2.35	2.15	2.14
14b	2.10	2.70	2.70	2.71
15	5.27	5.27	5.12	5.10
17	6.50	6.50	6.50	6.52
19	7.35	7.35	7.33	7.34
21	2.65	2.65	2.65	2.67
22	0.94	0.94	0.91	0.93
23	1.21	1.21	1.20	1.21
24	1.06	1.06	1.06	1.06
25	0.90	0.90	0.89	0.88
26	-	-	-	-
27	2.10	2.10	2.12	2.14

## References and comments:

1. G. Höfle et al. Angew. Chem. Int. Ed. Engl. 1996, 35, 1567-1569.
2. Spectrum taken Nov. 15, 1996 from a sample of epothilone C isolated Oct./Nov. 1996.
3. Opposition Statement, p. 54-55.

## Conclusion:

Chemical shifts for C1-C8 and C15-C27 in EP-B-1186606 are identical with epothilone A, those for C9-C14 are identical with epothilone C.

Tab. 4  $^1\text{H}$ -NMR chemical shifts of epothilone D in DMSO- $\text{D}_6$ 

H-Atoms	Epo B <sup>1</sup>	EP-B-1186606 18.11.96	GBF <sup>3</sup> 15.11.96	Kosan <sup>5</sup>
2a	2.35	2.35	2.32	2.34
2b	2.38	2.38	2.37	2.34
3	4.10	4.10	4.15	4.14
3OH	5.08	5.08	5.10	-
6	3.11	3.11	3.09	3.09
7	3.48	3.48	3.49	3.48
7OH	4.46	4.46	3.18	-
8	1.29	1.29	1.34	1.33
9a	1.14	1.14	1.15	1.15
9b	1.38	1.38	1.35	1.35
10a	1.14	1.14	1.02	1.02
10b	1.43	1.35	1.65	1.65
11a	1.31	1.75	1.76	1.75
11b	1.61	2.10	2.30	2.29
12	-	-	-	-
13	2.84	5.08	5.10	5.14
14a	2.05	2.30	2.12	2.12
14b	1.84	2.65	2.66	2.66
15	5.29	5.29	5.10	5.09
17	6.51	6.51	6.48	6.48
19	7.35	7.35	7.33	7.33
21	2.65	2.65	2.65	2.65
22	0.90	0.90	0.90	0.90
23	1.19	1.19	1.18	1.18
24	1.07	1.07	1.08	1.08
25	0.91	0.91	0.91	0.91
26	1.19	1.63	1.64	1.64
27	2.11	2.11	2.11	2.11

## References and comments:

1. G. Höfle et al. Angew. Chem. Int. Ed. Engl. 1996, 35, 1567-1569.
2. Spectrum taken Nov. 15, 1969 from a sample of epothilone D isolated Oct./Nov. 1996.
3. Recent sample of epothilone D.
4. Opposition Statement, p. 58-59.

## Conclusion:

Chemical shifts for C1-C8 and C15-C27 in EP-B-1186606 are identical with epothilone A, those for C9-C14 are identical with epothilone C.

Tab. 5  $^{13}\text{C}$ -NMR chemical shifts of epothilone isomers (Epos) with molecular mass  $m/z = 477$  in  $\text{CDCl}_3$

Nr.	Epo C Hardt <sup>1</sup>	trans-Epo C Schinzer <sup>2</sup>	trans-Epo C Danishefsky <sup>3</sup>	Epo D <sub>1</sub> Hardt <sup>1</sup>	Epo D <sub>2</sub> Hardt <sup>1</sup>	Max. delta > 2.0
1	220.6	219.9	219.9	217.0	216.8	3.6
2	170.4	170.5	170.5	169.7	170.4	
3	165.0	164.9	165.0	165.0	165.9	
4	152.1	152.1	152.0	152.2	152.3	
5	138.7	137.1	137.1	138.5	139.8	
6	133.5	134.3	134.4	137.7	137.5	4.2
7	125.0	125.7	125.7	120.7	120.5	4.8
8	119.5	119.8	119.8	121.1	119.2	
9	115.8	116.0	116.0	116.3	116.3	
10	78.5	76.6	77.6	78.8	80.8	2.3
11	74.2	75.8	75.8	77.2	74.3	3.0
12	72.4	72.4	72.4	67.7	69.7	4.7
13	53.4	52.5	52.5	52.5	48.6	4.8
14	41.8	43.6	43.6	46.5	48.4	6.6
15	39.3	38.9	38.8	30.6	39.9	
16	38.6	37.7	37.8	37.6	36.6	
17	31.8	36.2	36.2	32.3	32.7	4.4
18	31.5	32.4	32.5	31.8	32.2	
19	27.6	30.5	30.6	29.5	30.9	3.3
20	27.5	27.2	27.3	25.5	26.0	
21	22.7	21.0	21.0	22.1	23.6	
22	19.1	20.7	20.7	19.2	19.2	
23	18.7	19.1	19.0	16.6	17.1	2.1
24	15.9	16.4	16.4	15.5	15.4	
25	15.5	15.7	15.7	14.5	12.7	2.8
26	13.5	14.8	14.8	9.7	12.4	3.8

#### Refences and comments:

1. I. H. Hardt et al., *J. Nat. Prod.* **2001**, *64*, 847- 856.
2. D. Schinzer et al., *Chem. Eur. J.* **1999**, *5*, 2483- 2491.
3. PCT/US97/22381; D. Meng et al., *J. Am Chem. Soc.* **1997**, *119*, 10073- 10092.

#### Concnclusion:

Chemical shifts for individual carbon atoms vary by 2.1 up to 6.6 ppm.

Tab. 6  $^{13}\text{C}$ -NMR chemical shifts of epothilone C in  $\text{CDCl}_3$ 

Nr.	Danishefsky Original <sup>1,2</sup>	Danishefsky Corrected <sup>3</sup>	Nicolaou <sup>4</sup>	Nicolaou <sup>5</sup>	Schinzler <sup>6</sup>	Hardt <sup>7</sup>	Max. delta
1	226.5	220.4	220.6	220.2	220.5	220.6	0.4
2	176.5	170.4	170.4	170.6	170.3	170.4	0.3
3	171.1	165.0	165.0	165.4	165.0	165.0	0.4
4	158.2	152.1	151.9	153.8	152.0	152.1	1.8 <sup>9</sup>
5	144.7	138.6	138.7	139.2	138.6	138.7	0.6
6	139.6	133.5	133.4	134.1	133.4	133.5	0.7
7	131.1	125.0	125.0	126.1	125.0	125.0	1.1
8	125.7	119.6	119.4	120.4	119.5	119.5	1.0
9	122.0	115.9	115.8	116.9	115.8	115.8	0.8
10	84.6	78.5	78.4	79.2	78.4	78.5	0.8
11	80.2	74.1	74.1	74.9	74.1	74.2	0.8
12	78.6	72.5	72.3	73.2	72.4	72.4	0.9
13	59.4	53.3	53.3	54.2	53.3	53.4	0.9
14	47.9	41.8	41.7	42.5	41.8	41.8	0.8
15	45.4	39.3	39.2	40.3	39.2	39.3	1.1
16	44.6	38.5	38.5	39.5	38.5	38.6	1.0
17	38.5	32.4	32.4	32.9	32.5	31.8	1.1
18	37.9	31.8	31.7	32.6	31.7	31.5	1.1
19	33.7	27.6	27.6	28.6	27.6	27.6	1.0
20	33.6	27.5	27.4	28.4	27.5	27.5	1.0
21	28.7	22.6	22.7	23.3	22.7	22.7	0.7
22	25.1	19.0	19.0	19.3	19.0	19.1	0.3
23	25.0	18.9	18.6	19.1	18.7	18.7	0.5
24	21.9	15.8	15.9	16.4	15.8	15.9	0.6
25	21.7	15.6	15.5	16.3	15.5	15.5	0.8
26	19.6	13.5	13.5	14.4	13.5	13.5	0.9

## References and comments:

1. PCT/US97/22381
2. D. Meng et al., *J. Am Chem. Soc.* **1997**, *119*, 10073- 10092.
3. Offset of 6.1 ppm.
4. K. C. Nicolaou et al., *J. Amer. Chem. Soc.* **1997**, *119*, 7960, **1997**.
5. K. C. Nicolaou et al., *J. Amer. Chem. Soc.* **1997**, *119*, 7974, **1997**.
6. D. Schinzler et al., *Chem. Eur. J.* **1999**, *5*, 2483- 2491.
7. I. H. Hardt et al., *J. Nat. Prod.* **2001**, *64*, 847- 856.

## Conclusion:

Chemical shifts for individual carbon atoms vary by 0.3 up to 1.1 ppm.

Tab. 7  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR chemical shifts of epothilones C and D in  $\text{DMSO-}D_6$

Epothilone C					Epothilone D				
H - Atoms	GBF <sup>1</sup> 1. 9. 05	Kosan <sup>2</sup>	GBF <sup>1</sup> 1. 9. 05	Kosan <sup>2</sup>	C - Atoms	GBF <sup>1</sup> 1. 9. 05	Kosan <sup>2</sup>	GBF <sup>1</sup> 1. 9. 05	Kosan <sup>2</sup>
2a	2.34	2.35	2.34	2.34	1	170.08	170.6	170.08	170.3
2b	2.41	2.43	2.37	2.34	2	38.77	38.8	38.88	39.1
3	4.11	4.14	4.14	4.14	3	70.85	70.8	70.81	71.0
3OH	5.10	-	5.08	-	4	53.18	53.2	53.27	53.5
6	3.08	3.10	3.09	3.09	5	217.50	217.5	217.41	217.6
7	3.49	3.51	3.48	3.48	6	44.28	44.3	44.46	44.7
7OH	-	-	4.41	-	7	75.13	75.1	75.45	75.6
8	1.36	1.38	1.34	1.33	8	36.53	36.6	36.29	36.5
9a	1.03	1.05	1.15	1.15	9	27.57	27.6	29.91	30.1
9b	1.55	1.56	1.35	1.35	10	29.98	30.0	25.91	26.1
10a	1.16	1.19	1.01	1.02	11	27.57	27.6	31.57	31.8
10b	1.36	1.37	1.66	1.65	12	133.08	133.1	138.38	138.6
11a	1.89	1.90	1.76	1.75	13	124.54	124.5	120.28	120.5
11b	2.21	2.22	2.30	2.29	14	31.05	31.1	31.86	32.1
12	5.47	5.48	-	-	15	78.44	78.4	78.94	79.1
13	5.38	5.40	5.15	5.14	16	137.35	137.3	137.57	137.8
14a	2.15	2.14	2.12	2.12	17	118.72	118.7	118.78	119.0
14b	2.69	2.71	2.66	2.66	18	152.25	152.3	152.24	152.5
15	5.13	5.10	5.09	5.09	19	117.48	117.5	117.46	117.7
17	6.50	6.52	6.48	6.48	20	164.20	164.2	164.19	164.4
19	7.33	7.34	7.34	7.33	21	18.86	18.9	18.85	19.1
21	2.65	2.67	2.66	2.65	22	20.22	20.2	19.93	20.1
22	0.91	0.93	0.90	0.90	23	22.49	22.5	22.54	22.7
23	1.19	1.21	1.18	1.18	24	16.01	16.0	16.24	16.4
24	1.06	1.06	1.08	1.08	25	17.37	17.5	17.71	17.9
25	0.89	0.88	0.91	0.91	26	-	-	22.95	23.2
26	-	-	1.64	1.64	27	14.65	14.7	14.52	14.7
27	2.12	2.14	2.11	2.11					

#### References and comments:

- 1 New isolates from *So ce90wild* DSM 6773 (produced August 1 – 31, 2005).
- 2 Opposition Statement, p. 54-55.

**Conclusion:** All signals for GBF and Kosan samples are identical within the experimental error. The maximal shift differences of 0.52 and 0.22 ppm are observed for C-1.